Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation

Through the CRISPR/Cas system and the optimized Cas9 enzyme, efficient editing of the eukaryotic genome is achieved, solving the problem that genome editing is difficult to achieve multi-position targeting in the existing technology, and improving the cataloging and mapping of biological functions and disease factors ability.

CN113355357BActive Publication Date: 2024-12-03THE BROAD INST INC +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110502128.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2013-06-17
Filing Date
2013-12-12
Publication Date
2024-12-03
Estimated Expiration
2033-12-12

AI Technical Summary

Technical Problem

Existing genome editing technologies are difficult to achieve efficient, economical and harmless multi-position targeted editing of eukaryotic genomes, especially when cataloging and mapping a wide range of biological functions and disease-related genetic factors is lacking convenient methods. .

Method used

Using the CRISPR/Cas system, the specific DNA targets are identified by designing short RNA molecules, combining optimized Cas9 enzymes and chimera enzymes to achieve genome editing and regulation of various cell types, including deletion, insertion, translocation, and inactivation. , activation and methylation operations.

Benefits of technology

It significantly improves the cataloging and mapping capabilities of biological functions and disease-related genetic factors, and provides a simplified and efficient genome editing tool, which is widely used in the fields of gene therapy, drug discovery and disease diagnosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113355357B_ABST
    Figure CN113355357B_ABST
Patent Text Reader

Abstract

The present invention provides systems, methods, and compositions for engineering and optimizing the activity of manipulating sequences and / or target sequences. Compositions and methods are provided that relate to components of CRISPR complexes that specifically include Cas ortholog enzymes.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of an invention patent application with an application date of December 12, 2013, application number 201380072821.X, and invention name “Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation”.

[0002] Related applications and references

[0003] This application claims priority to U.S. Provisional Patent Application No. 61 / 836,101, filed on June 17, 2013, entitled ENGINEERING AND OPTIMIZATION OF IMPROVED SYSTEMS, METHODS AND ENZYME COMPOSITIONS FOR SEQUENCE MANIPULATION. This application also claims priority to U.S. Provisional Patent Applications Nos. 61 / 758,468; 61 / 769,046; 61 / 802,174; 61 / 806,375; 61 / 814,263; 61 / 819,803 and 61 / 828,130, each entitled ENGINEERING AND OPTIMIZING SYSTEMS, METHODS, AND COMPOSITIONS FOR SEQUENCE MANIPULATION, filed on Jan. 30, 2013; Feb. 25, 2013; Mar. 15, 2013; Mar. 28, 2013; Apr. 20, 2013; May 6, 2013 and May 28, 2013, respectively. This application also claims priority to U.S. Provisional Patent Applications 61 / 736,527 and 61 / 748,427, both filed on December 12, 2012 and January 2, 2013, respectively, both entitled "SYSTEMS METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION". Priority is also claimed to U.S. Provisional Patent Applications 61 / 791,409 and 61 / 835,931, filed on March 15, 2013 and June 17, 2013, respectively.

[0004] Reference is made to U.S. Provisional Patent Applications 61 / 836,127, 61 / 835,936, 61 / 836,080, 61 / 836,123, and 61 / 835,973, each filed on June 17, 2013.

[0005] The aforementioned applications, and all documents cited therein or during their prosecution ("application cited documents") and all documents cited or referenced in these application cited documents, and all documents cited or referenced herein ("herein cited documents"), all documents cited or referenced in the herein cited documents, together with any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or incorporated by reference in any document herein, are hereby incorporated by reference herein, and may be employed in the practice of the present invention. More specifically, all referenced documents are incorporated by reference herein to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference herein. Field of the Invention

[0006] The present invention generally relates to the engineering and optimization of systems, methods, and compositions for controlling gene expression involving sequence targeting, such as genome perturbation or gene editing involving Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and components thereof.

[0007] Statement Regarding Federally Funded Research

[0008] This invention was made with government support under a NIH Pioneer Award (1DP1MH100706) awarded by the National Institutes of Health. The U.S. Government has certain rights in this invention. Background of the Invention

[0009] Recent advances in genome sequencing technologies and analytical methods have significantly accelerated the ability to catalog and map genetic factors associated with a wide range of biological functions and diseases. Accurate genome targeting technologies are needed to enable systematic reverse engineering of causal genetic variations by allowing selective interference of individual genetic elements, as well as to advance synthetic biology, biotechnology applications, and medical applications. Although genome editing technologies such as designer zinc fingers, transcription activator-like effectors (TALEs), or homing meganucleases are available for generating targeted genome interferences, new genome engineering technologies that are affordable, easy to establish, scalable, and convenient for targeting multiple locations within the eukaryotic genome are still needed. SUMMARY OF THE INVENTION

[0010] CRISPR / Cas or CRISPR-Cas systems (both terms are used interchangeably throughout this application) do not require the production of custom proteins targeting specific sequences, but rather a single Cas enzyme can be programmed to recognize a specific DNA target through a short RNA molecule, in other words, the Cas enzyme can be recruited to a specific DNA target using the short RNA molecule. Adding the CRISPR-Cas system to the repertoire of genome sequencing technologies and analytical methods can significantly simplify the methodology and improve the ability to catalog and map genetic factors associated with a wide range of biological functions and diseases. In order to effectively and without deleterious effects utilize the CRISPR-Cas system for genome editing, it is critical to understand the engineering and optimization aspects of these genome engineering tools, which are aspects of the present invention for which protection is sought.

[0011] Therefore, there is an urgent need for alternative robust systems and techniques for sequence targeting for a wide range of applications. Various aspects of the present invention address this need and provide related advantages. An exemplary CRISPR complex includes a CRISPR enzyme compounded with a guide sequence hybridized to a target sequence within a target polynucleotide, wherein the CRISPR enzyme is a Cas ortholog of a genus including but not limited to Corynebacterium, Sutterella, Legionella, Treponema, Mycobacterium, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma, and Campylobacter. The guide sequence is linked to a tracr mate sequence, which in turn hybridizes to a tracr sequence.

[0012] In one aspect, the present invention provides methods for using one or more elements of a CRISPR system. The CRISPR complex of the present invention provides an effective means for modifying a target polynucleotide. The CRISPR complex of the present invention has a variety of practicalities, including modifying (e.g., deleting, inserting, translocating, inactivating, activating, suppressing, changing methylation, transferring a specific part) a target polynucleotide in a variety of cell types. Because of this, the CRISPR complex of the present invention has a broad spectrum of applications in, for example, gene or genome editing, gene regulation, gene therapy, drug discovery, drug screening, disease diagnosis, and prognosis. In preferred aspects of the invention, the CRISPR complex comprises a Cas enzyme, preferably a Cas9 ortholog of a genus including but not limited to Corynebacterium, Sutterella, Legionella, Treponema, Mycobacterium, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Bacteroides, Flaviivola, Flavobacter, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma and Campylobacter.

[0013] Aspects of the invention relate to CRISPR enzymes with optimized functionality. As for CRISPR enzymes that are Cas enzymes, preferred embodiments of the invention relate to Cas9 orthologs with improved target specificity in a CRISPR-Cas9 system. This can be achieved by approaches including, but not limited to, designing and preparing guide RNAs with optimal activity, selecting a Cas9 enzyme with a specific length, truncating the Cas9 enzyme so that it is smaller in length than the corresponding wild-type Cas9 enzyme by truncation of the nucleic acid molecule encoding it, and generating chimeric Cas9 enzymes in which different parts of the enzyme are swapped or exchanged between different orthologs to obtain a chimeric enzyme with customized specificity. Aspects of the invention also relate to methods for improving the target specificity of a Cas9 ortholog enzyme or designing a CRISPR-Cas9 system, comprising designing or preparing a guide RNA with optimized activity and / or selecting or preparing a Cas9 ortholog enzyme having a smaller size or length than the corresponding wild-type Cas9, thereby packaging the nucleic acid encoding it into an advanced delivery vector (because its coding sequence is less in the delivery vector than the corresponding wild-type Cas9), and / or generating a chimeric Cas9 enzyme.

[0014] Also provided are uses of the sequences, vectors, enzymes or systems of the invention in medicine. Also provided are uses of them in gene or genome editing. Also provided are uses of them in the manufacture of a medicament for gene or genome editing, such as treatment by gene or genome editing. Also provided are sequences, vectors, enzymes or systems of the invention for use in therapy.

[0015] In another aspect of the invention, a CRISPR enzyme, such as a Cas9 enzyme, may comprise one or more mutations and may be used as a universal DNA binding protein with or without being fused to a functional domain or operably connected thereto. The mutation may be an artificially introduced mutation and may include, but is not limited to, one or more mutations in the catalytic domain. Examples of the catalytic domain of the Cas9 enzyme may include, but are not limited to, RuvC I, RuvC II, RuvC III, and HNH domains. Preferred examples of suitable mutations are one or more catalytic residues in the N-terminal RuvC I domain of Cas9 or one or more catalytic residues in the internal HNH domain. In some embodiments, the Cas9 is (or is derived from) Streptococcus pyogenes Cas9 (SpCas9). In such embodiments, Preferred mutations are at any or all of 10, 762, 840, 854, 863, and / or 986 positions of SpCas9 or at corresponding positions of position numbers of other Cas9 orthologs with respect to SpCas9 (which may be determined, for example, by standard sequence comparison tools, such as ClustalW or MegAlign of the Lasergene 10 suite). Specifically, any or all of the following mutations in SpCas9 are preferred: D10A, E762A, H840A, N854A, N863A and / or D986A; and conservative substitutions of any of these replacement amino acids are also contemplated. The same mutations (or conservative substitutions of these mutations) at corresponding positions with respect to the position numbering of SpCas9 in other Cas9 orthologs are also preferred. Particularly preferred are D10 and H840 in SpCas9. However, in other Cas9s, residues corresponding to SpCas9 D10 and H840 are also preferred. These are advantageous when mutated alone, they provide nickase activity and when two mutations are present, the Cas9 is converted into a catalytically ineffective mutant useful for general DNA binding. Other mutations have been identified and characterized. Other aspects of the invention relate to mutant Cas 9 enzymes fused to or operably linked to domains including, but not limited to, transcriptional activators, transcriptional repressors, recombinases, transposases, histone remodelers, DNA methyltransferases, cryptochromes, light-inducible / controllable domains, or chemically-inducible / controllable domains.

[0016] Another aspect of the present invention provides chimeric Cas9 proteins and methods for producing chimeric Cas9 proteins. Chimeric Cas9 proteins are proteins including the following fragments, which originate from different Cas9 orthologs. For example, the N-terminus of a first Cas9 ortholog can be fused to the C-terminus of a second Cas9 ortholog to produce a generated Cas9 chimeric protein. Compared to the original specificity or efficiency of any one of the individual Cas9 enzymes (the chimeric protein is produced from it), these chimeric Cas9 proteins may have higher specificity or higher efficiency. These chimeric proteins may also include one or more mutations or may be connected to one or more functional domains. Therefore, aspects of the present invention relate to a chimeric Cas enzyme, wherein the enzyme includes one or more fragments from a first Cas ortholog and one or more fragments from a second Cas ortholog. In one embodiment of the present invention, one or more fragments of the first Cas ortholog or the second Cas ortholog are C-terminal or N-terminal from the first Cas ortholog or the second Cas ortholog. In another embodiment, the first Cas ortholog or the second Cas ortholog is selected from a genus belonging to the following group, the group consisting of: Corynebacterium, Sutterella, Legionella, Treponema, Mycobacterium, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma and Campylobacter.

[0017] In another embodiment, the present invention provides methods for generating mutant components of a CRISPR complex comprising a Cas enzyme (e.g., a Cas9 ortholog). These mutant components may include, but are not limited to, mutant tracrRNAs and tracr matching sequences or mutant chimeric guide sequences that allow for enhanced performance of these RNAs in cells. Also provided is the use of a composition or enzyme of the present invention in the preparation of a drug for modifying a target sequence.

[0018] In yet another aspect, the present invention provides compositions and methods involving a non-naturally occurring or engineered composition comprising:

[0019] A)-I. A CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises:

[0020] (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell,

[0021] (b) a tracr mate sequence, and

[0022] (c) a tracr sequence, and

[0023] II. a polynucleotide sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences,

[0024] Among them, (a), (b) and (c) are arranged in the 5' to 3' direction.

[0025] wherein upon transcription, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of the CRISPR complex to the target sequence, and

[0026] wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) a guide sequence hybridized to the target sequence, and (2) a tracr mate sequence hybridized to the tracr sequence, and the polynucleotide sequence encoding the CRISPR enzyme is DNA or RNA,

[0027] or

[0028] (B) I. A polynucleotide comprising:

[0029] (a) a guide sequence capable of hybridizing to a target sequence in a prokaryotic cell, and

[0030] (b) at least one or more tracr mate sequences,

[0031] II. A polynucleotide sequence encoding a CRISPR enzyme, and

[0032] III. A polynucleotide sequence comprising a tracr sequence

[0033] wherein upon transcription, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of the CRISPR complex to the target sequence, and

[0034] wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) a guide sequence hybridized to the target sequence, and (2) a tracr mate sequence hybridized to the tracr sequence, and the polynucleotide sequence encoding the CRISPR enzyme is DNA or RNA, and

[0035] wherein the CRISPR enzyme is a Cas9 ortholog of a genus belonging to the following group, the group consisting of: Corynebacterium, Sutterella, Legionella, Treponema, Mycobacterium, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma and Campylobacter.

[0036] The present invention provides in yet another aspect: (A) a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising:

[0037] I. A first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, (b) a tracr mate sequence, and (c) a tracr sequence, and II. A second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences, wherein (a), (b) and (c) are arranged in a 5' to 3' orientation, wherein components I and II are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence hybridized to the target sequence, and (2) the tracr mate sequence hybridized to the tracr sequence, wherein the CRISPR enzyme is a Cas9 belonging to a genus of the following group orthologs of the genera Corynebacterium, Sutterella, Legionella, Treponema, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma, and Campylobacter, or (B) a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising I. a first regulatory element operably linked to (a) a guide sequence capable of hybridizing to a target sequence in a prokaryotic cell, and (b) at least one or more tracr mate sequences, II. a second regulatory element operably linked to an enzyme coding sequence encoding a CRISPR enzyme, and III.a third regulatory element operably linked to a tracr sequence, wherein components I, II and III are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) the guide sequence hybridized to the target sequence, and (2) the tracr mate sequence hybridized to the tracr sequence, wherein the CRISPR enzyme is a Cas9 ortholog belonging to a genus belonging to the following group, the group consisting of: Corynebacterium, Sutterella, Legionella, Treponema, Mycobacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma, and Campylobacter, and wherein: at least one of the following criteria applies.

[0038] These criteria are as follows and it is understood that any number of these may apply, preferably 1 or more, preferably 2 or more, and preferably 3 or more, 4 or more, or 5 or more, or all may apply:

[0039] - the CRISPR enzyme has a specific size selected and has a length of at least 500 amino acids, at least 800-899 amino acids, at least 900-999 amino acids, at least 1000-1099 amino acids, at least 1100-1199 amino acids, at least 1200-1299 amino acids, at least 1300-1399 amino acids, at least 1400-1499 amino acids, at least 1500-1599 amino acids, at least 1600-1699 amino acids or at least 2000 amino acids;

[0040] - and / or the CRISPR enzyme is truncated compared to a corresponding wild-type CRISPR enzyme;

[0041] - and / or the CRISPR enzyme is a nuclease that directs cleavage of both strands at the location of the target sequence, or the CRISPR enzyme is a nickase that directs cleavage of one strand at the location of the target sequence;

[0042] - and / or the guide sequence comprises at least 10, at least 15 or at least 20 nucleotides;

[0043] - and / or the CRISPR enzyme is codon-optimized or codon-optimized for expression in eukaryotic cells;

[0044] - and / or the CRISPR enzyme comprises one or more mutations;

[0045] - and / or the CRISPR enzyme comprises a chimeric CRISPR enzyme;

[0046] -and / or the CRISPR enzyme has one or more other properties discussed herein.

[0047] In some embodiments, the CRISPR enzyme is truncated compared to a wild-type CRISPR enzyme or the CRISPR enzyme consists of at least 500 amino acids, at least 800-899 amino acids, at least 900-999 amino acids, at least 1000-1099 amino acids, at least 1100-1199 amino acids, at least 1200-1299 amino acids, at least 1300-1399 amino acids, at least 1400-1499 amino acids, at least 1500-1599 amino acids, at least 1600-1699 amino acids or at least 2000 amino acids. In preferred embodiments, the CRISPR enzyme is a Cas enzyme, such as a Cas9 ortholog.

[0048] In some embodiments, the CRISPR enzyme is a nuclease that directs cleavage of both strands at the location of the target sequence, or the CRISPR enzyme is a nickase that directs cleavage of one strand at the location of the target sequence. In further embodiments, the CRISPR enzyme is a catalytically null mutant that is a universal DNA binding protein. In preferred embodiments, the CRISPR enzyme is a Cas enzyme, such as a Cas9 ortholog.

[0049] In some embodiments, the guide sequence comprises at least fifteen nucleotides. In some embodiments, the CRISPR enzyme is codon-optimized or codon-optimized for expression in a eukaryotic cell. In some embodiments, the CRISPR enzyme comprises one or more mutations. In some embodiments, the CRISPR enzyme comprises a chimeric CRISPR enzyme. In some embodiments, the CRISPR enzyme has one or more other properties discussed herein. In a preferred embodiment, the CRISPR enzyme is a Cas enzyme, such as a Cas9 ortholog.

[0050] In certain embodiments, the CRISPR enzyme comprises one or more mutations. The one or more mutations may be in a specific domain of the enzyme. In a preferred embodiment, the one or more mutations may be in a catalytic domain. In another preferred embodiment, the catalytic domain is a RuvC I, RuvC II, RuvC III, or HNH domain. In a more preferred embodiment, the one or more mutations are in the RuvC1 or HNH domain of the CRISPR enzyme. In another preferred embodiment, the CRISPR enzyme is a Cas enzyme, such as a Cas9 ortholog, and the mutation may be in one or more positions including, but not limited to, positions corresponding to D10A, E762A, H840A, N854A, N863A, or D986A with respect to position numbering of SpCas9, and / or a mutation as otherwise discussed herein. In some embodiments, the CRISPR enzyme has one or more mutations in a specific domain of the enzyme, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence, and the guide sequence directs sequence-specific binding of the CRISPR complex to the target sequence, and wherein the enzyme further comprises a functional domain. The functional domain may include, but is not limited to, a transcriptional activator, a transcriptional repressor, a recombinase, a transposase, a histone remodeler, a DNA methyltransferase, a cryptochrome, a light-inducible / controllable domain, or a chemically-inducible / controllable domain.

[0051] In some embodiments, the functional domain is a transcriptional activator domain VP64. In some embodiments, the functional domain is a transcriptional repressor domain KRAB. In some embodiments, the transcriptional repressor domain is SID or a concatemer of SID (i.e. SID4X). In some embodiments, an epigenetic modification enzyme is provided, such as a histone modification protein or an epigenetic chromatin modification protein. In some embodiments, an activator domain is provided, which can be a P65 activator domain.

[0052] Another aspect of the invention includes a method for modifying two or more genomic loci of interest. In a preferred embodiment of the invention, two or more genomic loci are differentially regulated by utilizing one or more CRISPR enzymes (e.g., two or more Cas9 orthologs, each ortholog operably linked to one or more functional domains). In one aspect, the invention provides a method for modifying two or more genomic loci in a eukaryotic cell. Therefore, aspects of the invention provide a method for regulating the expression of two or more genomic loci of interest in an organism, the method comprising delivering a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors, the one or more vectors comprising

[0053] I. A first regulatory element operably linked to a first CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the first polynucleotide sequence comprises:

[0054] (i) a first guide sequence capable of hybridizing to a first target sequence at a first genomic locus in a cell of the organism,

[0055] (ii) a first tracr mate sequence, and

[0056] (iii) a first tracr sequence, and

[0057] II. A second regulatory element operably linked to a second CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the second polynucleotide sequence comprises

[0058] (i) a second guide sequence capable of hybridizing to a second target sequence at a second genomic locus in a cell of the organism,

[0059] (ii) a second tracr mate sequence, and

[0060] (iii) a second tracr sequence, and

[0061] III. a third regulatory element operably linked to an enzyme coding sequence encoding a first CRISPR enzyme comprising at least one or more nuclear localization sequences and operably linked to a first functional domain,

[0062] IV. A fourth regulatory element operably linked to an enzyme coding sequence encoding a second CRISPR enzyme comprising at least one or more nuclear localization sequences and operably linked to a second functional domain, wherein (i), (ii) and (iii) of I and II are arranged in a 5' to 3' direction, wherein components I, II, III and IV are located on the same or different vectors of the system, wherein when transcribed, each tracr mate sequence hybridizes to its corresponding tracr sequence, and the first guide sequence and the second guide sequence direct sequence-specific binding of the first and second CRISPR complexes to the first and second target sequences, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, and wherein expression of the CRISPR enzyme provides for manipulation of the target sequence, wherein the first and second CRISPR enzymes each comprise two or more mutations, wherein the first and second CRISPR The enzyme is a Cas9 ortholog of a genus belonging to the following group, and the group is composed of the following items: Corynebacterium, Sutterella, Legionella, Treponema, Linebacterium, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Micrococcus, Staphylococcus, Nitratifractor, Mycoplasma and Campylobacter, and wherein the first genomic locus is regulated by the activity of the first functional domain, and the second genomic locus is regulated by the activity of the second functional domain. In another embodiment, the first functional domain is selected from the group consisting of the following items: transcriptional activators, transcriptional repressors, recombinases, transposases, histone remodeling agents, DNA methyltransferases, cryptochromes, and light-inducible / controllable domains or chemically inducible / controllable domains. In another embodiment, the second functional domain is selected from the group consisting of a transcriptional activator, a transcriptional repressor, a recombinase, a transposase, a histone remodeler, a DNA methyltransferase, a cryptochrome, and a light-inducible / controllable domain or a chemically-inducible / controllable domain.In a preferred embodiment, the first CRISPR enzyme or the second CRISPR enzyme is Sutterella wadsworthii Cas9, Filifactor alocis Cas9, Lactobacillus johnsonii Cas9, Campylobacter gullus Cas9, Corynebacterium diphtheriae Cas9, Parvibaculum lavamentivorans Cas9, Mycoplasma gallisepticum Cas9, Staphylococcus aureus subsp. aureus Cas9, Legionella pneumophila Cas9, Treponema denticola Cas9, Staphylococcus pseudintermedius Cas9, Neisseria griseus Cas9.

[0063] In some embodiments, the CRISPR enzyme is a type I, type II or type III CRISPR enzyme, preferably a type II CRISPR enzyme. This type II CRISPR enzyme can be any Cas enzyme. A Cas enzyme can be identified as Cas9, as this can refer to the general class of enzymes that share homology with the largest nuclease with multiple nuclease domains from a type II CRISPR system. Most preferably, the Cas9 enzyme is from or derived from SpCas9 or Staphylococcus aureus subspecies aureus SaCas9. With respect to derivatives, it is meant that the derived enzyme is largely based on the meaning of having a high sequence homology with the wild-type enzyme, but it has been mutated (modified) in some aspects as described herein.

[0064] It should be understood that the terms Cas and CRISPR enzymes are generally used interchangeably herein, unless otherwise specified. As mentioned above, many of the residue numbers used in this article refer to the Cas9 enzyme from the type II CRISPR site in Streptococcus pyogenes. However, it should be understood that the present invention includes more Cas9s from other microbial species, such as those belonging to the following genus, Corynebacterium, Sutterella, Legionella, Treponema, Linebacterium, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Microbacillum, Staphylococcus, Nitratifractor, Mycoplasma or Campylobacter, such as SpCas9, SaCas9, St1Cas9, St3Cas9, etc., wherein St is Streptococcus thermophilus.

[0065] Examples of codon optimized sequences that are optimized for humans (i.e., optimized for expression in humans) are provided herein, see SaCas9 human codon optimized sequence. While this is optimized, it should be understood that other examples are possible and codon optimization for host species is known.

[0066] Other aspects of the invention relate to improved cleavage specificity, optimized tracr sequences, optimized chimeric guide RNAs, co-folded structures of tracrRNA and tracr pairing sequences, stabilized secondary structures of tracr RNAs, tracrRNAs with shortened base pairing regions, tracrRNAs with fused RNA elements, simplified cloning and delivery, reduced toxicity and / or inducible systems. Another aspect of the invention relates to stabilization of chimeric RNA and / or guide sequences and or a portion thereof of CRISPR complexes, wherein the CRISPR enzyme is a CRISPR ortholog, wherein the chimeric RNA and / or guide sequence and or a portion thereof is stabilized by synthetic or chemically modified nucleotides (e.g., LNA / BNA: thiol modification, 2' / 3'-OH cross-link modification), modified to become resistant to degradation / hydrolysis, and to which elements of structural stability have been added.

[0067] The present invention further includes, in certain embodiments, a method of modifying an organism or non-human organism by manipulating a target sequence in a genomic locus of interest, the method comprising delivering a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors, the one or more vectors operably encoding the composition discussed herein for expression of the composition. Preferably, the vector can be a viral vector, such as a lentiviral or baculoviral or preferably an adenoviral / adeno-associated viral vector, but other delivery means are also known (such as yeast systems, microvesicles, gene guns / means of attaching vectors to gold nanoparticles) and are provided.

[0068] Various means of delivery are described herein and discussed further in this section.

[0069] Virus delivery:The CRISPR enzyme, such as Cas9, and / or any RNA of the present invention, such as a guide RNA, can be delivered using adeno-associated virus (AAV), lentivirus, adenovirus or other viral vector types, or a combination thereof. Cas9 and one or more guide RNAs can be packaged into one or more viral vectors. In some embodiments, the viral vector can be delivered to the tissue of interest, for example, by intramuscular injection, and sometimes the virus is delivered via intravenous, transdermal, intranasal, oral, mucosal, or other delivery methods. Such delivery can be carried out via a single dose or multiple doses. It is understood by those skilled in the art that the actual dose to be delivered herein may vary to a large extent depending on a variety of factors, such as vector selection, target cells, organisms, or tissues, the general condition of the subject to be treated, the degree of transformation / modification sought, the route of administration, the mode of administration, the type of transformation / modification sought, and the like.

[0070] Such a dose may further contain, for example, a carrier (water, saline, ethanol, glycerol, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, etc.), a diluent, a pharmaceutically acceptable carrier (e.g., phosphate buffered saline), a pharmaceutically acceptable excipient, an adjuvant to enhance antigenicity, an immunostimulatory compound or molecule, and / or other compounds known in the art. The adjuvant herein may contain a suspension of a mineral (alum, aluminum hydroxide, aluminum phosphate) to which the antigen is adsorbed; or an oil-in-water emulsion in which the antigen solution is emulsified in oil (MF-59, Freund's incomplete adjuvant), sometimes containing killed mycobacteria (Freund's complete adjuvant) to further enhance antigenicity (inhibit degradation of the antigen and / or cause migration of macrophages). Adjuvants also include immunostimulatory molecules, such as cytokines, costimulatory molecules, for example, immunostimulatory DNA or RNA molecules, such as CpG oligonucleotides. Such a dosage formulation can be easily determined by those skilled in the art. The dosage form may further contain one or more pharmaceutically acceptable salts, such as, for example, inorganic acid salts such as hydrochloride, hydrobromide, phosphate, sulfate, etc.; and organic acid salts such as acetate, propionate, malonate, benzoate, etc. In addition, auxiliary substances such as wetting agents or emulsifiers, pH buffer substances, gel or gelling materials, flavoring agents, coloring agents, microspheres, polymers, suspending agents, etc. may also be present. In addition, one or more other conventional pharmaceutical ingredients such as preservatives, humectants, suspending agents, surfactants, antioxidants, anticaking agents, fillers, chelating agents, coating agents, chemical stabilizers, etc. may also be present, especially when the dosage form is a reconstituted form. Suitable exemplary ingredients include microcrystalline cellulose, sodium carboxymethyl cellulose, polysorbate 80, phenylethyl alcohol, chlorobutanol, potassium sorbate, ascorbic acid, sulfur dioxide, propyl gallate, parabens, ethyl vanillin, glycerol, phenol, parachlorophenol, gelatin, albumin, and combinations thereof. A thorough discussion of pharmaceutically acceptable excipients is available in REMINGTON'S PHARMACEUTICAL SCIENCES (Mack Publishing Co., New York, 1991), which is incorporated herein by reference.

[0071] In one embodiment herein, delivery is via an adenovirus, which may contain at least 1×10 5 A single booster dose of at least about 1×10 adenoviral vector particles (also referred to as particle units, pu). In one embodiment herein, the dose is preferably at least about 1×10 6 particles (e.g., about 1×10 6 -1×10 12 particles), more preferably at least about 1×10 7 particles, more preferably at least about 1×108 particles (e.g., about 1×10 8 -1×10 11 particles or about 1×10 8 -1×10 12 particles), and most preferably at least about 1×10 0 particles (e.g., about 1*×10 9 -1×10 10 particles or about 1×10 9 -1×10 12 particles), or even at least about 1×10 10 particles (e.g., about 1×10 10 -1×10 12 particles). Alternatively, the dose comprises no more than about 1×10 14 particles, preferably no more than about 1×10 13 particles, even more preferably no more than about 1 × 10 12 particles, even more preferably no more than about 1×10 11 particles, and most preferably no more than about 1×10 10 particles (e.g., no more than about 1×10 9 particles). Thus, the dose may contain a single dose of adenoviral vector having, for example, about 1×10 6 Particle unit (pu), about 2×10 6 pu, about 4×10 6 pu, about 1×10 7 pu, about 2×10 7 pu, about 4×10 7 pu, about 1×10 8 pu, about 2×10 8 pu, about 4×10 8 pu, about 1×10 9 pu, about 2×10 9 pu, about 4×10 9 pu, about 1×10 10 pu, about 2×10 10 pu, about 4×10 10 pu, about 1×10 11 pu, about 2×10 11 pu, about 4×10 11 pu, about 1×10 12 pu, about 2×10 12 pu, or about 4×10 12See, e.g., the adenoviral vectors in U.S. Pat. No. 8,454,972 B2 to Nabel et al., issued Jun. 4, 2013 (incorporated herein by reference) and the dosage forms at column 29, lines 36-58 thereof. In one embodiment herein, the adenovirus is delivered via multiple doses.

[0072] In one embodiment herein, the delivery is via AAV. A therapeutically effective dose for in vivo delivery of AAV to humans is believed to be in the range of about 1×10 10 To about 1×10 10 The dosage ranges from about 20 to about 50 ml of saline solution per functional AAV / ml solution. The dosage can be adjusted to balance the therapeutic benefit against any side effects. In one embodiment herein, the AAV dosage ranges from about 1×10 5 to 1×10 50 AAV genomes, from about 1×10 8 to 1×10 20 AAV genomes, from about 1×10 10 To about 1×10 16 genomes, or about 1×10 11 To about 1×10 16 AAV genome concentrations are in the range of 1 × 10 13 The invention relates to a method for delivering a humanized human leukemia virus (HAV) to a human leukemia virus (HAV) comprising at least one genome of the human leukemia virus (HAV). Such concentrations can be delivered in a carrier solution of from about 0.001 ml to about 100 ml, from about 0.05 to about 50 ml, or from about 10 to about 25 ml. Other effective doses can be readily established by one of ordinary skill in the art through routine experimentation to establish dose response curves. See, e.g., U.S. Pat. No. 8,404,658 B2 to Hajjar et al., issued March 26, 2013, at column 27, lines 45-60.

[0073] In one embodiment herein, the delivery is carried out via a plasmid. In such a plasmid composition, the dosage should be an amount of the plasmid sufficient to elicit a response. For example, an appropriate amount of the plasmid DNA in the plasmid composition can be from about 0.1 to about 2 mg, or from about 1 μg to about 10 μg.

[0074] The dosages herein are based on an average 70 kg individual. The frequency of dosing is within the scope of the medical or veterinary practitioner (eg, physician, veterinarian) or scientist skilled in the art.

[0075] The viral vector can be injected into the tissue of interest. For cell type specific genome modification, the expression of Cas9 can be driven by a cell type specific promoter. For example, liver specific expression can use the albumin promoter, while neuron specific expression can use the synapsin I promoter.

[0076] RNA delivery: The CRISPR enzyme, such as Cas9, and / or any RNA of the present invention, such as a guide RNA, can also be delivered in the form of RNA. Cas9 mRNA can be produced using in vitro transcription. For example, a PCR box containing the following elements can be used to synthesize Cas9 mRNA: T7_promoter-kozak sequence (GCCACC)-Cas9-3'UTR from β-globin-polyA tail (a string of 120 or more adenines). The box can be used for transcription via T7 polymerase. Guide RNA can also be transcribed from a box containing a T7_promoter-GG-guide RNA sequence using in vitro transcription.

[0077] To enhance expression and reduce toxicity, the CRISPR enzyme and / or guide RNA can be modified with pseudo-U or 5-methyl-C.

[0078] Nanoparticles or lipid envelopes can be used to deliver CRISPR enzyme mRNA and guide RNA simultaneously.

[0079] For example, Su X, Fricke J, Kavanagh DG, Irvine DJ ("In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles") Mol Pharm. 2011 Jun 6;8(3):774-87. doi:10.1021 / mp100390w. Epub 2011 Apr 1 describes biodegradable core-shell nanoparticles having a poly(β-amino ester) (PBAE) core encapsulated by a phospholipid bilayer shell. These were developed for in vivo mRNA delivery. The pH-responsive PBAE was selected to promote endosomal disruption, while the lipid surface layer was selected to minimize the toxicity of the polycationic core. Thus, these are preferred for delivery of the RNA of the invention.

[0080] In addition, Michael SD Kormann et al. ("Expression of therapeutic proteins after delivery of chemically modified mRNA in mice": Nature Biotechnology, Vol. 29, pp. 154-157, (2011) published online on January 9, 2011) describe the use of lipid envelopes for delivering RNA. The use of lipid envelopes is also preferred in the present invention.

[0081] mRNA delivery methods are particularly promising for current liver delivery.

[0082] CRISPR enzyme mRNA and guide RNA can also be delivered separately. CRISPR enzyme mRNA can be delivered before the guide RNA is given time to wait for CRISPR enzyme expression. CRISPR enzyme mRNA can be administered 1-12 hours (preferably about 2-6 hours) before the guide RNA is administered.

[0083] Alternatively, CRISPR enzyme mRNA and guide RNA can be administered together. Advantageously, a second booster dose of guide RNA can be administered 1-12 hours (preferably about 2-6 hours) after the initial administration of CRISPR enzyme mRNA + guide RNA.

[0084] To achieve the most efficient level of genome modification, additional administration of CRISPR enzyme mRNA and / or guide RNA may be useful.

[0085] In order to minimize toxicity and off-target effects, it is important to control the concentration of the delivered CRISPR enzyme mRNA and guide RNA. The optimal concentration of CRISPR enzyme mRNA and guide RNA can be determined by testing different concentrations in cells or animal models and using deep sequencing to analyze the range of modifications at potential off-target genomic loci. For example, for the guide sequence of 5'-GAGTCCGAGCAGAAGAAGAA-3' in the EMX1 gene targeting the human genome, deep sequencing can be used to assess the modification levels at the following two off-target sites, 1: 5'-GAGTCCTAGCAGGAGAAGAA-3' and 2: 5'-GAGTCTAAGCAGAAGAAGAA-3'. For in vivo delivery, the concentration that produces the highest on-target modification level while reducing the off-target modification level to a minimum should be selected.

[0086] Alternatively, in order to minimize toxicity levels and off-target effects, a pair of guide RNAs targeting sites of interest can be used to deliver CRISPR enzyme nickase mRNA (e.g., Streptococcus pyogenes Cas9 with D10A modification). The two guide RNAs need to be spaced apart as follows. Respectively in red (single underline) and blue (double underline) guide sequences (these examples are based on the PAM required by Streptococcus pyogenes Cas9).

[0087]

[0088]

[0089] Further interrogation of the system provided Applicants with evidence of a 5' overhang (see, e.g., Ran et al., Cell 2013 Sep 12; 154(6): 1380-9 and U.S. Provisional Patent Application Serial No. 61 / 871,301 filed Aug 28, 2013). Applicants further identified parameters related to efficient cleavage by Cas9 nickase mutants when combined with two guide RNAs, and these parameters include, but are not limited to, the length of the 5' overhang. In an embodiment of the invention, the 5' overhang has at most 200 base pairs, preferably at most 100 base pairs, or more preferably at most 50 base pairs. In an embodiment of the invention, the 5' overhang has at least 26 base pairs, preferably at least 30 base pairs, or more preferably 34-50 base pairs or 1-34 base pairs. In other preferred methods of the invention, the first guide sequence directing cleavage of one strand of the DNA duplex adjacent to the first target sequence and the second guide sequence directing cleavage of the other strand adjacent to the second target sequence produce a blunt cut or a 3' overhang. In embodiments of the invention, the 3' overhang has at most 150, 100 or 25 base pairs, or at least 15, 10 or 1 base pairs. In preferred embodiments, the 3' overhang has 1-100 base pairs.

[0090] Aspects of the present invention relate to the expression of a reduced gene product or a template polynucleotide further introduced into a DNA molecule encoding a gene product or an intervening sequence that is precisely cut off by allowing two 5' overhangs to reanneal and connect, or the activity or function of a changed gene product, or the expression of an increased gene product. In one embodiment of the present invention, the gene product is a protein.

[0091] Only sgRNA pairs that generated 5' overhangs with less than 8 bp overlap between these guide sequences (greater than -8 bp offset) mediated detectable insertion / deletion (indel) messages. Importantly, each guide used in these analyses was important for efficient induction of indels when paired with wild-type Cas9, indicating that the relative position of these guide pairs is the most important parameter in predicting double cleavage activity.

[0092] Since Cas9n and Cas9H840A cut opposite strands of DNA, for a given sgRNA pair, replacing Cas9n with Cas9H840A will result in a reversal of the overhang type. For example, a pair of sgRNAs that will produce a 5' overhang with Cas9n will in principle produce a corresponding 3' overhang instead. Therefore, the sgRNA pair that results in the production of a 3' overhang with Cas9n can be used with Cas9H840A to produce a 5' overhang. Unexpectedly, the applicant tested Cas9H840A using a set of sgRNA pairs designed to produce both 5' and 3' overhangs (offset range from –278 to +58bp), but indel information could not be observed. Further work may be needed to identify the necessary design rules for sgRNA pairing to allow double cutting via Cas9H840A.

[0093] Additional delivery options for the brain include encapsulating CRISPR enzymes and guide RNAs in the form of DNA or RNA into liposomes and conjugating to molecular Trojan horses for delivery across the blood-brain barrier (BBB). Molecular Trojan horses have been shown to be effective for delivering B-gal expression vectors to the brain of non-human primates. The same approach can be used to deliver delivery vectors containing CRISPR enzymes and guide RNAs. For example, Xia CF and Boado RJ, Pardridge WM "Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology." Mol Pharm. 2009 May-June; 6(3):747-51. doi:10.1021 / mp800194 describes how to deliver short interfering RNA (siRNA) to cells in culture and in vivo, and can be used in combination with receptor-specific monoclonal antibodies (mAbs) and avidin-biotin technology. The authors also report that, with avidin-biotin technology, RNAi effects at distant sites (e.g., brain) were observed in vivo after intravenous administration of the targeted siRNA, because the bond between the targeting mAb and the siRNA was stable.

[0094] Zhang Y, Schlachetzki F, Pardridge WM. ("Global non-viral gene transfer to the primate brain following intravenous administration." 2003 Jan;7(1):11-8.) describe how an expression plasmid encoding a reporter molecule such as luciferase is encapsulated inside an "artificial virus" containing 85 nm PEGylated immunoliposomes that are targeted to the rhesus monkey brain in vivo together with a monoclonal antibody (MAb) against the human insulin receptor (HIR). The HIRMab causes the liposomes carrying the foreign gene to undergo transcytosis across the blood-brain barrier and endocytosis across the neuronal plasma membrane after intravenous injection. The luciferase gene expression level in the brain of the rhesus monkey is 50 times higher than that of the rat. Widespread neuronal expression of the β-galactosidase gene in the primate brain was demonstrated by both histochemistry and confocal microscopy. The authors indicate that this approach enables reversible adult transgenesis within 24 hours. Therefore, the use of immunoliposomes is preferred. These can be combined with antibodies to target specific tissues or cell surface proteins.

[0095] Other delivery means or RNA are also preferred, such as via nanoparticles (Cho S., Goldberg M., Son S., Xu Q., Yang F., Mei Y., Bogatyrev S., Langer R., and Anderson D., "Lipid-like nanoparticles for small interfering RNA delivery to endothelial cells," Advanced Functional Materials, 19:3112-3118, 2010) or exosomes (Schroeder A., ​​Levins C., Cortez C., Langer R., and Anderson D., "Lipid-based nanotherapeutics for siRNA delivery" Nanotherapeutics for siRNA delivery, Journal of Internal Medicine, 267:9-21, 2010, PMID:20059641). In fact, exosomes have been shown to be particularly useful in delivering siRNA, a system that has some similarities to the CRISPR system. For example, El-Andaloussi et al. "Exosome-mediated delivery of siRNA in vitro and in vivo." Nat Protoc. 2012 Dec; 7(12):2112-26. doi:10.1038 / nprot.2012.131. The electronic version of November 15, 2012 describes that exosomes are promising tools for drug delivery across different biological barriers and can be used to deliver siRNA in vitro and in vivo. The approach consists in generating targeted exosomes by transfecting an expression vector containing an exosomal protein fused to a peptide ligand. These exosomes are then purified and characterized from the supernatant of transfected cells, and then siRNA is loaded into the exosomes.

[0096] One aspect of manipulating a target sequence also refers to epigenetic manipulation of the target sequence. This can be manipulation of the chromatin state of the target sequence, such as by modifying the methylation state of the target sequence (i.e., methylation or methylation pattern or addition or removal of CpG islands), histone modification, thereby increasing or decreasing the accessibility of the target sequence, or by promoting or reducing 3D folding.

[0097] A vector may refer not only to viral or yeast systems (for example, where the nucleic acid of interest may be operably linked to and under the control of a promoter (in terms of expression, thereby ultimately providing processed RNA)), but also directs delivery of the nucleic acid into a host cell.

[0098] The present invention, in certain embodiments, also comprises a method of treating or inhibiting a condition caused by a defect in a target sequence within a genomic locus of interest in a subject or non-human subject in need thereof, the method comprising correcting the subject or non-human subject by manipulating the target sequence, and wherein the condition is susceptible to treatment or inhibition by manipulation of the target sequence, the method comprising providing a treatment comprising: delivering a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors, the one or more vectors comprising a protein operably encoding a composition discussed herein for expression of the composition, wherein upon expression, the target sequence is manipulated by the composition.

[0099] In certain embodiments of the methods herein, the methods may include inducing expression, which may be inducing expression of the CRISPR enzyme and / or inducing expression of the guide sequence, tracr or tracr mate sequence. In certain embodiments of the methods herein, the organism or subject is a eukaryote or a non-human eukaryote. In certain embodiments of the methods herein, the organism or subject is a plant. In certain embodiments of the methods herein, the organism or subject is a mammal or a non-human mammal. In certain embodiments of the methods herein, the organism or subject is an algae.

[0100] Although the vector can be a viral vector in the methods herein and AAV is advantageous here, other viral vectors as discussed herein can be employed. For example, baculovirus can be used for expression in insect cells. These insect cells can in turn be used to produce large quantities of other vectors, such as AAV vectors suitable for delivery of the present invention.

[0101] Also contemplated is a method of delivering a CRISPR enzyme of the invention comprising delivering to a cell an mRNA encoding the CRISPR enzyme. It is understood that the CRISPR enzyme is truncated, has a specific size as described herein, is a nuclease or nickase or universal DNA binding protein, is codon optimized, comprises one or more mutations, and / or comprises a chimeric CRISPR enzyme, or other options as discussed herein.

[0102] Also contemplated is a method of preparing a vector for delivering a composition or CRISPR enzyme of the invention and for use in a method of the invention.

[0103] AAV viral vectors are preferred. Therefore, in another aspect, a method for preparing an AAV viral vector is provided, the method comprising transfecting one or more plasmids containing or consisting essentially of one or more nucleic acid molecules encoding AAV into cells infected with AAV, and providing AAV rep and / or cap necessary for the replication and packaging of AAV. In this regard, it should be understood that the CRISPR enzyme is truncated, consists of less than one thousand amino acids or less than four thousand amino acids, is a nuclease or nickase, is codon-optimized, contains one or more mutations, and / or contains a chimeric CRISPR enzyme, as discussed herein. In some embodiments, the AAV rep and / or cap necessary for the replication and packaging of AAV are provided by transfecting these cells with one or more helper plasmids or one or more helper viruses. In some embodiments, the helper virus is a poxvirus, an adenovirus, a herpes virus, or a baculovirus. In some embodiments, the poxvirus is a vaccinia virus. In some embodiments, these cells are mammalian cells. And in some embodiments, these cells are insect cells, and the helper virus is a baculovirus.

[0104] The present invention further comprises a modified CRISPR enzyme in certain embodiments. The differences from a wild-type CRISPR enzyme may include: the modified CRISPR enzyme is truncated compared to a wild-type CRISPR enzyme, or the CRISPR enzyme has a specific size, such as at least 500 amino acids, at least 800-899 amino acids, at least 900-999 amino acids, at least 1000-1099 amino acids, at least 1100-1199 amino acids, at least 1200-1299 amino acids, at least 1300-1399 amino acids, at least 1400-1499 amino acids, at least 1500-1599 amino acids, at least 1600-1699 amino acids or at least 2000 amino acids; and / or the CRISPR enzyme is a nuclease that directs cleavage of both strands at the location of the target sequence, or the CRISPR enzyme is a nickase that directs cleavage of one strand at the location of the target sequence, or the CRISPR enzyme is a catalytically ineffective mutant that functions as a DNA binding protein; and / or the CRISPR enzyme is codon-optimized or codon-optimized for expression in a eukaryotic cell, and / or the CRISPR enzyme comprises one or more mutations, and / or the CRISPR enzyme comprises a chimeric CRISPR enzyme, and / or the CRISPR enzyme has one or more other properties discussed herein. Thus, in certain embodiments, the CRISPR enzyme comprises one or more mutations in catalytic residues such as spCas9 D10A, E762A, H840A, N854A, N863A or D986A or those corresponding thereto with respect to position numbering of SpCas9 in other Cas enzymes (as described herein), and / or has one or more mutations in RuvC I, RuvC II, RuvC III, HNH or other domains described herein of the CRISPR enzyme, and / or the CRISPR enzyme has one or more mutations in the catalytic domain, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of the CRISPR complex to the target sequence, and wherein the enzyme further comprises a functional domain. The functional domain may include, but is not limited to, a transcriptional activator, a transcriptional repressor, a recombinase, a transposase, a histone remodeler, a DNA methyltransferase, a cryptochrome, a light-inducible / controllable domain or a chemically-inducible / controllable domain. In certain embodiments, the CRISPR enzyme may have a functional domain that is a transcriptional activator domain (e.g., VP64). In some embodiments, a transcriptional repressor domain is KRAB. In some embodiments, a transcriptional repressor domain is SID, or a concatemer of SIDs (i.e., SID4X).In some embodiments, an epigenetic modification enzyme is provided.

[0105] In preferred embodiments, the CRISPR enzyme is a Cas enzyme, such as a Cas9 ortholog.

[0106] Aspects of the invention also include identifying novel orthologs of CRISPR enzymes. Methods of identifying novel orthologs of CRISPR enzymes may involve identifying a tracr sequence in a genome of interest. Identifying a tracr sequence may involve the following steps: searching a database for these direct repeats or tracr mate sequences to identify a CRISPR region that includes a CRISPR enzyme, e.g. Fig.18 . Search for homologous sequences in the CRISPR region flanking the CRISPR enzyme in both sense and antisense directions. Look for transcription terminators and secondary structures. Identify as a possible tracr sequence any sequence that is not a direct repeat or a tracr mate sequence but has more than 50% identity to a direct repeat of a tracr mate sequence. Take the possible tracr sequence and analyze its associated transcription terminator sequence.

[0107] The present invention in certain embodiments comprises the use of a composition or a CRISPR enzyme as described herein in medicine. The present invention in certain embodiments further comprises a composition or a CRISPR enzyme of the present invention used in a method of the present invention. The present invention also in certain embodiments comprises the use of a composition or a CRISPR enzyme of the present invention in preferably ex vivo gene or genome editing, or preferably an ex vivo gene or genome editing method. Thus the present invention also in certain embodiments comprises the use of a composition or a CRISPR enzyme of the present invention in the manufacture of a medicament for ex vivo gene or genome editing or for use in a method as discussed herein.

[0108] In addition, the present invention in certain embodiments comprises a composition or a CRISPR enzyme of the present invention, wherein the target sequence is flanked or downstream at its 3' end by a PAM suitable for a CRISPR enzyme (typically Cas, and particularly Cas9). This PAM sequence is specific for each Cas9 but can be easily determined by the methods described herein.

[0109] For example, a suitable PAM is 5'-NRG or 5'-NNGRR for SpCas9 or SaCas9 enzymes (or derived enzymes), respectively. It should be understood that references to S. aureus herein preferably include S. aureus subsp. aureus.

[0110] It is therefore an object of the present invention that any previously known product, process for making the product, or method for using the product is not covered in the present invention, such that the applicant reserves and hereby publicly disclaims the right to any previously known product, process, or method. It is further noted that within the scope of the present invention, the present invention is not intended to cover any product, process, or method for making the product or using the product that does not meet the written description and enforceability requirements of the USPTO (35 U.S.C. §112, first paragraph) or the EPO (Article 83 of the EPC), such that the applicant reserves and hereby publicly disclaims the right to any previously described product, process for making the product, or method for using the product.

[0111] It should be noted that in this disclosure, especially in the claims and / or paragraphs, terms such as "comprises," "comprised," "comprising," and the like may have the meanings ascribed to them in U.S. patent law; for example, they may mean "includes," "included," "including," and the like; and that terms such as "consisting essentially of" and "consists essentially of" have the meanings ascribed to them in U.S. patent law, for example, they allow for elements not expressly recited, but exclude elements that are found in the prior art or that affect the basic or novel characteristics of the invention.

[0112] These and other embodiments are disclosed in, or are apparent from and encompassed by, the following detailed description.

[0113] The present invention also relates to the following items:

[0114] 1. (A) A non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising

[0115] I. A first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises

[0116] (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell,

[0117] (b) a tracr mate sequence, and

[0118] (c) a tracr sequence, and

[0119] II. a second regulatory element operably linked to an enzyme coding sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences,

[0120] Among them, (a), (b) and (c) are arranged in the 5' to 3' direction.

[0121] wherein components I and II are located on the same or different carriers of the system,

[0122] wherein upon transcription, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of the CRISPR complex to the target sequence, and

[0123] wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) a guide sequence hybridized to the target sequence, and (2) a tracr mate sequence hybridized to the tracr sequence,

[0124] or

[0125] (B) a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising:

[0126] I. A first regulating element, the first regulating element is operably connected to

[0127] (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, and

[0128] (b) at least one or more tracr mate sequences,

[0129] II. a second regulatory element operably linked to an enzyme coding sequence encoding a CRISPR enzyme, and

[0130] III. a third regulatory element operably linked to a tracr sequence,

[0131] wherein components I, II and III are located on the same or different vectors of the system,

[0132] wherein upon transcription, the tracr mate sequence hybridizes to the tracr sequence, and the guide sequence directs sequence-specific binding of the CRISPR complex to the target sequence,

[0133] wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) a guide sequence hybridized to the target sequence, and (2) a tracr mate sequence hybridized to the tracr sequence, and

[0134] wherein in (A) or (B), the CRISPR enzyme is a Cas9 ortholog of a genus belonging to the following group, the group consisting of: Corynebacterium, Sutterella, Legionella, Treponema, Mycobacterium, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibacillum, Staphylococcus, Nitratifractor, Mycoplasma and Campylobacter.

[0135] 2. A modified CRISPR enzyme, wherein the enzyme is a Cas9 ortholog of a genus belonging to the following group, the group consisting of: Corynebacterium, Sutterella, Legionella, Treponema, Mycobacterium, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibacillum, Staphylococcus, Nitratifractor, Mycoplasma, and Campylobacter, and wherein the differences from the corresponding wild-type CRISPR enzyme include:

[0136] The modified CRISPR enzyme is truncated compared to a wild-type CRISPR enzyme, or

[0137] The CRISPR enzyme has a length of at least 500 amino acids, at least 800-899 amino acids, at least 900-999 amino acids, at least 1000-1099 amino acids, at least 1100-1199 amino acids, at least 1200-1299 amino acids, at least 1300-1399 amino acids, at least 1400-1499 amino acids, at least 1500-1599 amino acids, at least 1600-1699 amino acids or at least 2000 amino acids, and / or

[0138] The CRISPR enzyme is a nuclease that directs cleavage of both strands at the location of the target sequence, or the CRISPR enzyme is a nickase that directs cleavage of one strand at the location of the target sequence, and / or

[0139] The CRISPR enzyme is codon-optimized or codon-optimized for expression in eukaryotic cells, and / or

[0140] The CRISPR enzyme comprises one or more mutations, and / or

[0141] The CRISPR enzyme includes a chimeric CRISPR enzyme.

[0142] 3. The composition of claim 1, or the enzyme of claim 2, wherein the CRISPR enzyme has one or more mutations in any domain of the enzyme.

[0143] 4. The composition or enzyme of any preceding item, wherein the CRISPR enzyme has one or more mutations in a catalytic domain.

[0144] 5. The composition or enzyme of item 3 or 4, wherein the one or more mutations are in the RuvC I, RuvC II, RuvC III or HNH domain of the CRISPR enzyme.

[0145] 6. A composition or enzyme according to item 4 or 5, wherein the CRISPR enzyme comprises one or more mutations at position D10A, E762A, H840A, N854A, N863A or D986A corresponding to position numbering of SpCas9.

[0146] 7. The composition or enzyme according to any preceding item, wherein the enzyme further comprises a functional domain.

[0147] 8. The composition or enzyme according to item 7, wherein the functional domain is a transcription activator domain.

[0148] 9. The composition or enzyme according to item 8, wherein the transcription activator domain is VP64.

[0149] 10. The composition or enzyme according to items 7 to 9, wherein the functional domain is a transcription repressor domain.

[0150] 11. The composition or enzyme according to item 10, wherein the transcription repressor domain is KRAB, SID or SID4X.

[0151] 12. A method of modifying an organism or non-human organism by manipulating a target sequence in a genomic locus of interest, the method comprising:

[0152] Delivering a non-naturally occurring or engineered composition comprising a vector system operably encoding a composition as described in any of the preceding items for expression of the composition.

[0153] 13. The method of claim 12, wherein the delivery is performed via one or more viral vectors.

[0154] 14. A non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising

[0155] I. A first regulatory element operably linked to a first CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the first polynucleotide sequence comprises:

[0156] (i) a first guide sequence capable of hybridizing to a first target sequence at a first genomic locus in a cell of the organism,

[0157] (ii) a first tracr mate sequence, and

[0158] (iii) a first tracr sequence, and

[0159] II. A second regulatory element operably linked to a second CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the second polynucleotide sequence comprises

[0160] (i) a second guide sequence capable of hybridizing to a second target sequence at a second genomic locus in a cell of the organism,

[0161] (ii) a second tracr mate sequence, and

[0162] (iii) a second tracr sequence, and

[0163] III. a third regulatory element operably linked to an enzyme coding sequence encoding a first CRISPR enzyme comprising at least one or more nuclear localization sequences and operably linked to a first functional domain,

[0164] IV. a fourth regulatory element operably linked to an enzyme coding sequence encoding a second CRISPR enzyme comprising at least one or more nuclear localization sequences and operably linked to a second functional domain,

[0165] Wherein (i), (ii) and (iii) in I and II are arranged in the 5' to 3' direction,

[0166] wherein components I, II, III and IV are located on the same or different vectors of the system,

[0167] wherein upon transcription, each tracr mate sequence hybridizes to its corresponding tracr sequence, and the first guide sequence and the second guide sequence direct sequence-specific binding of the first and second CRISPR complexes to the first and second target sequences,

[0168] wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) a guide sequence that is hybridized to the target sequence, and (2) a tracr mate sequence that is hybridized to the tracr sequence, and wherein expression of the CRISPR enzyme provides for manipulation of the target sequence,

[0169] wherein the first CRISPR enzyme and the second CRISPR enzyme each comprise two or more mutations, and

[0170] wherein the first and second CRISPR enzymes are a Cas9 ortholog of a genus belonging to the following group, the group consisting of Corynebacterium, Sutterella, Legionella, Treponema, Mycobacterium, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibacillum, Staphylococcus, Nitratifractor, Mycoplasma and Campylobacter.

[0171] 15. A method of regulating the expression of two or more genomic loci of interest in an organism, the method comprising

[0172] Delivering a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising

[0173] I. A first regulatory element operably linked to a first CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the first polynucleotide sequence comprises:

[0174] (i) a first guide sequence capable of hybridizing to a first target sequence at a first genomic locus in a cell of the organism,

[0175] (ii) a first tracr mate sequence, and

[0176] (iii) a first tracr sequence, and

[0177] II. A second regulatory element operably linked to a second CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the second polynucleotide sequence comprises

[0178] (i) a second guide sequence capable of hybridizing to a second target sequence at a second genomic locus in a cell of the organism,

[0179] (ii) a second tracr mate sequence, and

[0180] (iii) a second tracr sequence, and

[0181] III. a third regulatory element operably linked to an enzyme coding sequence encoding a first CRISPR enzyme comprising at least one or more nuclear localization sequences and operably linked to a first functional domain,

[0182] IV. a fourth regulatory element operably linked to an enzyme coding sequence encoding a second CRISPR enzyme comprising at least one or more nuclear localization sequences and operably linked to a second functional domain,

[0183] Wherein (i), (ii) and (iii) in I and II are arranged in the 5' to 3' direction,

[0184] wherein components I, II, III and IV are located on the same or different vectors of the system,

[0185] wherein upon transcription, each tracr mate sequence hybridizes to its corresponding tracr sequence, and the first guide sequence and the second guide sequence direct sequence-specific binding of the first and second CRISPR complexes to the first and second target sequences,

[0186] wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) a guide sequence that is hybridized to the target sequence, and (2) a tracr mate sequence that is hybridized to the tracr sequence, and wherein expression of the CRISPR enzyme provides for manipulation of the target sequence,

[0187] wherein the first CRISPR enzyme and the second CRISPR enzyme each comprise two or more mutations,

[0188] wherein the first and second CRISPR enzymes are a Cas9 ortholog of a genus belonging to the following group, the group consisting of Corynebacterium, Sutterella, Legionella, Treponema, Mycobacterium, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibacillum, Staphylococcus, Nitratifractor, Mycoplasma and Campylobacter, and

[0189] wherein the first genomic locus is regulated by the activity of the first functional domain and the second genomic locus is regulated by the activity of the second functional domain.

[0190] 16. The composition according to item 14, or the method according to item 15, wherein the first functional domain is selected from the group consisting of a transcriptional activator, a transcriptional repressor, a recombinase, a transposase, a histone remodeler, a DNA methyltransferase, a cryptochrome, and a light-inducible / controllable domain or a chemically-inducible / controllable domain.

[0191] 17. The composition according to item 14 or 16, or the method according to item 15 or 16, wherein the second functional domain is selected from the group consisting of a transcriptional activator, a transcriptional repressor, a recombinase, a transposase, a histone remodeler, a DNA methyltransferase, a cryptochrome, and a light-inducible / controllable domain or a chemically-inducible / controllable domain.

[0192] 18. The composition or method according to item 16 or 17, wherein the first functional domain or the second functional domain is a transcription activator domain.

[0193] 19. The composition or method of item 47, wherein the transcriptional activator domain is VP64.

[0194] 20. The composition or method according to item 16 or 17, wherein the first functional domain or the second functional domain is a transcription repressor domain.

[0195] 21. The composition or method according to item 20, wherein the transcriptional repressor domain is KRAB, SID or SID4X.

[0196] 22. The composition or method of any one of items 14 to 21, wherein the first CRISPR enzyme or the second CRISPR enzyme is a Sutterella wadsworthii Cas9.

[0197] 23. The composition or method of any one of items 14 to 21, wherein the first CRISPR enzyme or the second CRISPR enzyme is a Glechoma sulcifolia Cas9.

[0198] 24. The composition or method of any one of items 14 to 21, wherein the first CRISPR enzyme or the second CRISPR enzyme is a Lactobacillus johnsonii Cas9.

[0199] 25. The composition or method of any one of items 14 to 21, wherein the first CRISPR enzyme or the second CRISPR enzyme is a Campylobacter gullus Cas9.

[0200] 26. The composition or method of any one of items 14 to 21, wherein the first CRISPR enzyme or the second CRISPR enzyme is a Corynebacterium diphtheriae Cas9.

[0201] 27. The composition or method of any one of items 14 to 21, wherein the first CRISPR enzyme or the second CRISPR enzyme is a C. parvum Cas9.

[0202] 28. The composition or method of any one of items 14 to 21, wherein the first CRISPR enzyme or the second CRISPR enzyme is a Mycoplasma gallisepticum Cas9.

[0203] 29. The composition or method of any one of items 14 to 21, wherein the first CRISPR enzyme or the second CRISPR enzyme is a Staphylococcus aureus subsp. aureus Cas9.

[0204] 30. The composition or method of any one of items 14 to 21, wherein the first CRISPR enzyme or the second CRISPR enzyme is a Legionella pneumophila Cas9.

[0205] 31. The composition or method of any one of items 14 to 21, wherein the first CRISPR enzyme or the second CRISPR enzyme is a Treponema denticola Cas9.

[0206] 32. The composition or method of any one of items 14 to 21, wherein the first CRISPR enzyme or the second CRISPR enzyme is a Staphylococcus pseudintermedius Cas9.

[0207] 33. The composition or method of any one of items 14 to 21, wherein the first CRISPR enzyme or the second CRISPR enzyme is a Neisseria griseus Cas9.

[0208] 34. A method of treating or inhibiting a condition caused by a defect in a target sequence within a genomic locus of interest in a subject or non-human subject in need thereof, the method comprising modifying the subject or non-human subject by manipulating the target sequence, and wherein the condition is susceptible to treatment or inhibition by manipulation of the target sequence, the method comprising providing a treatment comprising:

[0209] Delivering a non-naturally occurring or engineered composition comprising an AAV vector system, the AAV vector system comprising one or more AAV vectors, the one or more AAV vectors comprising an operably encoding composition as described in any of items 1 or 3 to 11 for expressing the composition, wherein when expressed, the target sequence is manipulated by the composition.

[0210] 35. The method of claim 34, comprising inducing expression.

[0211] 36. The method of item 34 or 35, wherein the organism or subject is a eukaryotic organism or a non-human eukaryotic organism.

[0212] 37. The method of any one of items 34 to 36, wherein the organism or subject is a plant.

[0213] 38. The method of any one of items 34 to 36, wherein the organism or subject is a mammal or a non-human mammal.

[0214] 39. The method of any one of items 34 to 37, wherein the organism or subject is algae.

[0215] 40. The method of any one of items 34 to 39, wherein the viral vector is AAV.

[0216] 41. A composition or enzyme according to any one of items 1-11, 14, or 16-33 for use in medicine or for use in therapy.

[0217] 42. The composition or enzyme of any one of items 1-11, 14, or 16-33, for use in the method of any one of items 12, 13, or 15-40.

[0218] 43. Use of the composition or enzyme according to any one of items 1-11, 14, or 16-33 in ex vivo gene or genome editing.

[0219] 44. Use of a composition or enzyme according to any one of items 1-11, 14, or 16-33 in the manufacture of an agent for ex vivo gene or genome editing or for use in a method according to any one of items 12, 13, or 15-40.

[0220] 45. The composition or enzyme of any one of items 1-11, 14, or 16-33, wherein the target sequence is flanked at its 3' end by 5'-NRG (wherein N is any nucleotide), in particular wherein the Cas9 is (or is derived from) Streptococcus pyogenes or Staphylococcus aureus Cas9.

[0221] 46. ​​A method for preparing an AAV for delivering a composition or enzyme according to any one of items 1-11, 14, or 16-33, the method comprising transfecting one or more plasmids containing or consisting essentially of one or more nucleic acid molecules encoding AAV into cells infected with AAV and providing AAV rep and / or cap necessary for replication and packaging of the AAV.

[0222] 47. The method of item 46, wherein the AAV rep and / or cap necessary for replication and packaging of the AAV is provided by transfecting the cells with one or more helper plasmids or one or more helper viruses.

[0223] 48. The method of item 47, wherein the helper virus is a poxvirus, an adenovirus, a herpes virus or a baculovirus.

[0224] 49. The method of item 48, wherein the poxvirus is vaccinia virus.

[0225] 50. The method of any one of items 46 to 49, wherein:

[0226] - the cells are mammalian cells; or

[0227] The cells are insect cells and the helper virus is a baculovirus.

[0228] 51. A method of delivering a CRISPR enzyme as described in any of items 2-11, the method comprising delivering mRNA encoding the CRISPR enzyme to a cell.

[0229] 52. A chimeric Cas enzyme, wherein the enzyme comprises one or more fragments from a first Cas ortholog and one or more fragments from a second Cas ortholog.

[0230] 53. The enzyme according to item 52, wherein the one or more fragments of the first Cas ortholog or the second Cas ortholog are from the C-terminus or N-terminus of the first Cas ortholog or the second Cas ortholog.

[0231] 54. The enzyme according to item 52 or 53, wherein the first Cas ortholog or the second Cas ortholog is a genus selected from the group consisting of Corynebacterium, Sutterella, Legionella, Treponema, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibacillum, Staphylococcus, Nitratifractor, Mycoplasma and Campylobacter.

[0232] 55. Use of the composition or enzyme according to any one of items 1-11, 14, 16-33, or 52-54 in the preparation of a medicament for modifying a target sequence.

[0233] 56. The composition of any one of items 1 to 11, wherein the CRISPR enzyme is truncated compared to a wild-type CRISPR enzyme, or the CRISPR enzyme consists of 500-2000 amino acids.

[0234] 57. A composition according to any one of items 1 to 11 or 56, wherein the CRISPR enzyme is a nuclease that directs cleavage of both strands at the location of the target sequence, or the CRISPR enzyme is a nickase that directs cleavage of one strand at the location of the target sequence.

[0235] 58. The composition according to any one of items 1 to 11 or 56-57, wherein the guide sequence comprises at least fifteen nucleotides.

[0236] 59. The composition of any one of items 1 to 11 or 56-58, wherein the CRISPR enzyme is codon-optimized or codon-optimized for expression in eukaryotic cells.

[0237] 60. A composition according to any one of items 1 to 11 or 56-59, wherein the CRISPR enzyme comprises one or more mutations.

[0238] 61. A composition according to any one of items 1 to 11 or 56-60, wherein the CRISPR enzyme comprises a chimeric CRISPR enzyme.

[0239] 62. A non-naturally occurring or engineered composition comprising:

[0240] A)-I. A CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises:

[0241] (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell,

[0242] (b) a tracr mate sequence, and

[0243] (c) a tracr sequence, and

[0244] II. a polynucleotide sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences,

[0245] Among them, (a), (b) and (c) are arranged in the 5' to 3' direction.

[0246] wherein upon transcription, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of the CRISPR complex to the target sequence, and

[0247] wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) a guide sequence hybridized to the target sequence, and (2) a tracr mate sequence hybridized to the tracr sequence, and the polynucleotide sequence encoding the CRISPR enzyme is DNA or RNA,

[0248] or

[0249] (B) I. A polynucleotide comprising:

[0250] (a) a guide sequence capable of hybridizing to a target sequence in a prokaryotic cell, and

[0251] (b) at least one or more tracr mate sequences,

[0252] II. A polynucleotide sequence encoding a CRISPR enzyme, and

[0253] III. A polynucleotide sequence comprising a tracr sequence

[0254] wherein upon transcription, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of the CRISPR complex to the target sequence, and

[0255] wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) a guide sequence hybridized to the target sequence, and (2) a tracr mate sequence hybridized to the tracr sequence, and the polynucleotide sequence encoding the CRISPR enzyme is DNA or RNA, and

[0256] wherein the CRISPR enzyme is a Cas9 ortholog of a genus belonging to the following group, the group consisting of: Corynebacterium, Sutterella, Legionella, Treponema, Mycobacterium, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibacillum, Staphylococcus, Nitratifractor, Mycoplasma and Campylobacter.

[0257] 63.A A method of modifying an organism or non-human organism by manipulating a target sequence in a genomic locus of interest, the method comprising: delivering a non-naturally occurring or engineered composition comprising:

[0258] A)-I. A CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises:

[0259] (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell,

[0260] (b) a tracr mate sequence, and

[0261] (c) a tracr sequence, and

[0262] II. a polynucleotide sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences,

[0263] Among them, (a), (b) and (c) are arranged in the 5' to 3' direction.

[0264] wherein upon transcription, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of the CRISPR complex to the target sequence, and

[0265] wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) a guide sequence hybridized to the target sequence, and (2) a tracr mate sequence hybridized to the tracr sequence, and the polynucleotide sequence encoding the CRISPR enzyme is DNA or RNA,

[0266] or

[0267] (B) I. A polynucleotide comprising:

[0268] (a) a guide sequence capable of hybridizing to a target sequence in a prokaryotic cell, and

[0269] (b) at least one or more tracr mate sequences,

[0270] II. A polynucleotide sequence encoding a CRISPR enzyme, and

[0271] III. a polynucleotide sequence comprising a tracr sequence,

[0272] wherein upon transcription, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of the CRISPR complex to the target sequence, and

[0273] wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) a guide sequence hybridized to the target sequence, and (2) a tracr mate sequence hybridized to the tracr sequence, and the polynucleotide sequence encoding the CRISPR enzyme is DNA or RNA, and

[0274] wherein the CRISPR enzyme is a Cas9 ortholog of a genus belonging to the following group, the group consisting of: Corynebacterium, Sutterella, Legionella, Treponema, Mycobacterium, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibacillum, Staphylococcus, Nitratifractor, Mycoplasma and Campylobacter.

[0275] 64. The composition according to item 62, or the method according to item 63, wherein the CRISPR enzyme is truncated compared to a wild-type CRISPR enzyme, or the CRISPR enzyme consists of 500-2000 amino acids.

[0276] 65. The composition or method of items 62-64, wherein the CRISPR enzyme is a nuclease that directs cleavage of both strands at the location of the target sequence, or the CRISPR enzyme is a nickase that directs cleavage of one strand at the location of the target sequence.

[0277] 66. The composition or method of items 62-65, wherein the guide sequence comprises at least fifteen nucleotides.

[0278] 67. The composition or method of items 62-66, wherein the CRISPR enzyme is codon-optimized or codon-optimized for expression in eukaryotic cells.

[0279] 68. A composition or method according to items 62-67, wherein the CRISPR enzyme comprises one or more mutations.

[0280] 69. The composition or method of items 62-68, wherein the CRISPR enzyme comprises a chimeric CRISPR enzyme. BRIEF DESCRIPTION OF THE DRAWINGS

[0281] The novel features of the invention are particularly set forth in the appended claims. A better understanding of the features and advantages of the invention will be obtained by reference to the following detailed description which sets forth illustrative embodiments in which the principles of the invention are utilized, and in the accompanying drawings:

[0282] Figure 1 Schematic diagram showing RNA-guided Cas9 nuclease. The Cas9 nuclease from Streptococcus pyogenes targets genomic DNA via a synthetic guide RNA (sgRNA) consisting of a 20 nt guide sequence and a scaffold. The guide sequence base pairs with the DNA target, directly upstream of the necessary 5'-NGG protospacer adjacent motif (PAM), and Cas9 mediates a double-strand break (DSB) approximately 3 bp upstream of the PAM (indicated by a triangle).

[0283] Figure 2A -F shows an exemplary CRISPR system, with a possible mechanism of action (A), an exemplary adaptation for expression in eukaryotic cells, and results of assays assessing nuclear localization and CRISPR activity (BF).

[0284] Figure 3 Schematic representation showing the use of an AAV in vivo delivery plasmid with inverted terminal repeat (ITR) sequences and guide chimeric RNA to preferentially facilitate delivery by AAV or AAV-related systems.

[0285] Figure 4A -D shows a circular depiction of a phylogenetic analysis revealing five Cas9 families, including three groups of large Cas9s (about 1400 amino acids) and two groups of small Cas9s (about 1100 amino acids).

[0286] Figure 5A-F shows a linear depiction of phylogenetic analysis revealing five Cas9 families, including three groups of large Cas9 (about 1400 amino acids) and two groups of small Cas9 (about 1100 amino acids).

[0287] Figure 6 A graph representing the length distribution of Cas9 orthologs is shown.

[0288] Figure 7 Representation of the sequence diagrams of the PAMs of these Cas9 orthologs are shown as reverse complement sequences.

[0289] Fig. 8A -J shows 18 chimeric RNA structures that retain the sequence and secondary structure of the tracr pairing:tracr sequence duplex when the base pairing region is shortened and the two RNA elements are fused through an artificial loop.

[0290] Fig. 9A -O displays the Fig. 8A A list of chimeric guide RNA-paired human codon-optimized Cas9 sequences is provided in -J.

[0291] Fig. 10A -M shows the sequence in the case where the mutation point is located within the SpCas9 gene.

[0292] Fig.11 Type II CRISPR loci in different organisms are shown.

[0293] Fig.12 Guide RNA sequences corresponding to CRISPR loci in different organisms are shown.

[0294] Fig.13A -II shows a table listing Cas9 orthologs and their corresponding PAM sequences.

[0295] Fig.14 It was shown that the PAM of Staphylococcus aureus subsp. aureus Cas9 is NNGRR.

[0296] Fig.15 AD shows single and multiple vector designs for SpCas9.

[0297] Fig.16 A vector design and gel image showing Cas9 orthologs used to cleave two candidate targets present in a pUC19-based library and the respective sgRNAs.

[0298] Fig.17In vitro cleavage by SpCas9, St3Cas9, Sp_St3 chimera, and St3_Sp chimera is shown. The PAM for St3Cas9 and St3_Sp chimeric Cas9 is NGG.

[0299] Fig.18 An image showing the CRISPR web server.

[0300] Fig.19A -L shows a multiple sequence alignment of 12 Cas9 orthologs. Two catalytic residues are highlighted. The first residue highlighted is the catalytic Asp residue in the RuvCI domain, and the second residue highlighted is the catalytic His residue in the HNH domain. Mutation of always one residue to Ala converts Cas9 into a nickase. Mutation of both residues converts Cas9 into a catalytically inactive mutant – useful for general DNA binding.

[0301] Fig. 20 A western blot is shown showing that Cas9 orthologs are expressed in HEK293FT cells; DNA plasmids encoding Cas9 orthologs were transfected into HEK 293FT cells and cell lysates were harvested for western blot. No DNA was transfected for Cas9 ortholog #8.

[0302] Fig.21 In vitro cleavage of candidate targets by 10 Cas9 orthologs on pUC19 plasmid is shown. The consensus PAM ( Figure 7 ), candidate targets on pUC19 were selected based on these sequence icons. Seven of the nine new Cas9 orthologs tested successfully cleaved at least one pUC19 target. SpCas9 can also cleave NGA in vitro.

[0303] Fig. 22 A representative Surveyor gel showing genomic cleavage by SaCas9 is shown.

[0304] Fig.23 Genomic cleavage efficiency of PAM sequences (all targets) is shown.

[0305] Fig.24 Genomic cleavage efficiency of the PAM sequence (target of cleavage) is shown.

[0306] Fig.25 Genomic cleavage efficiency by PAM sequence (all targets, low efficiency and orphan targets discarded) is shown.

[0307] Fig.26Genomic cleavage efficiency by PAM sequence (targets cleaved, low efficiency and orphan targets discarded) is shown.

[0308] Fig. 27 Sequence icon showing spacer & PAM for operational cleavage (new endogenous genome testing shows T is not required).

[0309] The figures herein are for illustrative purposes only and are not necessarily drawn to scale.

[0310] Detailed description of the invention

[0311] The present invention relates to the engineering and optimization of systems, methods, and compositions for controlling gene expression involving sequence targeting, such as genome perturbations or gene editing involving CRISPR-Cas systems and components thereof. In advantageous embodiments, the CRISPR enzyme is a Cas enzyme, such as a Cas9 ortholog.

[0312] The present invention uses nucleic acids to bind to target TDNA sequences. This is advantageous because nucleic acids are much easier and cheaper to produce than, for example, peptides, and specificity can be varied depending on the length of the stretch in which homology is sought. Complex 3-D complex positioning, such as multi-fingered, is not required.

[0313] The terms "polynucleotide", "nucleotide", "nucleotide sequence", "nucleic acid" and "oligonucleotide" are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. A polynucleotide may have any three-dimensional structure and may perform any function, known or unknown. The following are non-limiting examples of polynucleotides: coding or non-coding regions of a gene or gene fragment, multiple loci (a locus) defined by linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, short interfering RNA (siRNA), short hairpin RNA (shRNA), micro-RNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. The term also encompasses nucleic acid-like structures with synthetic backbones, see, e.g., Eckstein, 1991; Baserga et al., 1992; Milligan, 1993; WO 97 / 03211; WO 96 / 39154; Mata, 1997; Strauss-Soukup, 1997; and Samstag, 1996. A polynucleotide may comprise one or more modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modification of the nucleotide structure may be performed before or after polymer assembly. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeled component.

[0314] In various aspects of the invention, the terms "chimeric RNA", "chimeric guide RNA", "guide RNA", "single guide RNA" and "synthetic guide RNA" are used interchangeably and refer to a polynucleotide sequence comprising a guide sequence, a tracr sequence and a tracr mate sequence. The term "guide sequence" refers to a sequence of about 20 bp within a guide RNA that specifies a target site and can be used interchangeably with the terms "guide" or "spacer". The term "tracr mate sequence" can also be used interchangeably with the term "direct repeat(s)".

[0315] The term "wild type" as used herein is a term understood by those skilled in the art and refers to the typical form of an organism, strain, gene, or characteristic that distinguishes it from mutant or variant forms as it occurs in nature.

[0316] The term "variant" as used herein should be understood to mean a display having properties derived from a pattern found in nature.

[0317] The terms "non-naturally occurring" or "engineered" are used interchangeably and indicate the involvement of human effort. These terms, when referring to nucleic acid molecules or polypeptides, indicate that the nucleic acid molecules or polypeptides are at least substantially free from at least one other component with which they are associated in nature or as found in nature.

[0318] "Complementarity" refers to the ability of a nucleic acid to form one or more hydrogen bonds with another nucleic acid sequence by means of traditional Watson-Crick base pairing or other non-traditional types. The percentage of complementarity represents the percentage of residues in a nucleic acid molecule that can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10 are 50%, 60%, 70%, 80%, 90%, and 100% complementary). "Complete complementarity" means that all consecutive residues of a nucleic acid sequence form hydrogen bonds with the same number of consecutive residues in a second nucleic acid sequence. As used herein, "substantially complementary" refers to a degree of complementarity of at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50 or more nucleotides, or to two nucleic acids that hybridize under stringent conditions.

[0319] As used herein, "stringent conditions" for hybridization refer to conditions in which a nucleic acid having complementarity with a target sequence hybridizes primarily with the target sequence and does not substantially hybridize to a non-target sequence. Stringent conditions are generally sequence-dependent and vary depending on many factors. Generally speaking, the longer the sequence, the higher the temperature at which the sequence specifically hybridizes to its target sequence. Non-limiting examples of stringent conditions are described in Tijssen (1993) Laboratory Techniques In Biochemistry And Molecular Biology-Hybridization With Nucleic Acid Probes, Part I, Chapter II, "Overview of principles of hybridization and the strategy of nucleic acid probe assay", Elsevier, New York. When referring to a polynucleotide sequence, complementary or partially complementary sequences are also envisioned. These sequences that can hybridize to a reference sequence under high stringency conditions are preferred. Typically, in order to maximize the hybridization rate, relatively low stringency hybridization conditions are selected: about 20 to 25 ° C below the thermal melting point (Tm). Tm is the temperature at which 50% of the specific target sequence hybridizes to a fully complementary probe in a solution with a specified ionic strength and pH. Typically, in order to require at least about 85% nucleotide complementarity of the hybridization sequence, high stringency washing conditions are selected to be about 5 to 15 ° C below Tm. In order to require at least about 70% nucleotide complementarity of the hybridization sequence, medium stringency washing conditions are selected to be about 15 to 30 ° C below Tm. High permissive (very low stringency) washing conditions can be as low as 50 ° C below Tm, thereby allowing high-level mismatches between hybridization sequences. Those skilled in the art will recognize that other physical and chemical parameters in the hybridization and washing stages can also be changed, thereby affecting the results of detectable hybridization signals from a specific homology level between the target sequence and the probe sequence. Preferred high stringency conditions include incubation in 50% formamide, 5X SSC, and 1% SDS at 42°C, or incubation in 5X SSC and 1% SDS at 65°C, with a wash in 0.2X SSC and 0.1% SDS at 65°C.

[0320] "Hybridization" refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized via hydrogen bonding of bases between the nucleotide residues. Hydrogen bonding can occur by means of Watson-Crick base pairing, Hoogstein binding, or in any other sequence-specific manner. The complex may contain two chains forming a duplex, three or more chains forming a multi-stranded complex, a single self-hybridizing chain, or any combination of these. The hybridization reaction may constitute a step in a broader process (such as the start of PCR or the cutting of polynucleotides via an enzyme). A sequence that is capable of hybridizing to a given sequence is referred to as the "complement" of the given sequence.

[0321] As used herein, the term "genomic locus" or "locus" (plural loci) is a specific location of a gene or DNA sequence on a chromosome. A "gene" refers to a stretch of DNA or RNA encoding a polypeptide or RNA chain that plays a functional role in an organism and is therefore the molecular unit of heredity in a living organism. For the purposes of the present invention, genes that include regions that regulate the production of a gene product may be considered, regardless of whether such regulatory sequences are proximal to coding and / or transcribed sequences. Thus, genes include, but are not necessarily limited to, promoter sequences, terminators, translation regulatory sequences (such as ribosome binding sites and internal ribosome entry sites), enhancers, silencers, insulators, boundary elements, origins of replication, nuclear matrix attachment sites, and locus control regions.

[0322] As used herein, "expression of a genomic locus" or "gene expression" is a process by which information from a gene is used in the synthesis of a functional gene product. The product of gene expression is often a protein, but in non-protein coding genes such as rRNA genes or tRNA genes, the product is a functional RNA. The process of gene expression is used by all known organisms - eukaryotic organisms (including multicellular organisms), prokaryotes (bacteria and archaea), and viruses that produce functional products in order to survive. As used herein, "expression" of a gene or nucleic acid not only encompasses cellular gene expression, but also encompasses the transcription and translation of one or more nucleic acids in a cloning system or in any other context. As used herein, "expression" refers to a process by which a polynucleotide is transcribed from a DNA template (such as transcribed into mRNA or other RNA transcripts) and / or a process by which a transcribed mRNA is subsequently translated into a peptide, polypeptide, or protein. Transcripts and encoded polypeptides can be collectively referred to as "gene products". If the polynucleotide is derived from genomic DNA, expression can include splicing of mRNA in a eukaryotic cell.

[0323] The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may contain modified amino acids, and it may be interrupted by non-amino acids. These terms also encompass amino acid polymers that have been modified; such modifications include disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation to a labeling component. The term "amino acid" as used herein includes natural and / or non-natural or synthetic amino acids, including glycine and D and L optical isomers, as well as amino acid analogs and peptide mimetics.

[0324] As used herein, the term "domain" or "protein domain" refers to a portion of a protein sequence that can exist and function independently of the rest of the protein chain.

[0325] As described in aspects of the present invention, sequence identity is related to sequence homology. Homology comparison can be performed by naked eye, more generally by means of available sequence comparison programs. These commercially available computer programs can calculate the percentage (%) of homology between two or more sequences and can also calculate the sequence identity shared by two or more amino acid or nucleotide sequences. Sequence homology can be generated by many computer programs known in the art (such as BLAST or FASTA, etc.). The computer program suitable for performing such comparison is GCG Wisconsin Bestfit software package (University of Wisconsin, USA; Devereux et al., 1984, " Nucleic Acids Research " (Nucleic Acids Research) 12:387). Examples of other software that can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al., 1999, supra - Chapter 18), FASTA (Atschul et al., 1990, J. Mol. Biol., 403-410) and the GENEWORKS series of comparison tools. Both BLAST and FASTA can be used for offline and online searches (see Ausubel et al., 1999, supra, pp. 7-58 to pp. 7-60). However, it is preferred to use the GCG Bestfit program.

[0326] Homology % can be calculated over contiguous sequences, i.e., one sequence is aligned with the other sequence and each amino acid or nucleotide in one sequence is directly compared with the corresponding amino acid or nucleotide in the other sequence, one residue at a time. This is called a "non-gap" alignment. Typically, such non-gap alignments are performed only over a relatively small number of residues.

[0327] While this is a very simple and consistent approach, it fails to take into account that, for example, in an otherwise identical pair of sequences, an insertion or deletion may cause subsequent amino acid residues to be excluded from the alignment, thus potentially leading to a substantial reduction in % homology when a global alignment is performed. Therefore, most sequence comparison methods are designed to produce an optimized alignment that takes into account possible insertions and deletions without unduly penalizing the overall homology or identity score. This is achieved by inserting "gaps" in the sequence alignment in an attempt to maximize local homology or identity.

[0328] In some embodiments, the present invention relates to the comparison of the sequence alignment of amino acids in the sequence comparison of the present invention. The present invention relates to the comparison of the sequence alignment of amino acids in the present invention. The present invention relates to the comparison of the sequence alignment of amino acids in the present invention. The present invention relates to the comparison of the sequence alignment of amino acids in the present invention. The present invention relates to the comparison of the sequence alignment of amino acids in the present invention. The present invention relates to the comparison of the sequence alignment of amino acids in the present invention. The present invention relates to the comparison of the sequence alignment of amino acids in the present invention. The present invention relates to the comparison of the sequence alignment of amino acids in the present invention. The present invention relates to the comparison of the sequence alignment of amino acids in the present invention. The present invention relates to the comparison of the sequence alignment of amino acids in the present invention. The present invention relates to the comparison of the sequence alignment of amino acids in the present invention. The present invention relates to the comparison of the sequence alignment of amino acids in the present invention. The present invention relates to the comparison of the sequence alignment of amino acids in the present invention. The present invention relates to the comparison of the sequence alignment of amino acids in the present invention. The present invention relates to the comparison of the sequence alignment of amino acids in the present invention. The present invention relates to the comparison of the sequence alignment of amino acids in the present invention. The present invention relates to the comparison of the sequence alignment of amino acids in the present invention.

[0329] Calculation of maximum % homology therefore first requires the production of an optimal alignment, taking into account gap penalties. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (Devereux et al., 1984, Nucleic Acids Research 12 p387). Examples of other software that can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al., 1999 Short Protocols in Molecular Biology, 4th ed. - Chapter 18), FASTA (Altschul et al., 1990 J. Mol. Biol. 403-410). Both BLAST and FASTA can be used for offline and online searches (see Ausubel et al., 1999 Short Protocols in Molecular Biology, pp. 7-58 to 7-60). However, for some applications, it is preferred to use the GCG Bestfit program. A new tool, called BLAST 2 Sequences, can also be used to compare protein and nucleotide sequences (see FEMS Microbiol Lett. 1999). 174(2):247-50; FEMS Microbiol Lett 1999 177(1):187-8 and at the National Center for Biotechnology Information website of the National Institutes of Health).

[0330] Although the final homology % can be measured according to consistency, the alignment process itself is typically not based on all-or-nothing pair comparisons. On the contrary, a scaled similarity score matrix is ​​usually used to score each paired comparison based on chemical similarity or evolutionary distance. An example of this matrix commonly used is the BLOSUM62 matrix-the default matrix of the BLAST series of programs. The GCG Wisconsin program usually uses a public default value or a custom symbol comparison table (see the user manual for more details). For some applications, it is preferred to use the public default values ​​of the GCG software package, or the default matrix in other software situations, such as BLOSUM62.

[0331] Alternatively, can be based on similar to CLUSTAL (Higgins DG (Higgins DG) and Sharp PM (SharpPM) (1988), " gene " (Gene) 73 (1), 237-244) a kind of algorithm, use the multiple alignment feature in DNASISTM (Hitachi Software) to calculate homology percentage.Once the software has produced the best comparison, just may calculate homology %, preferably sequence identity %.Software typically does so, as part of sequence comparison, and produces digital result.

[0332] These sequences may also have deletions, insertions or substitutions of amino acid residues, which produce silent changes and generate functionally equivalent materials. Intentional amino acid substitutions may be made based on similarities in amino acid properties (such as polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathicity of the residue), and therefore it is useful in grouping amino acids into functional groups. They may be grouped together based solely on the side chain properties of the amino acids. However, it is also more useful to include mutation data. For structural reasons, the amino acid sets derived in this way are likely to be conservative. These sets can be described in the form of a Venn diagram (Livingstone CD and Barton GJ (1993) "Protein sequence alignments: a strategy for the hierarchical analysis of residue conservation" Comput. Appl. Biosci. 9:745-756) (Taylor WR (1986) "The classification of amino acid conservation" J. Theor. Biol. 119; 205-218). For example, conservative substitutions can be made according to the following table, which describes the generally accepted Venn diagram groupings of amino acids.

[0333]

[0334]

[0335] Embodiments of the invention include sequences (both polynucleotides and polypeptides) that may contain homologous substitutions (both substitution and replacement are used herein to refer to the interchange of existing amino acid residues or nucleotides with alternative residues and nucleotides), i.e., like-for-like substitutions in the case of amino acids, such as basic for basic, acidic for acidic, polar for polar. Non-homologous substitutions may also occur, i.e., from one class of residues to another, or alternatively involving the inclusion of unnatural amino acids such as ornithine (hereinafter referred to as Z), diaminobutyric acid ornithine (hereinafter referred to as B), norleucine ornithine (hereinafter referred to as O), pyridylalanine, thienylalanine, naphthylalanine, and phenylglycine.

[0336] Variant amino acid sequences may include suitable spacers that may be inserted between any two amino acid residues in the sequence, including alkyl groups other than amino acid spacers (such as glycine or -alanine), such as methyl, ethyl or propyl groups. Another variant, which involves the presence of one or more amino acid residues in a peptoid form, is also well known to those skilled in the art. For the avoidance of doubt, "the peptoid form" is used to refer to variant amino acid residues, wherein the -carbon substituent is on the nitrogen atom of the residue, rather than on the -carbon. Methods for preparing peptides in the peptoid form are known in the art, such as Simon RJ et al., PNAS (1992) 89 (20), 9367-9371 and Horwell DC, Trends Biotechnol. (1995) 13 (4), 132-134.

[0337] The practice of the present invention employs, unless otherwise indicated, conventional techniques of immunology, biochemistry, chemistry, molecular biology, microbiology, cell biology, genomics and recombinant DNA, which are within the skill of the art. See Sambrook, Fritsch and Maniatis, MOLECULAR CLONING: A LABORATORY MANUAL, 2nd ed. (1989); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (FM Ausubel et al., eds., (1987)); METHODS IN ENZYMOLOGY series (Academic Press): PCR 2: A PRACTICAL APPROACH (MJ MacPherson, BD Hames and GR Taylor, eds. (1995)); ANTIBODIES, A LABORATORY MANUAL, 2nd ed. (1988); MANUAL, and ANIMAL CELL CULTURE (RI Freshney, ed. (1987)).

[0338] In one aspect, the invention provides vectors for use in the engineering and optimization of CRISPR-Cas systems.

[0339] As used herein, a "vector" is a tool that allows or facilitates the transfer of an entity from one environment to another. It is a replicon, such as a plasmid, a phage, or a cosmid, into which another DNA fragment can be inserted, thereby causing the replication of the inserted fragment. Generally, when associated with appropriate control elements, a vector is capable of replication. In general, the term "vector" refers to a nucleic acid molecule that is capable of transporting another nucleic acid molecule connected to it. Vectors include, but are not limited to, single-stranded, double-stranded, or partially double-stranded nucleic acid molecules; nucleic acid molecules including one or more free ends, no free ends (e.g., circular); nucleic acid molecules including DNA, RNA, or both; and other diverse polynucleotides known in the art. One type of vector is a "plasmid", which refers to a circular double-stranded DNA loop into which additional DNA fragments can be inserted, for example, by standard molecular cloning techniques. Another type of vector is a viral vector, in which a virally derived DNA or RNA sequence is present in a vector used to package a virus (e.g., a retrovirus, a replication-defective retrovirus, an adenovirus, a replication-defective adenovirus, and an adeno-associated virus). Viral vectors also include polynucleotides carried by viruses for transfection into a host cell. Some vectors (e.g., bacterial vectors and additional mammalian vectors with bacterial replication origins) can replicate autonomously in the host cells into which they are introduced. Other vectors (e.g., non-additional mammalian vectors) are integrated into the genome of the host cell after being introduced into the host cell, and thus replicated together with the host genome. Moreover, some vectors can instruct the expression of genes that they can be operably connected. Such vectors are referred to as "expression vectors" herein. The common expression vectors used in recombinant DNA technology are typically in plasmid form. This paper provides further discussion of vectors.

[0340] Recombinant expression vectors may include nucleic acids of the present invention in a form suitable for expression of nucleic acids in a host cell, which means that these recombinant expression vectors include one or more regulatory elements selected based on the host cell to be used for expression, and the regulatory elements are operably connected to the nucleic acid sequence to be expressed. In recombinant expression vectors, "operably connected" is intended to represent that the nucleotide sequence of interest is connected to the one or more regulatory elements (e.g., in a kind of in vitro transcription / translation system or when the vector is introduced into a host cell, in the host cell) in a manner that allows the expression of the nucleotide sequence. Regarding recombination and cloning methods, U.S. Patent Application No. 10 / 815,730 disclosed with US 2004-0171156 A1 on September 2, 2004 is mentioned, and the content of the patent is incorporated herein by reference in its entirety.

[0341] Aspects and embodiments of the present invention relate to bicistronic vectors for chimeric RNA and Cas9 or Cas9 orthologs. In some embodiments, the Cas9 is driven by a CBh promoter. In some embodiments, the chimeric RNA is driven by a U6 promoter. Preferably, the CBh and U6 are used together in the sense that the Cas9 is driven by the CBh promoter and the chimeric RNA is driven by the U6 promoter. In some embodiments, the chimeric guide RNA consists of a 20bp guide sequence (N) joined to the tracr sequence (from the first "U" of the lower chain to the end of the transcript), which is truncated at each position as indicated. The guide sequence and the tracr sequence are preferably separated by the tracr pairing sequence. A preferred example of a tracr pairing sequence is GUUUUAGAGCUA. Preferably this is followed by a loop sequence. The loop is preferably GAAA, but is not limited to this sequence or is actually only 4bp in length. In fact, the preferred loop-forming sequence for use in a hairpin structure is four nucleotides in length, and most preferably has the sequence GAAA. However, longer or shorter loop sequences can be used, as can alternative sequences. These sequences preferably include triplets (e.g., AAA), and additional nucleotides (e.g., C or G). Examples of loop-forming sequences include CAAA and AAAG. Throughout this application, chimeric RNAs may also be referred to as single guides, or synthetic guide RNAs (sgRNAs).

[0342] For example, as described in particular detail in Example 2, chimeric guide RNAs can be designed as shown in Figure 8. CRISPR loci in some of these families are depicted in Fig.11 The corresponding guide RNA sequence is in Fig.12Shown in. We analyzed the genomic DNA sequence within about 2kb of the Cas9 protein, and identified the direct repeats ranging from 35bp to 50bp, which had an intervening spacer ranging from 29bp to 35bp. Based on the direct repeat sequence, we searched for tracrRNA candidate sequences with the following criteria: outside the crRNA array but containing a high degree of homology with the direct repeat (as required for direct repeat: tracrRNA base pairing; custom computational analysis), outside the coding region of these protein components, about 60bp-120bp downstream of the region with homology to the direct repeat contains a transcription termination signal that does not rely on Rho, and co-folds with the direct repeat to form a duplex, followed by two or more hairpin structures at the far end of the tracrRNA sequence. Based on these prediction criteria, We selected an initial set of 18 Cas9 proteins, and their uniquely associated direct repeats and tracrRNAs were distributed across all five Cas9 families. Applicants further generated a set of 18 chimeric RNA structures that retain the sequence and secondary structure of the natural direct repeat:tracrRNA duplex while shortening the base pairing region and fusing the two RNA elements through an artificial loop ( Figures 8A-8J ).

[0343] The term "regulatory element" is intended to include promoters, enhancers, internal ribosome entry sites (IRES), and other expression control elements (e.g., transcription termination signals, such as polyadenylation signals and poly-U sequences). Such regulatory sequences are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, California (1990). Regulatory elements include those sequences that direct the constitutive expression of a nucleotide sequence in many types of host cells and those sequences that direct the nucleotide sequence to be expressed only in certain host cells (e.g., tissue-specific regulatory sequences). Tissue-specific promoters can primarily direct expression in desired tissues of interest, such as muscle, neurons, bone, skin, blood, specific organs (e.g., liver, pancreas), or special cell types (e.g., lymphocytes). Regulatory elements can also direct expression in a timing-dependent manner (e.g., in a cell cycle-dependent or developmental stage-dependent manner), which may or may not be tissue- or cell-type-specific. In some embodiments, a vector comprises one or more pol III promoters (e.g., 1, 2, 3, 4, 5, or more pol III promoters), one or more pol II promoters (e.g., 1, 2, 3, 4, 5, or more pol II promoters), one or more pol I promoters (e.g., 1, 2, 3, 4, 5, or more pol I promoters), or a combination thereof. Examples of pol III promoters include, but are not limited to, U6 and H1 promoters. Examples of pol II promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with a RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with a CMV enhancer) [see, e.g., Boshart et al., Cell 41:521-530 (1985)], the SV40 promoter, the dihydrofolate reductase promoter, the β-actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF1α promoter.Also encompassed by the term "regulatory element" are enhancer elements such as WPRE; CMV enhancer; R-U5' fragment in the LTR of HTLV-I (Mol. Cell. Biol., Vol. 8(1), pp. 466-472, 1988); SV40 enhancer; and intronic sequences between exons 2 and 3 of rabbit β-globin (Proc. Natl. Acad. Sci. USA., Vol. 78(3), pp. 1527-31, 1981). Those skilled in the art will appreciate that the design of the expression vector may depend on factors such as the choice of the host cell to be transformed, the desired expression level, and the like. A vector may be introduced into a host cell to thereby produce a transcript, protein, or peptide, including a fusion protein or peptide encoded by a nucleic acid as described herein (e.g., a clustered regularly interspaced short palindromic repeat (CRISPR) transcript, protein, enzyme, mutant form thereof, fusion protein thereof, etc.). With regard to regulatory sequences, reference is made to US patent application Ser. No. 10 / 491,026, the contents of which are incorporated herein by reference in their entirety. With regard to promoters, reference is made to PCT Publication No. WO 2011 / 028929 and US application Ser. No. 12 / 511,940, the contents of which are incorporated herein by reference in their entirety.

[0344] The vector can be designed to express CRISPR transcripts (e.g., nucleic acid transcripts, proteins, or enzymes) in prokaryotic or eukaryotic cells. For example, CRISPR transcripts can be expressed in bacterial cells such as Escherichia coli, insect cells (using baculovirus expression vectors), yeast cells, or mammalian cells. Suitable host cells are further discussed in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS INENZYMOLOGY 185, Academic Press, San Diego, California (Calif.) (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example, using T7 promoter regulatory sequences and T7 polymerase.

[0345] Vectors can be introduced into prokaryotes or prokaryotic cells and propagated therein. In some embodiments, prokaryotes are used to amplify multiple copies of vectors to be introduced into eukaryotic cells, or as intermediate vectors in the production of vectors to be introduced into eukaryotic cells (e.g., amplification plasmids as part of a viral vector packaging system). In some embodiments, prokaryotes are used to amplify multiple copies of a vector and express one or more nucleic acids, such as providing a source for one or more proteins delivered to a host cell or host organism. The expression of proteins in prokaryotes is most often carried out in Escherichia coli using vectors containing constitutive or inducible promoters that direct the expression of fusion or non-fusion proteins. Fusion vectors add multiple amino acids to the protein encoded therein, such as the amino terminus of the recombinant protein. Such fusion vectors can be used for one or more purposes, such as: (i) increasing the expression of recombinant proteins; (ii) increasing the solubility of recombinant proteins; and (iii) assisting the purification of recombinant proteins by acting as ligands in affinity purification. Typically, in fusion expression vectors, protein cleavage sites are introduced into the junction of the fusion moiety and the recombinant protein so that the recombinant protein can be separated from the fusion moiety after the fusion protein is purified. Such enzymes and their homologous recognition sequences include factor Xa, thrombin and enterokinase. Exemplary fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. Gene 67:31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, NJ), which fuse glutathione S-transferase (GST), maltose E binding protein or protein A to the target recombinant protein, respectively.

[0346] Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amrann et al. (1988) Gene 69:301-315) and pET 11d (Studier et al., GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89.

[0347] In some embodiments, the vector is a yeast expression vector. Examples of vectors for expression in yeast Saccharomyces cerevisiae include pYepSec1 (Baldari et al., 1987. EMBO J 6: 229-234), pMFa (Kurjan and Herskowitz, 1982. Cell 30: 933-943), pJRY88 (Schultz et al., 1987. Gene 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif), and picZ (Invitrogen Corp, San Diego, Calif).

[0348] In some embodiments, baculovirus vectors are used, and the vector drives protein expression in insect cells. Baculovirus vectors that can be used to express proteins in cultured insect cells (e.g., SF9 cells) include pAc series (Smith et al., 1983. Mol. Cell. Biol. 3: 2156-2165) and pVL series (Lucklow and Summers, 1989. Virology 170: 31-39).

[0349] In some embodiments, a mammalian expression vector is used, and the vector is capable of driving one or more sequences to be expressed in mammalian cells. Examples of mammalian expression vectors include pCDM8 (Seed, 1987. Nature 329:840) and pMT2PC (Kaufman et al., 1987. EMBO J. 6:187-195). When used in mammalian cells, the control function of the expression vector is typically provided by one or more regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, simian virus 40, and other viruses described herein and known in the art. For other suitable expression systems for both prokaryotic and eukaryotic cells, see, e.g., Chapters 16 and 17 of Sambrook et al., Molecular Cloning: A Laboratory Manual. (2nd ed.), Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989.

[0350] In some embodiments, the recombinant mammalian expression vector is capable of directing the nucleic acid to be preferentially expressed in a particular cell type (e.g., using tissue-specific regulatory elements to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert et al., 1987. Genes Dev. 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. Advances in Immunology 43: 235-275), in particular the promoter of the T cell receptor (Winoto and Baltimore, 1989. EMBO J. 8: 729-733) and immunoglobulins (Baneiji et al., 1983. Cell 33:729-740; Queen and Baltimore, 1983. Cell 33:741-748), neuron-specific promoters (e.g., neurofilament promoter; Byrne and Ruddle, 1989. Proc. Natl. Acad. Sci USA 86:5473-5477), pancreas-specific promoters (Edlund et al., 1985. Science 230:912-916), and mammary gland-specific promoters (e.g., whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally regulated promoters are also contemplated, for example, the murine homeobox protein (hox) promoter Kessel (Kessel and Gruss, 1990. Science 249:374-379) and the alpha-fetoprotein promoter (Campes and Tilghman, 1989. Genes Dev. 3:537-546). With respect to these prokaryotic and eukaryotic vectors, reference is made to U.S. Patent No. 6,750,059, the contents of which are incorporated herein by reference in their entirety. Other embodiments of the invention may involve the use of viral vectors, with respect to which reference is made to U.S. Patent Application No. 13 / 092,085, the contents of which are incorporated herein by reference in their entirety. Tissue-specific regulatory elements are known in the art, and reference is made to U.S. Patent No. 7,776,321 in this regard, the contents of which are incorporated herein by reference in their entirety.

[0351] In some embodiments, the regulatory element is operably connected to one or more elements of the CRISPR system, so as to drive the expression of the one or more elements of the CRISPR system. In general, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), also known as SPIDR (SPacer Interspaced Direct Repeats), constitutes a family of DNA loci that are usually specific to a particular bacterial species. The CRISPR locus contains a different class of short sequence repeats (SSRs) that are spaced apart and identified in Escherichia coli (Ishino et al., J. Bacteriol., 169: 5429-5433; and Nakata et al., J. Bacteriol., 171: 3553-3556) and related genes. Similar interspersed SSRs have been identified in Haloferax mediterranei, Streptococcus pyogenes, Anabaena, and Mycobacterium tuberculosis (see, Groenen et al., Mol. Microbiol., 10: 1057-1065; Hoe et al., Emerg. Infect. Dis., 5: 254-263; Masepohl et al., Biochim. Biophys. Acta 1307: 26-30; and Mojica et al., Mol. Microbiol., 17: 85-93). These CRISPR loci are typically different from other SSRs in their repeat structure, which has been termed short regularly spaced repeats (SRSRs) (Janssen et al., OMICS J. Integ. Biol., 6:23-33; and Mojica et al., Mol. Microbiol., 36:244-246). In general, these repeats are short elements present in clusters that are regularly spaced apart by unique intervening sequences of substantially constant length (Mojica et al., supra). Although the repeat sequences are highly conserved between strains, the sequences of many spaced repeats and these spacers generally differ from strain to strain (van Embden et al., J. Bacteriol., 182:2393-2401). CRISPR loci have been identified in more than 40 prokaryotes (see, e.g., Janssen et al., Mol. Microbiol.), 43:1565-1575; and Mojica et al.,), including but not limited to: Aeropyrum, Pyrobaculum, Sulfolobus, Archaeoglobus, Halocarcula, Methanobacterium, Methanococcus, Methanosarcina, Methanopyrus, Pyrococcus, Picrophilus, Thermoplasma, Corynebacterium, Mycobacterium, Streptomyces, Aquifex, Porphyromonas, Chlorobium, Thermus, Bacillus, Listeria, Staphylococcus, Clostridium, Thermoanaerobacter, Mycoplasma, Fusobacterium, Azarcus, Chromobacterium, Neisseria, Nitrosomonas, Desulfovibrio, Geobacter, Myxococcus, Campylobacter, Wolinella, Acinetobacter, Erwinia, Escherichia, Legionella, Methylococcus, Pasteurella, Photobacterium, Salmonella, Xanthomonas, Yersinia, Treponema, and Thermotoga.

[0352] In general, "CRISPR system" refers collectively to transcripts and other elements related to the expression of CRISPR-related ("Cas") genes or directing their activity, including sequences encoding Cas genes, tracr (trans-activating CRISPR) sequences (e.g., tracrRNA or active partial tracrRNA), tracr pairing sequences (covering "direct repeats" and partial direct repeats processed by tracrRNA in the context of endogenous CRISPR systems), guide sequences (also referred to as "spacers" in the context of endogenous CRISPR systems), or other sequences and transcripts from CRISPR loci. In some embodiments, one or more elements of the CRISPR system are derived from type I, type II, or type III CRISPR systems. In some embodiments, one or more elements of the CRISPR system are derived from special organisms comprising an endogenous CRISPR system, such as Streptococcus pyogenes. In general, the CRISPR system is characterized by elements that promote the formation of a CRISPR complex (also referred to as a prototype spacer in the context of an endogenous CRISPR system) at the site of the target sequence. In the context of CRISPR complex formation, a "target sequence" refers to a sequence to which a guide sequence is designed to be complementary, wherein hybridization between the target sequence and the guide sequence promotes the formation of a CRISPR complex. A target sequence can comprise any polynucleotide, such as a DNA or RNA polynucleotide. In some embodiments, the target sequence is located in the nucleus or cytoplasm of a cell.

[0353] In a preferred embodiment of the invention, the CRISPR system is a type II CRISPR system, and the Cas enzyme is Cas9, which catalyzes DNA cleavage. Double-strand breaks at a target site sequence are generated by the enzymatic action of Cas9 derived from Streptococcus pyogenes or any closely related Cas9, the target site sequence hybridizes to 20 nucleotides of the guide sequence and has a protospacer adjacent motif (PAM) sequence NGG / NRG after 20 nucleotides of the target sequence (e.g., as discussed elsewhere, a suitable PAM for SpCas9 or SaCas9 enzymes (or derived enzymes) is 5'-NRG or 5'-NNGRR, respectively). CRISPR activity for site-specific DNA recognition and cleavage via Cas9 is defined by the guide sequence, the tracr sequence partially hybridized to the guide sequence, and the PAM sequence. Further aspects of this CRISPR system are described in Karginov and Hannon, "The CRISPR system: small RNA-guided defence in bacteria and archaea," Mole Cell. 2010, Jan 15;37(1):7.

[0354] The type II CRISPR locus is derived from Streptococcus pyogenes SF370, which contains a cluster of four genes, Cas9, Cas1, Cas2, and Csn1, as well as two non-coding RNA elements, tracrRNA, and a characteristic array of repetitive sequences (direct repeats) separated by short stretches of non-repetitive sequences (spacers, approximately 30 bp each). In this system, targeted DNA double-strand breaks (DSBs) are generated in four sequential steps ( Figure 2A ). In the first step, two non-coding RNAs, pre-crRNA array and tracrRNA, are transcribed from the CRISPR locus. In the second step, tracrRNA is hybridized to the direct repeats of pre-crRNA, which are then processed into mature crRNA containing a separate spacer sequence. In the third step, the mature crRNA:tracrRNA complex directs Cas9 to a DNA target consisting of a protospacer and a corresponding PAM via the formation of a heteroduplex between the spacer region of the crRNA and the protospacer DNA. Finally, Cas9 mediates the cleavage of the target DNA upstream of the PAM to generate a DSB within the protospacer ( Figure 2A ). Figure 2BNuclear localization of the codon-optimized Cas9 was demonstrated. To facilitate precise transcription initiation, the RNA polymerase III-based U6 promoter was selected to drive the expression of tracrRNA ( Figure 2C ). Similarly, a U6 promoter-based construct was developed to express a pre-crRNA array consisting of a single spacer flanked by two direct repeats (DRs, also encompassed by the term “tracr pairing sequence”; Figure 2C The initiator spacer was designed to target the human EMX1 locus ( Figure 2C ) in the 33-base pair (bp) target site (a 30-bp protospacer plus a 3-bp CRISPR motif (PAM) sequence that satisfies the NGG recognition motif of Cas9), which is a key gene in the development of the cerebral cortex.

[0355] Fig.16 Cas9 orthologs and respective sgRNAs are shown being used to cleave two candidate targets present in a pUC19-based library. Target 1 is followed by a randomized PAM containing 7 degenerate bases (5'-NNNNNNN-3'), and Target 1', containing the same target sequence as Target 1, is followed by a fixed PAM (5'-TGGAGAAT-3'). The sgRNA for each Cas9 ortholog contains a guide sequence for either Target 1 or Target 1'. The gel image shows successful cleavage by 20 Cas9 orthologs, indicating that these sgRNA designs are functional for their respective Cas9 enzymes.

[0356] In some embodiments, direct repeat or tracr mate sequences are downloaded from a CRISPR database or identified in silico by searching for repeat motifs that are 1. found in a 2 kb window of genomic sequence flanking the type II CRISPR locus, 2. spanning 20 to 50 bp, and 3. spaced apart by 20 to 50 bp. In some embodiments, 2 of these criteria may be used, e.g., 1 and 2, 2 and 3, or 1 and 3. In some embodiments, all 3 criteria may be used.

[0357] In some embodiments, candidate tracrRNAs are subsequently predicted by: 1. sequence homology with direct repeats (motif search with up to 18-bp mismatches in Geneious), 2. the presence of a predicted Rho-independent transcription terminator in the transcription direction, and 3. a stable hairpin secondary structure between tracrRNA and direct repeats. In some embodiments, 2 of these criteria can be used, such as 1 and 2, 2 and 3, or 1 and 3. In some embodiments, all 3 criteria can be used. In some embodiments, chimeric synthetic guide RNA (sgRNA) designs incorporate at least 8 bp of duplex structure between direct repeats and tracrRNA.

[0358] Several aspects of the CRISPR system can be further improved to increase the efficiency and versatility of CRISPR targeting. Optimized Cas9 activity can rely on the availability of free Mg2+ at levels higher than those present in mammalian cell nuclei (see, e.g., Jinek et al., 2012, Science, 337:816), and the preference for NGG / NRG motifs just downstream of the protospacer limits the ability to target an average of every 12-bp in the human genome.

[0359] Typically, in the context of an endogenous CRISPR system, formation of a CRISPR complex (comprising a guide sequence hybridized to a target sequence and complexed with one or more Cas proteins) results in cleavage of one or both strands in or near (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs of) the target sequence. Without wishing to be bound by theory, the tracr sequence (which may comprise or consist of all or a portion of a wild-type tracr sequence (e.g., about or more than about 20, 26, 32, 45, 48, 54, 63, 67, 85, or more nucleotides of a wild-type tracr sequence)) may also form part of a CRISPR complex, such as by hybridizing along at least a portion of the tracr sequence to all or a portion of a tracr mate sequence operably linked to the guide sequence. In some embodiments, one or more vectors driving expression of one or more elements of a CRISPR system are introduced into a host cell such that expression of the elements of the CRISPR system directs formation of a CRISPR complex at one or more target sites. For example, a Cas enzyme, a guide sequence connected to a tracr pairing sequence, and a tracr sequence can each be operably connected to a separate regulatory element on a separate vector. Alternatively, two or more elements expressed from the same or different regulatory elements can be combined in a single vector, wherein one or more additional vectors providing any component of the CRISPR system are not included in the first vector. The CRISPR system elements combined in a single vector can be arranged in any suitable orientation, such as one element is located 5' ("upstream") or 3' ("downstream") relative to the second element. The coding sequence of an element can be located on the same strand or opposite strand of the coding sequence of the second element, and oriented in the same or opposite direction. In some embodiments, a single promoter drives the expression of one or more of the transcript encoding the CRISPR enzyme and the guide sequence, the tracr pairing sequence (optionally operably connected to the guide sequence), and the tracr sequence embedded in one or more intron sequences (e.g., each in a different intron, two or more in at least one intron, or all in a single intron). In some embodiments, the CRISPR enzyme, guide sequence, tracr mate sequence, and tracr sequence are operably linked to and expressed from the same promoter.

[0360] In some embodiments, a vector comprises one or more insertion sites, such as restriction endonuclease recognition sequences (also referred to as "cloning sites"). In some embodiments, one or more insertion sites (e.g., about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more insertion sites) are located upstream and / or downstream of one or more sequence elements of one or more vectors. In some embodiments, a vector comprises an insertion site upstream of a tracr pairing sequence and optionally downstream of a regulatory element operably connected to the tracr pairing sequence, such that after the guide sequence is inserted into the insertion site and when expressed, the guide sequence guides the CRISPR complex to bind to the sequence-specific target sequence in a eukaryotic cell. In some embodiments, a vector comprises one or more insertion sites, each of which is located between two tracr pairing sequences, thereby allowing the insertion of a guide sequence at each site. In such an arrangement, two or more guide sequences may comprise two or more copies of a single guide sequence, two or more different guide sequences, or a combination of these. When a plurality of different guide sequences are used, a single expression construct may be used to target CRISPR activity to a plurality of different corresponding target sequences within a cell. For example, a single vector can contain about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or more guide sequences. In some embodiments, about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more such target sequence-containing vectors can be provided and, optionally, delivered to a cell.

[0361] In some embodiments, a vector comprises a regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme (such as a Cas protein). Non-limiting examples of Cas proteins include: Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas10, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, homologs thereof, or modified forms thereof. In some embodiments, an unmodified CRISPR enzyme such as Cas9 has DNA cleavage activity. In some embodiments, the CRISPR enzyme directs the cleavage of one or both strands at the target sequence location (e.g., within the target sequence and / or within the complement of the target sequence). In some embodiments, the CRISPR enzyme directs the cleavage of one or both strands within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500, or more base pairs from the first or last nucleotide of the target sequence. In some embodiments, a vector encodes a CRISPR enzyme that is mutated relative to the corresponding wild-type enzyme, such that the mutated CRISPR enzyme lacks the ability to cleave one and both strands of a target polynucleotide containing a target sequence. For example, an aspartate to alanine substitution (D10A) in the RuvC I catalytic domain of Cas9 from Streptococcus pyogenes converts Cas9 from a nuclease that cleaves two strands to a nickase (cleaving a single strand). Other examples of mutations that render Cas9 a nickase include, but are not limited to, H840A, N854A, and N863A in SpCas9. As discussed herein, with reference to the position numbering of SpCas9, the corresponding positions may be conserved in other Cas9s, i.e., in Cas9 orthologs from or derived from other bacterial species. (FIG. 19) shows a multiple sequence alignment of 12 Cas9 orthologs, and indicates the conserved catalytic Asp residues in the RuvC I domain and the conserved catalytic His residues in the HNH domain. There is always one residue that mutates to Ala that converts the Cas9 ortholog into a nickase. Mutations in two residues convert the Cas9 ortholog into a catalytically ineffective mutant—useful for general DNA binding.As a further example, two or more catalytic domains of Cas9 (RuvC I, RuvC II, and RuvC III or the HNH domain) can be mutated to produce a mutated Cas9 ortholog substantially lacking all DNA cleavage activity. In some embodiments, the D10A mutation is combined with one or more of the H840A, N854A, or N863A mutations to produce a Cas9 enzyme substantially lacking all DNA cleavage activity. In some embodiments, the enzyme is considered to be substantially lacking all DNA cleavage activity when the DNA cleavage activity of the mutant CRISPR enzyme is about 25%, 10%, 5%, 1%, 0.1%, 0.01%, or less than that of its non-mutated form.

[0362] In addition, an aspartate to alanine substitution (D10A) in the RuvC I catalytic domain of SpCas9 was engineered to convert the nuclease into a nickase (see, e.g., Sapranauskas et al., 2011, Nucleic Acids Research, 39:9275; Gasiunas et al., 2012, Proc. Natl. Acad. Sci. USA, 109:E2579), so that the nicked genomic DNA undergoes high-fidelity homology-directed repair (HDR). The applicant used SURVEYOR assay to confirm that SpCas9n does not produce indels at the EMX1 protospacer target. It can be seen that the co-expression of a chimeric crRNA targeting EMX1 (also with a tracrRNA component) and SpCas9 produces indels in the target site, while co-expression with SpCas9n is not (n=3). In addition, the sequencing of 327 amplicons did not detect any indel induced by SpCas9n. The same seat was selected to test the HR mediated by CRISPR by co-transfection of HEK 293FT cells with chimeric RNA targeting EMX1, hSpCas9 or hSpCas9n and for introducing a pair of restriction sites (HindIII and NheI) near the prototype spacer. SpCas9 and SpCas9n indeed catalyze the integration of HR templates into the EMX1 seat. PCR amplification target region, followed by restriction digestion with HindIII, reveals the cleavage product corresponding to the desired fragment size, wherein SpCas9 and SpCas9n mediate similar levels of HR efficiency. The applicant further uses the Sanger sequencing of genomic amplicons to verify HR, and proves that CRISPR is used to promote the practicality of the gene inserted into the mammalian genome. Given that 14-bp (12-bp from the spacer and 2-bp from the PAM) are specifically targeted to wild-type SpCas9, the accessibility of the nickase can significantly reduce the possibility of off-target modifications because single-strand breaks are not substrates for the error-prone NHEJ pathway. Fig. 10A -M provides a scheme that shows that the positions of mutations in SpCas9 and Cas9 orthologs typically share a common structure of 3-4 RuvC domains and one HNH domain. The 5' most RuvC domain cuts the non-complementary strand, while the HNH domain cuts the complementary strand.

[0363] The catalytic residues in the 5'RuvC domain were identified by homology comparison of the Cas9 of interest with other Cas9 orthologs (from S. pyogenes type II CRISPR loci, S. thermophilus CRISPR loci 1, S. thermophilus CRISPR loci 3, and Franciscilla novicida type II CRISPR loci), and the conserved Asp residues were mutated to alanine to convert Cas9 into a complementary strand nicking enzyme. Similarly, the conserved His and Asn residues in the HNH domain were mutated to alanine to convert Cas9 into a non-complementary strand nicking enzyme.

[0364] In some embodiments, the enzyme coding sequence encoding the CRISPR enzyme is codon optimized for expression in specific cells, such as eukaryotic cells. These eukaryotic cells may be those of or derived from specific organisms, such as mammals, including but not limited to humans, mice, rats, rabbits, dogs, or non-human mammals (including non-human primates). In some embodiments, methods for modifying the germline genetic identity of humans and / or methods for modifying the genetic identity of animals, and also animals that are the result of such methods, which are likely to cause suffering to humans or animals without any substantial medical benefit, may be excluded.

[0365] In general, codon optimization refers to a method of modifying a nucleic acid sequence to enhance expression in a host cell of interest by replacing at least one codon of the native sequence (e.g., about or more than about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more codons) with codons that are more frequently or most frequently used in the genes of the host cell while maintaining the native amino acid sequence. Different species exhibit specific preferences for certain codons with specific amino acids. Codon bias (differences in codon usage between organisms) is often correlated with the efficiency of translation of messenger RNA (mRNA), which in turn is believed to depend on (among other things) the nature of the codons being translated and the availability of specific transfer RNA (tRNA) molecules. The predominance of selected tRNAs in a cell generally reflects the codons that are most frequently used for peptide synthesis. Thus, genes can be tailored for optimal gene expression in a given organism based on codon optimization. Codon usage tables are readily available, such as the Codon Usage Database ("Codon Usage Database") available at www.kazusa.orjp / codon / (visited on July 9, 2002). See, Nakamura Y. et al., "Codon usage tabulated from the international DNA sequence databases: status for the year 2000." Nucl. Acids Res. 28:292 (2000). Computer algorithms for codon optimization of specific sequences for expression in specific host cells are also available, such as Gene Forge (Aptagen; Jacobus, PA). In some embodiments, one or more codons (e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more, or all codons) in the sequence encoding the CRISPR enzyme correspond to the most frequently used codons for a particular amino acid.

[0366] In some embodiments, a vector encodes a CRISPR enzyme comprising one or more nuclear localization sequences (NLSs), such as about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs. In some embodiments, the CRISPR enzyme comprises about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs at or near the amino terminus, about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs at or near the carboxyl terminus, or a combination of these (e.g., one or more NLSs at the amino terminus and one or more NLSs at the carboxyl terminus). When more than one NLS is present, each can be selected to be independent of the other NLSs, such that a single NLS can be present in more than one copy and / or combined with the presence of one or more other NLSs in one or more copies. In a preferred embodiment of the invention, the CRISPR enzyme comprises up to 6 NLSs. In some embodiments, an NLS can be considered close to the N-terminus or C-terminus when the nearest amino acid of the NLS is within about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, or more amino acids along the polypeptide chain from the N-terminus or C-terminus. Non-limiting examples of NLSs include NLS sequences derived from: the NLS of the SV40 virus large T antigen, which has the amino acid sequence PKKKRKV; an NLS from a nucleoplasmin (e.g., a nucleoplasmin bipartite NLS having the sequence KRPAATKKAGQAKKKK); a c-myc NLS having the amino acid sequence PAAKRVKLD or RQRRNELKRSP; an hRNPA1 M9 NLS having the sequence NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY; the sequence RMRIZFKNKGKDTAELRRRRVEVSVELRKAKKDEQILKRRNV from the IBB domain of importin-α; the sequences VSRKRPRP and PPKKARED of myoma T protein; the sequence POPKKKPL of human p53; the sequence of mouse c-abl sequence SALIKKKKKMAP of IV; sequence DRLRR and PKQKKRK of influenza virus NS1; sequence RKLKKKIKKL of hepatitis virus delta antigen; sequence REKKKFLKRR of mouse Mx1 protein; sequence KRKGDEVDGVDEVAKKKSKK of human poly (ADP-ribose) polymerase; and sequence RKCLQAGMNLEARKTKK of steroid hormone receptor (human) glucocorticoid.

[0367] In general, the one or more NLSs have sufficient strength to drive the CRISPR complex to accumulate in a detectable amount in the nucleus of a eukaryotic cell. In general, the intensity of nuclear localization activity can drive the number of NLSs in the CRISPR enzyme, the one or more specific NLSs used, or a combination of these factors. Detection of accumulation in the nucleus can be performed by any suitable technique. For example, a detection marker can be fused to the CRISPR enzyme so that the position in the cell can be visualized, such as in combination with a means for detecting the position of the nucleus (e.g., a dye specific for the nucleus, such as DAPI). The nucleus can also be separated from the cell, and its contents can then be analyzed by any suitable method for detecting proteins, such as immunohistochemistry, western blotting, or enzyme activity assays. Accumulation in the nucleus can also be determined indirectly, such as by assaying the effect of CRISPR complex formation (e.g., assaying DNA cleavage or mutation at the target sequence, or assaying gene expression activity that is altered due to the effect of CRISPR complex formation and / or CRISPR enzyme activity), compared to a control not exposed to the CRISPR enzyme or complex, or exposed to a CRISPR enzyme lacking the one or more NLSs.

[0368] In general, a guide sequence is any polynucleotide sequence that has sufficient complementarity to a target polynucleotide sequence to hybridize to the target sequence and direct sequence-specific binding of a CRISPR complex to the target sequence. In some embodiments, the degree of complementarity between a guide sequence and its corresponding target sequence is about or more than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more when optimally aligned using a suitable alignment algorithm. Optimal alignment can be determined using any suitable algorithm for aligning sequences, non-limiting examples of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g., the Burrows WheelerAligner), ClustalW, Clustal X, BLAT, Novoalign (Novocraft Technologies; available at www.novocraft.com), ELAND (Illumina, San Diego, CA), SOAP (available at soap.genomics.org.cn), and Maq (available at maq.sourceforge.net). In some embodiments, a guide sequence is about or more than about 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length. In some embodiments, a guide sequence is less than about 75, 50, 45, 40, 35, 30, 25, 20, 15, 12, or fewer nucleotides in length. The ability of a guide sequence to direct sequence-specific binding of a CRISPR complex to a target sequence can be assessed by any suitable assay. For example, components of a CRISPR system sufficient to form a CRISPR complex, including the guide sequence to be tested, can be provided to a host cell with a corresponding target sequence, for example by transfection with a vector encoding the components of the CRISPR sequence, followed by assessment of preferential cleavage within the target sequence by a Surveyor assay as described herein. Similarly, cleavage of a target polynucleotide sequence can be assessed in a test tube by providing the target sequence, components of a CRISPR complex including the guide sequence to be tested, and a control guide sequence different from the test guide sequence, and comparing binding or cleavage rates at the target sequence between the test guide sequence and the control guide sequence reactions.Other assays are possible and will occur to those skilled in the art.

[0369] Multiplexed Nickase: Cas9 nickases can also be produced using the optimization and teaching aspects of Cas9 described in detail in this application. Cas9 nickases can be advantageously combined with guide RNA pairs to produce DNA double-strand breaks with defined overhangs. When two pairs of guide RNAs are used, it is possible to excise intervening DNA fragments. If the exogenous DNA segment is cut by these two pairs of guide RNAs to produce overhangs that are compatible with genomic DNA, the exogenous DNA fragment can be ligated into the genomic DNA to replace the excised fragment. For example, it can be used to remove the trinucleotide repeat expansion in the huntingtin (HTT) gene to treat Huntington's disease.

[0370] Cas9 and its chimeric guide RNA or tracrRNA and crRNA combination can be delivered as DNA or RNA.Delivery is all as RNA (normal or comprising base or backbone modification) molecule Cas9 and guide RNA can be used to reduce the amount of time that Cas9 protein persists in cells.This can reduce the level of off-target cleavage activity in target cells.Due to the time spent translating into protein by delivering Cas9 as mRNA, it may be advantageous to deliver guide RNA several hours after delivering Cas9 mRNA, so that the level of guide RNA available for interaction with Cas9 protein is maximized.

[0371] In cases where the amount of guide RNA is limited, it may be desirable to introduce Cas9 as mRNA and the guide RNA in the form of a DNA expression cassette, with a promoter driving expression of the guide RNA. In this way, the amount of guide RNA available will be amplified via transcription.

[0372] A variety of delivery systems can be introduced to introduce Cas9 (DNA or RNA) and guide RNA (DNA or RNA) into host cells. These delivery systems include the use of liposomes, viral vectors, electroporation, nanoparticles, nanowires (Shalek et al., Nano Letters, 2012), exosomes. Molecular Trojan horse liposomes (Pardridge et al., Cold Spring Harb Protoc; 2010; doi: 10.1101 / pdb.prot5407) can be used to deliver Cas9 and guide RNA across the blood-brain barrier.

[0373] Discussion of guide RNAs for orthologs: In some embodiments, guide RNAs are selected to reduce the degree of secondary structure within the guide RNA. In some embodiments, when optimally folded, about or less than about 75%, 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 1%, or less nucleotides of the guide RNA participate in self-complementary base pairing. Optimal folding can be determined by any suitable polynucleotide folding algorithm. Some algorithms are based on calculating the minimum Gibbs free energy. An example of such an algorithm is mFold, as described by Zuker and Stiegler, Nucleic Acids Res. 9 (1981), 133-148). Another example of a folding algorithm is the use of an online web server RNAfold developed by the Institute for Theoretical Chemistry at the University of Vienna (see, e.g., AR Gruber et al., 2008, Cell 106(1):23-24; and PA Carr and GM Church, 2009, Nature Biotechnology 27(12):1151-62). A method of optimizing a guide RNA for a Cas9 ortholog includes disconnecting a PolyU tract in the guide RNA. The disconnectable polyU tract may include a series of 4, 5, 6, 7, 8, 9, or 10 Us.

[0374] In general, a tracr mate sequence includes any sequence that has sufficient complementarity to a tracr sequence to promote one or more of the following: (1) excision of a guide sequence flanked by tracr mate sequences in a cell containing the corresponding tracr sequence; and (2) formation of a CRISPR complex at a target sequence, wherein the CRISPR complex comprises the tracr mate sequence hybridized to the tracr sequence. Typically, the degree of complementarity is with respect to optimal alignment of the tracr mate sequence with the tracr sequence along the length of the shorter of the two sequences. The optimal alignment can be determined by any suitable alignment algorithm, and can further account for secondary structure, such as self-complementarity within the tracr sequence or tracr mate sequence. In some embodiments, when optimally aligned, the degree of complementarity between the tracr sequence and the tracr mate sequence along the length of the shorter of the two is about or more than about 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97.5%, 99%, or higher. In some embodiments, the tracr sequence is about or more than about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, or more nucleotides in length. In some embodiments, the tracr sequence and tracr mate sequence are contained in a single transcript such that hybridization between the two produces a transcript having a secondary structure (e.g., a hairpin). In one embodiment of the invention, the transcript or transcribed polynucleotide sequence has at least two or more hairpins. In a preferred embodiment, the transcript has two, three, four, or five hairpins. In a further embodiment of the invention, the transcript has up to five hairpins. In a hairpin structure, the portion of the sequence 5' at the final "N" and upstream of the loop corresponds to the tracr mate sequence, and the portion of the sequence 3' of the loop corresponds to the tracr sequence.Additional non-limiting examples of single polynucleotides comprising a guide sequence, a tracr mate sequence, and a tracr sequence are as follows (listed 5' to 3'), wherein "N" represents a base of the guide sequence, the first block in lower case letters represents the tracr mate sequence, and the second block in lower case letters represents the tracr sequence, and the last poly-T sequence represents a transcription terminator: (1) NNNNNNNNNNNNNNNNNNNNNNgtttttgtactctcaagatttaGAAAtaaatcttgcagaagctacaaaga taaggcttcatgccgaaatcaacaccctgtcattttatggcagggtgttttcgttatttaaTTTTTT; (2) NNNNNNNNNNNNNNNNNNNNgtttttgtactctcaGAAAtgcagaagctacaaagataaggcttcatgccgaaatcaacaccctgtcattttatggcagggtgttttcgttatttaaTTTTTT; (3) NNNNNNNNNNNNNNNNNNNNgtttttgtactctcaGAAAtgcagaagctacaaagataaggcttcatgccgaaatcaacaccctgtcattttatggcagggtgtTTTTTT; (4) NNNNNNNNNNNNNNNNNNgttttagagctaGAAAtagcaagttaaaataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggtgcTTTT TT; (5)NNNNNNNNNNNNNNNNNNNNgttttagagctaGAAATAGcaagttaaaataaggctagtccgttatcaacttgaaaaagtgTTTTTTT; and (6) NNNNNNNNNNNNNNNNNNgttttagagctagAAATAGcaagttaaaataaggctagtccgttatca TTTTTTTT. In some embodiments, sequences (1) to (3) are used in combination with Cas9 from CRISPR1 of Streptococcus thermophilus. In some embodiments, sequences (4) to (6) are used in combination with Cas9 from CRISPR1 of Streptococcus pyogenes. In some embodiments, the tracr sequence is a transcript separate from a transcript comprising the tracr mate sequence.

[0375] Discussion of tracr pairing of orthologs: In some embodiments, a recombination template is also provided. The recombination template can be a component of another vector as described herein, contained in a separate vector, or provided as a separate polynucleotide. In some embodiments, the recombination template is designed to be used as a template in homologous recombination, such as within or near a target sequence that is cut or cleaved by a CRISPR enzyme as part of a CRISPR complex. The template polynucleotide can have any suitable length, such as about or more than about 10, 15, 20, 25, 50, 75, 100, 150, 200, 500, 1000, or more nucleotides in length. In some embodiments, the template polynucleotide is complementary to a portion of a polynucleotide comprising the target sequence. When optimally aligned, the template polynucleotide may overlap with one or more nucleotides (e.g., about or more than about 1, 5, 10, 15, 20, or more nucleotides) of the target sequence. In some embodiments, when a template sequence is optimally aligned with a polynucleotide comprising a target sequence, the nearest nucleotide of the template polynucleotide is within about 1, 5, 10, 15, 20, 25, 50, 75, 100, 200, 300, 400, 500, 1000, 5000, 10000, or more nucleotides of the target sequence.

[0376] In some embodiments, the CRISPR enzyme is part of a fusion protein comprising one or more heterologous protein domains (e.g., about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more domains in addition to the CRISPR enzyme). The CRISPR enzyme fusion protein may comprise any other protein, and optionally a linker sequence between any two domains. Examples of protein domains that may be fused to the CRISPR enzyme include, but are not limited to, epitope tags, reporter gene sequences, and protein domains having one or more of the following activities: methylase activity, demethylase activity, transcriptional activation activity, transcriptional repression activity, transcriptional release factor activity, histone modification activity, RNA cleavage activity, and nucleic acid binding activity. Non-limiting examples of epitope tags include histidine (His) tags, V5 tags, FLAG tags, influenza virus hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Examples of reporter genes include, but are not limited to, glutathione-S-transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT), β-galactosidase, β-glucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), autofluorescent proteins including blue fluorescent protein (BFP). The CRISPR enzyme can be fused to a gene sequence encoding a protein or protein fragment that binds to a DNA molecule or binds to other cellular molecules, including, but not limited to, maltose binding protein (MBP), S-tag, Lex A DNA binding domain (DBD) fusion, GAL4 DNA binding domain fusion, and herpes simplex virus (HSV) BP16 protein fusion. Additional domains that may form part of a fusion protein comprising a CRISPR enzyme are described in US20110059502, which is incorporated herein by reference. In some embodiments, a labeled CRISPR enzyme is used to identify the location of a target sequence.

[0377] In some embodiments, the CRISPR enzyme may form a component of an inducible system. The inducible nature of the system will allow the system to use a form of energy to perform spatiotemporal control of gene editing or gene expression. The energy form may include, but is not limited to, electromagnetic radiation, acoustic energy, chemical energy, and thermal energy. Examples of inducible systems include tetracycline inducible promoters (Tet-On or Tet-Off), small molecule double hybrid transcriptional activation systems (FKBP, ABA, etc.)) or light inducible systems (photochrome, LOV domain or cryptochrome). In one embodiment, the CRISPR enzyme may be part of a light-induced transcriptional effector (LITE) that directs changes in transcriptional activity in a sequence-specific manner. The components of light may include CRISPR enzymes, light-responsive cytochrome heterodimers (e.g., from Arabidopsis), and transcriptional activation / repression domains. Other examples of inducible DNA binding proteins and methods for using them are provided in US 61 / 736465 and US 61 / 721,283, which are hereby incorporated by reference in their entirety.

[0378] In some aspects, the present invention provides the following methods, which include delivering one or more polynucleotides to a host cell, such as or as one or more vectors described herein, one or more transcripts thereof, and / or one or more proteins transcribed therefrom. In some aspects, the present invention further provides cells produced by such methods and animals including such cells or produced by such cells. In some embodiments, the CRISPR enzyme combined with (and optionally compounded with) a guide sequence is delivered to a cell. Conventional viral and non-viral gene transfer methods can be used to introduce nucleic acids into mammalian cells or target tissues. Such methods can be used to give nucleic acids encoding components of the CRISPR system to cells in culture or in a host organism. Non-viral vector delivery systems include DNA plasmids, RNA (transcripts of vectors such as described herein), naked nucleic acids, and nucleic acids compounded with delivery excipients (such as liposomes). Viral vector delivery systems include DNA and RNA viruses, which have free or integrated genomes after being delivered to cells. For reviews of gene therapy procedures, see Anderson, Science 256:808-813 (1992); Nabel & Felgner, TIBTECH 11:211-217 (1993); Mitani & Caskey, TIBTECH 11:162-166 (1993); Dillon, TIBTECH 11:167-175 (1993); Miller, Nature 357:455-460 (1992); Van Brunt, Biotechnology 6(10):1149-1154 (1988); Vigne, Restorative Neurology and Neuroscience. Neuroscience 8:35-36 (1995); Kremer & Perricaudet, British Medical Bulletin 51(1):31-44 (1995); Haddada et al., Current Topics in Microbiology and Immunology; Doerfler and Bohm, ed. (eds.) (1995); and Yu et al., Gene Therapy 1:13-26 (1994).

[0379] Non-viral delivery methods for nucleic acids include lipofection, microinjection, gene guns, viral particles, liposomes, immunoliposomes, polycations or lipid: nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. Lipofection is described in, for example, U.S. Pat. Nos. 5,049,386, 4,946,787, and 4,897,355, and lipofection reagents are commercially available (e.g., Transfectam TM Lipofectin TM Cationic and neutral lipids suitable for efficient receptor recognition lipofection of polynucleotides include those of Felgner, WO 91 / 17424; WO 91 / 16024. Delivery can be directed to cells (eg, in vitro or ex vivo administration) or to target tissues (eg, in vivo administration).

[0380] Preparation of lipid:nucleic acid complexes (including targeted liposomes such as immunolipid complexes) is well known to those skilled in the art (see, e.g., Crystal, Science 270:404-410 (1995); Blaese et al., Cancer Gene Ther. 2:291-297 (1995); Behr et al., Bioconjugate Chem. 5:382-389 (1994); Remy et al., Bioconjugate Chem. 5:647-654 (1994); Gao et al., Gene Therapy 2:710-722 (1995); Ahmad et al., Cancer Res. 2:414-415 (1996); Res.) 52:4817-4820 (1992); U.S. Patent Nos. 4,186,183, 4,217,344, 4,235,871, 4,261,975, 4,485,054, 4,501,728, 4,774,085, 4,837,028 and 4,946,787).

[0381] The system delivery nucleic acid using RNA or DNA virus base utilizes the specific cells in the virus targeting body and the highly evolved process that the virus payload (payload) is transported to the nucleus. The viral vector can be directly given to the patient (in vivo) or they can be used to treat cells in vitro, and optionally, the modified cells can be given to the patient (ex vivo). Conventional virus-based system can include retroviral vectors, slow virus vectors, adenovirus vectors, adeno-associated virus vectors and herpes simplex virus vectors for gene transfer. It is possible to integrate into the host genome with retrovirus, slow virus and adeno-associated virus gene transfer methods, which usually results in the long-term expression of the insertion transgene. In addition, high transduction efficiency has been observed in different cell types and target tissues.

[0382] The tropism of retrovirus can be changed by incorporating exogenous envelope proteins to expand the potential target population of target cells. Lentiviral vectors are retroviral vectors that can transduce or infect non-dividing cells and typically produce higher viral titers. Therefore, the selection of retroviral gene transfer systems will depend on the target tissue. Retroviral vectors are composed of cis-acting long terminal repeats, which have the ability to package up to 6-10kb of exogenous sequences. The minimum amount of cis-acting LTR is sufficient for the replication and packaging of the vector, and then these vectors are used to integrate the therapeutic gene into the target cell to provide permanent transgenic expression. Widely used retroviral vectors include those based on murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), simian immunodeficiency virus (SIV), human immunodeficiency virus (HIV), and combinations thereof (see, e.g., Buchscher et al., J. Virol. 66:2731-2739 (1992); Johann et al., J. Virol. 66:1635-1640 (1992); Sommnerfelt et al., Virol. 176:58-59 (1990); Wilson et al., J. Virol. 63:2374-2378 (1989); Miller et al., J. Virol. 65:2220-2224 (1991); PCT / US94 / 05700).

[0383] In applications where transient expression is preferred, adenovirus-based systems can be used. Adenovirus-based vectors can have very high transduction efficiencies in many cell types and do not require cell division. With such vectors, higher titers and expression levels have been achieved. This vector can be produced in large quantities in a relatively simple system.

[0384] Adeno-associated virus ("AAV") vectors can also be used to transduce cells with target nucleic acids, e.g., for in vitro production of nucleic acids and peptides, and for in vivo and ex vivo gene therapy procedures (see, e.g., West et al., Virology 160:38-47 (1987); U.S. Pat. No. 4,797,368; WO 93 / 24641; Kotin, Human Gene Therapy 5:793-801 (1994); Muzyczka, J. Clin. Invest. 94:1351 (1994)). The construction of recombinant AAV vectors is described in multiple publications, including U.S. Pat. No. 5,173,414; Tratschin et al., Mol. Cell. Biol. 5:3251-3260 (1985); Tratschin et al., Mol. Cell. Biol. 4:2072-2081 (1984); Hermonat & Muzyczka, PNAS 81:6466-6470 (1984); and Samulski et al., J. Virol. 63:03822-3828 (1989).

[0385] Typically, packaging cells are used to form viral particles capable of infecting host cells. Such cells include 293 cells that package adenovirus and ψ2 cells or PA317 cells that contain retroviruses. The viral vectors used in gene therapy are usually produced by cell lines that package nucleic acid vectors into viral particles. These vectors typically contain the minimum amount of sequences required for packaging and subsequent integration into the host, and other viral sequences are replaced by expression cassettes for one or more polynucleotides to be expressed. The lost viral function is typically provided in trans by the packaging cell line. For example, the AAV vector used in gene therapy typically has only ITR sequences from the AAV genome, which are required for packaging and integration into the host genome. The viral DNA is packaged into the following cell line, which contains other AAV genes encoding auxiliary plasmids, i.e., rep and cap, but lacks ITR sequences. The cell line can also be infected by adenovirus as an assistant. The helper virus promotes the replication of the AAV vector and expresses the AAV gene from the helper plasmid. Due to the lack of ITR sequences, the helper plasmid is not packaged in significant amounts. Adenovirus contamination can be reduced by, for example, heat treatment to which adenovirus is more sensitive than AAV. Additional methods for delivering nucleic acids to cells are known to those skilled in the art. See, for example, US20030087817, incorporated herein by reference.

[0386] Therefore, AAV is considered to be an ideal candidate for use as a transduction vector. Such an AAV transduction vector may include enough cis-acting functions to replicate in the presence of adenovirus or herpes virus or poxvirus (e.g., vaccinia virus) auxiliary functions provided in trans. Recombinant AAV (rAAV) can be used to carry foreign genes into cells of various lineages. In these vectors, AAV cap and / or rep genes are deleted from the viral genome and replaced with selected DNA segments. Current AAV vectors can accommodate up to 4300 bases of inserted DNA.

[0387] There are many ways to produce rAAV, and the present invention provides rAAV and methods for preparing rAAV. For example, one or more plasmids contain or substantially contain the desired viral construct, which is transfected into AAV infected cells. In addition, a second or additional helper plasmid is co-transfected into these cells to provide the AAV rep and / or cap genes necessary for the replication and packaging of the recombinant viral construct. Under these conditions, the rep and / or cap proteins of AAV act in trans to stimulate the replication and packaging of the rAAV construct. Two to three days after transfection, rAAV is harvested. Traditionally, rAAV is harvested from cells together with adenovirus. Then, the contaminated adenovirus is inactivated by heat treatment. In the present invention, rAAV is advantageously not harvested from the cells themselves, but from the cell supernatant. Thus, in an initial aspect, the invention provides for the preparation of rAAV, and in addition to the foregoing, rAAV may be prepared by a method comprising or consisting essentially of: infecting susceptible cells with rAAV comprising exogenous DNA (including DNA for expression) and a helper virus (e.g., adenovirus, herpes virus, pox virus such as vaccinia virus), wherein the rAAV lacks functional cap and / or rep (and a helper virus (e.g., adenovirus, herpes virus, pox virus such as vaccinia virus) that provides the cap and / or rev functions that the rAAV lacks); or infecting susceptible cells with rAAV comprising exogenous DNA (including DNA for expression), wherein the recombinant lacks functional cap and / or rep, and transfecting the cells with a plasmid that provides the cap and / or rep functions that the rAAV lacks; or infecting susceptible cells with rAAV comprising exogenous DNA (including DNA for expression). Infecting susceptible cells, wherein the recombinant lacks functional cap and / or rep, wherein the cells provide the cap and / or rep functions that the recombinant lacks; or transfecting susceptible cells with an AAV lacking functional cap and / or rep and a plasmid for inserting exogenous DNA into the recombinant so that the exogenous DNA is expressed by the recombinant and for providing rep and / or cap functions, thereby transfecting to produce rAAV lacking functional cap and / or rep that contains the exogenous DNA (including DNA for expression).

[0388] The rAAV can be from AAV as described herein, and advantageously can be rAAV1, rAAV2, AAV5 or rAAV with a hybrid or capsid, which can include AAV1, AAV2, AAV5 or any combination thereof. One can select the AAV of the rAAV with respect to the cells to be targeted by the rAAV; for example, one can select AAV serotypes 1, 2, 5 or hybrids or capsids AAV1, AAV2, AAV5 or any combination thereof for targeting brain or neuronal cells; and one can select AAV4 for targeting cardiac tissue, AAV8 for targeting liver tissue.

[0389] In addition to 293 cells, other cells that can be used in the practice of the present invention and the relative infectivity of certain in vitro AAV serotypes of these cells (see Grimm, D. et al., J. Virol. 82:5887-5911 (2008)) are as follows:

[0390]

[0391]

[0392] The present invention provides rAAV comprising or consisting essentially of an exogenous nucleic acid molecule encoding a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) system, for example, a plurality of cassettes, the plurality of cassettes comprising or comprising a first cassette, the first cassette comprising or consisting essentially of a promoter, a nucleic acid molecule encoding a CRISPR-associated (Cas) protein (putative nuclease or helicase protein) (e.g., Cas9) and a terminator, and two or more, advantageously up to the packaging size limit of the vector, for example a total of (including the first cassette) five cassettes, the cassettes comprising or consisting essentially of a promoter, a nucleic acid molecule encoding a guide RNA (gRNA) and a terminator (e.g., each cassette schematically consists of promoter-gRNA1-terminator, promoter-gRNA2-terminator... The invention relates to a plurality of rAAVs, each rAAV comprising one or more CRISPR system boxes, for example, a first rAAV comprising a first box comprising or consisting essentially of a promoter, a nucleic acid molecule encoding Cas (e.g., Cas9) and a terminator, and a second rAAV comprising a plurality of, four, boxes comprising or consisting essentially of a promoter, a nucleic acid molecule encoding a guide RNA (gRNA) and a terminator (e.g., each box is schematically represented by promoter-gRNA1-terminator, promoter-gRNA2-terminator ... promoter-gRNA (N)-terminator (where N is the number that can be inserted at the upper limit of the packaging size limit of the vector)). Since rAAV is a DNA virus, the nucleic acid molecule in this discussion involving AAV or rAAV is advantageously DNA. In some embodiments, the promoter is advantageously a human synapsin I promoter (hSyn).

[0393] Two ways of mediating in vivo genome modification, packaging of Cas9 encoding nucleic acid molecules such as DNA into viral vectors, are preferred:

[0394] To achieve NHEJ-mediated gene knockout:

[0395] Single virus vector:

[0396] Vectors containing two or more expression cassettes:

[0397] Promoter-Cas9 encoding nucleic acid molecule-terminator

[0398] Promoter-gRNA1-Terminator

[0399] Promoter-gRNA2-Terminator

[0400] Promoter-gRNA(N)-Terminator (until the size limit of the vector)

[0401] Dual Viral Vectors:

[0402] Vector containing an expression cassette for driving Cas9 expression1

[0403] Promoter-Cas9 encoding nucleic acid molecule-terminator

[0404] Vector 2 containing one or more expression cassettes for driving expression of one or more guide RNAs

[0405] Promoter-gRNA1-Terminator

[0406] Promoter-gRNA(N)-Terminator (until the size limit of the vector)

[0407] To mediate homology directed repair. In addition to the single and dual viral vector approaches described above, additional vectors can be used to deliver homology directed repair templates.

[0408] Promoters used to drive expression of Cas9 encoding nucleic acid molecules include:

[0409] AAV ITR can be used as a promoter: This is advantageous in that it eliminates the need for additional promoter elements (which can take up space in the vector). The additional space freed up can be used to drive the expression of additional elements (gRNA, etc.). Likewise, ITR activity is weak and can therefore be used to reduce toxicity due to overexpression of Cas9.

[0410] For ubiquitous expression, promoters can be used: CMV, CAG, CBh, PGK, SV40, ferritin heavy or light chain, etc.

[0411] For brain expression, the promoters can be used: Synapsin I for all neurons, CaMKIIα for excitatory neurons, GAD67 or GAD65 or VGAT for GABAergic neurons, etc.

[0412] For liver expression, the albumin promoter can be used.

[0413] For lung expression, SP-B can be used.

[0414] For endothelial cells, ICAM can be used.

[0415] For hematopoietic cells, IFNβ or CD45 can be used.

[0416] For osteoblasts, OG-2 can be used.

[0417] Promoters used to drive guide RNA may include:

[0418] Pol III promoters, such as U6 or H1

[0419] Using Pol II promoters and intronic cassettes to express gRNA

[0420] With respect to AAV, the AAV can be AAV1, AAV2, AAV5, or any combination thereof. One can select the AAV of the AAV with respect to the cells to be targeted; for example, one can select AAV serotype 1, 2, 5, or hybrids or capsid AAV1, AAV2, AAV5, or any combination thereof for targeting brain or neuronal cells; and one can select AAV4 for targeting cardiac tissue. AAV8 can be used for delivery to the liver. The above promoters and vectors are individually preferred.

[0421] Additional methods for delivering nucleic acids to cells are known to those skilled in the art. See, for example, US 20030087817, incorporated herein by reference.

[0422] In some embodiments, host cells are transiently or non-transiently transfected with one or more vectors described herein. In some embodiments, cells are transfected when they occur naturally in a subject. In some embodiments, the transfected cells are taken from a subject. In some embodiments, the cells are derived from cells taken from a subject, such as a cell line. A variety of cell lines for tissue culture are known in the art. Examples of cell lines include, but are not limited to, C8161, CCRF-CEM, MOLT, mIMCD-3, NHDF, HeLa-S3, Huh1, Huh4, Huh7, HUVEC, HASMC, HEKn, HEKa, MiaPaCell, Pancl, PC-3, TF1, CTLL-2, C1R, Rat6, CV1, RPTE, A10, T24, J82, A375, ARH-77, Calu1, SW480, SW620, SKOV3, SK-UT, CaCo2, P388D1, SEM-K2, WEHI-231, HB56, TIB55, Jurkat, J45.01, LRMB, Bcl-1, BC-3, IC21, DLD2, Raw264.7, NRK, NRK-52E, MRC5, MEF, HepG2, HeLa B, HeLa T4, COS, COS-1, COS-6, COS-M6A, BS-C-1 monkey kidney epithelial cells, BALB / 3T3 mouse embryonic fibroblasts, 3T3 Swiss, 3T3-L1, 132-d5 human fetal fibroblasts; 10.1 mouse fibroblasts, 293-T, 3T3, 721, 9L, A2780, A2780ADR, A2780cis, A172, A20, A253, A431, A-549, ALC, B16, B35, BCP-1 cells, BEAS-2B, bEnd.3, BHK-21, BR 293, BxPC3, C3H-10T1 / 2, C6 / 36, Cal-27, CHO, CHO-7, CHO-IR, CHO-K1, CHO-K2, CHO-T, CHO Dhfr- / -, COR-L23, COR-L23 / CPR, COR-L23 / 5010, COR-L23 / R23, COS-7, COV-434, CML T1, CMT, CT26, D17, DH82, DU145, DuCaP, EL4, EM2, EM3, EMT6 / AR1, EMT6 / AR10.0. FM3, H1299, H69, HB54, HB55, HCA2, HEK-293, HeLa, Hepa1c1c7, HL-60, HMEC, HT-29, Jurkat, JY cells, K562 cells, Ku812, KCL22, KG1, KYO1, LNCap, Ma-Mel 1-48, MC-38, MCF-7, MCF-10A, MDA-MB-231, MDA-MB-468, MDA-MB-435, MDCKII, MDCK II, MOR / 0.2R, MONO-MAC 6, MTD-1A, MyEnd, NCI-H69 / CPR, NCI-H69 / LX10, NCI-H69 / LX20, NCI-H69 / LX4, NIH-3T3, NALM-1, NW-145, OPCN / OPCT cell line, Peer, PNT-1A / PNT2, RenCa, RIN-5F, RMA / RMAS, Saos-2 cell, Sf-9, SkBr3, T2, T-47D, T84, THP1 cell line, U373, U87, U937, VCaP, Vero (Vero) cell, WM39, WT-49, X63, YAC-1, YAR and transgenic variant thereof. Cell line can be obtained from a variety of sources known to those skilled in the art (see, for example, American Type Culture Collection (ATCC) (Manassas (Manassus), Virginia)). In certain embodiments, a new cell line is established using a cell transfected with one or more vectors described herein, and the new cell line includes sequences of one or more vector sources. In some embodiments, cells transfected with components of a CRISPR system as described herein (such as by transient transfection with one or more vectors or transfection with RNA) and modified by the activity of a CRISPR complex are used to establish new cell lines, including cells that contain the immobilized protein but lack any other exogenous sequences. In some embodiments, cells transiently or non-transiently transfected with one or more vectors described herein, or cell lines derived from such cells, are used in evaluating one or more test compounds. .

[0423] In some embodiments, one or more vectors described herein are used to produce non-human transgenic animals or transgenic plants. In some embodiments, the transgenic animal is a mammal, such as a mouse, rat, or rabbit. Methods for producing transgenic plants and animals are known in the art and typically begin with cell transfection methods as described herein.

[0424] With recent advances in crop genomics, the ability to perform efficient and cost-effective gene editing and manipulation using CRISPR-Cas systems will allow rapid selection and comparison of single and multiple genetic manipulations to transform such genomes for improved production and enhanced traits. In this regard, reference is made to U.S. patents and publications: U.S. Patent No. 6,603,061 - Agrobacterium-Mediated Plant Transformation Method; U.S. Patent No. 7,868,149 - Plant Genome Sequences and Uses Thereof and US 2009 / 0100536 - Transgenic Plants with Enhanced Agronomic Traits, all contents and disclosures of each of which are incorporated herein by reference in their entirety. In the practice of the present invention, the contents and disclosures of Morrell et al. "Crop genomics: advances and applications" Nat Rev Genet. 2011 Dec 29; 13(2): 85-96 are also incorporated herein by reference in their entirety. In an advantageous embodiment of the present invention, the CRISPR / Cas9 system is used to engineer microalgae (Example 7). Therefore, mutatis mutandis, references to animal cells herein also apply to plant cells unless otherwise apparent.

[0425] In one aspect, the invention provides methods for modifying target polynucleotides in eukaryotic cells, which methods can be in vivo, in vitro or in vitro. In some embodiments, the method includes sampling cells or cell groups from humans or non-human animals or plants (including microalgae), and modifying the cells or cells. Cultivation can occur at any stage in vitro. The cells or cells can even be reintroduced into the non-human animal or plant (including microalgae). For the cells reintroduced, it is particularly preferred that the cells are stem cells.

[0426] In some embodiments, the method comprises allowing a CRISPR complex to bind to the target polynucleotide to effect cleavage of said target polynucleotide thereby modifying the target polynucleotide, wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said target polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence.

[0427] In one aspect, the invention provides a method for modifying the expression of a polynucleotide in a eukaryotic cell. In some embodiments, the method includes allowing a CRISPR complex to bind to the polynucleotide such that the binding results in an increase or decrease in the expression of the polynucleotide; wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within the target polynucleotide, wherein the guide sequence is linked to a tracr pairing sequence, which in turn hybridizes to a tracr sequence. Similar considerations apply as above for methods of modifying target polynucleotides. In fact, these sampling, culturing, and reintroduction options apply across multiple aspects of the invention.

[0428] In one aspect, the invention provides the following kits, which include any one or more of the elements disclosed in the above methods and compositions. The elements can be provided individually or in combination, and can be provided in any suitable container, such as a vial, bottle or tube. In certain embodiments, the kit includes instructions in one or more languages, such as more than one language.

[0429] In some embodiments, the kit includes one or more reagents for use in the method utilizing one or more of the elements described herein. The reagent may be provided in any suitable container. For example, the kit may provide one or more reaction or storage buffers. The reagent may be provided in a form available in a specific assay or in a form (e.g., in a concentrated or lyophilized form) in which one or more other components need to be added before use. The buffer may be any buffer, including but not limited to sodium carbonate buffer, sodium bicarbonate buffer, borate buffer, Tris buffer, MOPS buffer, HEPES buffer and combinations thereof. In some embodiments, the buffer is alkaline. In some embodiments, the buffer has a pH from about 7 to about 10. In some embodiments, the kit includes one or more oligonucleotides corresponding to a guide sequence for insertion into a vector so as to operably connect the guide sequence and a regulatory element. In some embodiments, the kit includes a homologous recombination template polynucleotide.

[0430] In one aspect, the present invention provides methods for using one or more elements of a CRISPR system. The CRISPR complex of the present invention provides an effective means for modifying a target polynucleotide. The CRISPR complex of the present invention has a variety of practicability, including modification (e.g., deletion, insertion, translocation, inactivation, activation) of target polynucleotides in a variety of cell types. Because of this, the CRISPR complex of the present invention has a broad spectrum of applications in, for example, gene therapy, drug screening, disease diagnosis, and prognosis. An exemplary CRISPR complex includes a CRISPR enzyme compounded with a guide sequence that hybridizes with a target sequence within a target polynucleotide. The guide sequence is connected to a tracr pairing sequence, which in turn hybridizes with a tracr sequence.

[0431] In one embodiment, the present invention provides a method for cutting a target polynucleotide. The method includes modifying the target polynucleotide using a CRISPR complex, which binds to the target polynucleotide and implements the cutting of the target polynucleotide. Typically, when introduced into a cell, the CRISPR complex of the present invention produces a break (e.g., a single-strand or double-strand break) in the genomic sequence. For example, the method can be used to cut a disease gene in a cell.

[0432] The breaks produced by the CRISPR complex can be repaired by repair processes, such as error-prone non-homologous end joining (NHEJ) pathways or high-fidelity homology-directed repair (HDR). During these repair processes, an exogenous polynucleotide template can be introduced into the genomic sequence. In some methods, the HDR process is used to modify the genomic sequence. For example, an exogenous polynucleotide template is introduced into the cell, and the exogenous polynucleotide template includes a sequence to be integrated flanked by an upstream sequence and a downstream sequence. The upstream and downstream sequences have sequence similarity to either side of the integration site in the chromosome.

[0433] Where desired, the donor polynucleotide can be DNA, such as a DNA plasmid, a bacterial artificial chromosome (BAC), a yeast artificial chromosome (YAC), a viral vector, a linear stretch of DNA, a PCR fragment, naked nucleic acid, or a nucleic acid complexed with a delivery vehicle such as a liposome or poloxamer.

[0434] The exogenous polynucleotide template includes a sequence to be integrated (e.g., a mutated gene). The sequence to be integrated can be a sequence that is endogenous or exogenous to the cell. Examples of sequences to be integrated include polynucleotides or non-coding RNAs (e.g., microRNAs) that encode proteins. Therefore, the sequence to be integrated can be operably connected to one or more appropriate control sequences. Alternatively, the sequence to be integrated can provide a regulatory function.

[0435] The upstream and downstream sequences in the exogenous polynucleotide template are selected to promote the recombination between the chromosomal sequence of interest and the donor polynucleotide. The upstream sequence is a nucleic acid sequence with a sequence similarity to the genomic sequence upstream of the targeting site for integration. Similarly, the downstream sequence is a nucleic acid sequence with a sequence similarity to the chromosomal sequence downstream of the targeting site for integration. The upstream and downstream sequences in the exogenous polynucleotide template can have 75%, 80%, 85%, 90%, 95% or 100% sequence identity with the genomic sequence of targeting. Preferably, the upstream and downstream sequences in the exogenous polynucleotide template have about 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the genomic sequence of targeting. In some methods, the upstream and downstream sequences in the exogenous polynucleotide template have about 99% or 100% sequence identity with the genomic sequence of targeting.

[0436] The upstream or downstream sequence can include from about 20bp to about 2500bp, such as about 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400 or 2500bp. In some methods, exemplary upstream or downstream sequence has about 200bp to about 2000bp, about 600bp to about 1000bp or more specifically about 700bp to about 1000bp.

[0437] In some methods, the exogenous polynucleotide template can further include a marker. Such a marker makes it easy to screen for targeted integration. Examples of suitable markers include restriction sites, fluorescent proteins, or selective markers. Recombinant techniques can be used to construct the exogenous polynucleotide template of the present invention (see, for example, Sambrook et al., 2001 and Ausubel et al., 1996).

[0438] In an exemplary method for modifying a target polynucleotide by integrating an exogenous polynucleotide template, a double-strand break is introduced into a genomic sequence by a CRISPR complex, and the break is repaired via homologous recombination of an exogenous polynucleotide template, such that the template is integrated into the genome. The presence of the double-strand break promotes the integration of the template.

[0439] In other embodiments, the invention provides a method for modifying the expression of a polynucleotide in a eukaryotic cell. The method comprises increasing or decreasing the expression of a target polynucleotide by using a CRISPR complex bound to the polynucleotide.

[0440] In some methods, the target polynucleotide can be inactivated to implement the modification of expression in the cell. For example, when the CRISPR complex binds to a target sequence in the cell, the target polynucleotide is inactivated so that the sequence is not transcribed, the encoded protein is not produced, or the sequence does not function like the wild-type sequence. For example, a protein or microRNA encoding sequence can be inactivated so that the protein is not produced.

[0441] In some methods, a control sequence can be inactivated so that it no longer functions as a control sequence. As used herein, a "control sequence" refers to any nucleic acid sequence that affects the transcription, translation, or accessibility of a nucleic acid sequence. Examples of control sequences include promoters, transcription terminators, and enhancers, which are control sequences.

[0442] Inactivated target sequences can include deletion mutations (i.e., deletion of one or more nucleotides), insertion mutations (i.e., insertion of one or more nucleotides), or nonsense mutations (i.e., substitution of a single nucleotide with another nucleotide, such that a stop codon is introduced). In some methods, inactivation of a target sequence results in a "knock-out" of the target sequence.

[0443] The altered expression of one or more genomic sequences associated with a signal transduction biochemical pathway can be determined by measuring the difference in the mRNA levels of the corresponding genes between the test model cells and the control cells when they are contacted with the candidate agent. Alternatively, the differential expression of sequences associated with a signal transduction biochemical pathway can be determined by detecting the difference in the levels of the encoded polypeptide or gene product.

[0444] In order to determine the changes induced by the reagent at the level of mRNA transcripts or corresponding polynucleotides, the nucleic acids contained in the sample are first extracted according to standard methods in the art. For example, mRNA can be isolated using various hydrolases according to the procedures set forth in Sambrook et al. (1989) or extracted by nucleic acid binding resins following the accompanying instructions provided by the manufacturer. Then, the mRNA contained in the extracted nucleic acid sample is detected by amplification procedures or conventional hybridization assays (e.g., Northern blot analysis) according to methods widely known in the art or based on the methods exemplified herein.

[0445] For purposes of the present invention, amplification means any method that can replicate a target sequence with reasonable fidelity using primers and polymerases. Amplification can be performed by natural or recombinant DNA polymerases, such as TaqGoldTM, T7 DNA polymerase, Klenow fragment of E. coli DNA polymerase, and reverse transcriptase. A preferred amplification method is PCR. Specifically, the isolated RNA can be subjected to a reverse transcription assay coupled to a quantitative polymerase chain reaction (RT-PCR) to quantify the expression level of sequences associated with a signal transduction biochemical pathway.

[0446] In the amplification assay, the detection of gene expression level can be performed in real time. In one aspect, the amplified product can be directly visualized with a fluorescent DNA binding agent, which includes but is not limited to a DNA intercalator and a DNA groove binding agent. Because the amount of the intercalator incorporated into the double-stranded DNA molecule is typically proportional to the amount of the amplified DNA product, the amount of the amplified product can be routinely determined by using the fluorescence of the dye quantitatively embedded by the conventional optical system of the art. Suitable DNA binding dyes for the present application include SYBR green, SYBR blue, DAPI, iodide propidium, Hoeste, SYBR gold, ethidium bromide, acridine, proflavine, acridine orange, acridine yellow, fluorcoumanin (fluorcoumanin), ellipticine, daunomycin, chloroquine, distamycin D, chromomycin, second phenanthridine (homidium), mithramycin, polypyridyl ruthenium, anthramycin etc.

[0447] In another aspect, other fluorescent markers (such as sequence-specific probes) can be used in the amplification reaction to facilitate detection and quantification of the amplified product. Probe-based quantitative amplification relies on sequence-specific detection of the desired amplified product. It utilizes fluorescent target-specific probes (e.g., Probes), resulting in increased specificity and sensitivity. Methods for performing probe-based quantitative amplification are established in the art and are taught in U.S. Pat. No. 5,210,015.

[0448] In another aspect, conventional hybridization assays can be performed using hybridization probes with sequence homology to the following sequences, which are associated with signal transduction biochemical pathways. Typically, in hybridization reactions, probes are allowed to form stable complexes with sequences associated with signal transduction biochemical pathways, which are contained in biological samples derived from test subjects. It should be appreciated by those skilled in the art that, in the case where antisense nucleic acids are used as probe nucleic acids, the target polynucleotides provided in the sample are selected to be complementary to the sequence of the antisense nucleic acids. On the contrary, in the case where the nucleotide probe is a sense nucleic acid, the target polynucleotides are selected to be complementary to the sequence of the sense nucleic acid.

[0449] Hybridization can be performed under different stringency conditions, such as described herein. Suitable hybridization conditions for practicing the present invention are such that the recognition interaction between the probe and the sequence associated with the signal transduction biochemical pathway is both sufficiently specific and sufficiently stable. The conditions for increasing the stringency of the hybridization reaction are widely known and disclosed in the art. See, for example, (Sambrook et al., (1989); Nonradioactive In Situ Hybridization Application Manual, Boehringer Mannheim, Second Edition). Hybridization assays can be performed using probes fixed on any solid support, including but not limited to nitrocellulose, glass, silicon, and a variety of gene arrays. As described in U.S. Patent No. 5,445,934, preferred hybridization assays are performed on high-density gene chips.

[0450] For conventional detection of the probe-target complex formed during hybridization assays, the nucleotide probe is complexed to a detectable label. Detectable labels suitable for use in the present invention include any composition detectable by photochemical, biochemical, spectroscopy, immunochemical, electrical, optical or chemical means. Various suitable detectable labels are known in the art, including fluorescent or chemiluminescent labels, radioisotope labels, enzymes or other ligands. In a preferred embodiment, it may be desirable to utilize fluorescent labels or enzyme tags, such as digoxin, beta-galactosidase, urease, alkaline phosphatase or peroxidase, avidin / biotin complexes.

[0451] The detection method for detecting or quantitative hybridization intensity will typically depend on the above selected label. For example, radioactive labels can be detected using photographic film or photosensitive imagers. Photodetectors that detect emitted light can be used to detect and quantify fluorescent labels. Enzyme labels are typically detected by providing a substrate for the enzyme and measuring the reaction product produced by the effect of the enzyme on the substrate; and finally, colorimetric labels are detected by simply visualizing the painted label.

[0452] Agent-induced expression changes of sequences associated with a signaling biochemical pathway can also be determined by examining the corresponding gene products. Determining protein levels typically involves a) contacting proteins contained in a biological sample with an agent that specifically binds to proteins associated with a signaling biochemical pathway; and (b) identifying any agent:protein complexes so formed. In one aspect of this embodiment, the agent that specifically binds to a protein associated with a signaling biochemical pathway is an antibody, preferably a monoclonal antibody.

[0453] The reaction is carried out by contacting the reagent with a sample of a protein associated with a signal transduction biochemical pathway derived from a test sample under conditions that will allow a complex to be formed between the reagent and the protein associated with the signal transduction biochemical pathway. The formation of the complex can be detected directly or indirectly according to standard procedures in the art. In direct detection methods, these reagents are provided with detectable labels and unreacted reagents can be removed from the complex; the amount of the remaining label indicates the amount of the complex formed. For such methods, it is preferred to select labels that are still attached to these reagents even during stringent washing conditions. Preferably, the label does not interfere with the binding reaction. In an alternative, an indirect detection procedure can use a reagent comprising a label introduced by a chemical method or an enzymatic method. Desirable labels do not usually interfere with the binding or stability of the resulting reagent: polypeptide complex. However, labels are typically designed to be accessible to antibodies for effective binding and thus producing detectable signals.

[0454] A wide variety of labels suitable for detecting protein levels are known in the art. Non-limiting examples include radioisotopes, enzymes, colloidal metals, fluorescent compounds, bioluminescent compounds, and chemiluminescent compounds.

[0455] The reagent formed during the binding reaction can be quantified by standard quantitative assays: the amount of the polypeptide complex. As shown above, the formation of the reagent: polypeptide complex can be directly measured by the amount of the marker still left at the binding site. In an alternative, the competitiveness of the protein associated with the signal transduction biochemical pathway and the labeled analog binding site on the specific reagent is tested. In this competitive assay, the amount of the captured marker is inversely proportional to the amount of the protein sequence associated with the signal transduction biochemical pathway present in the test sample.

[0456] A variety of techniques for protein analysis based on the general principles outlined above are available in the art. They include, but are not limited to, radioimmunoassay, ELISA (enzyme-linked immunoradiometric assay), "sandwich immunoassay, immunoradiometric assay, in situ immunoassay (using, for example, colloidal gold, enzyme or radioisotope labels), western blot analysis, immunoprecipitation assay, immunofluorescence assay and SDS-PAGE.

[0457] Antibodies that specifically recognize or bind to proteins associated with signal transduction biochemical pathways are preferred for performing the aforementioned protein analysis. Where desired, antibodies that recognize specific types of post-translational modifications (e.g., modifications induced by signal transduction biochemical pathways) can be used. Post-translational modifications include, but are not limited to, glycosylation, lipidation, acetylation, and phosphorylation. These antibodies can be purchased from commercial suppliers. For example, anti-phosphotyrosine antibodies that specifically recognize tyrosine phosphorylated proteins can be obtained from multiple suppliers, including Invitrogen and Perkin Elmer. Anti-phosphotyrosine antibodies are particularly useful in detecting proteins that are differentially phosphorylated on their tyrosine residues in response to ER stress. Such proteins include, but are not limited to, eukaryotic translation initiation factor 2α (eIF-2α). Alternatively, these antibodies can be produced using conventional polyclonal or monoclonal antibody techniques by immunizing host animals or antibody-producing cells with target proteins that display desired post-translational modifications.

[0458] In practicing the subject methods, it may be desirable to discern the expression profiles of proteins associated with signaling biochemical pathways in different body tissues, in different cell types, and / or in different subcellular structures. These studies may be performed using tissue-specific, cell-specific, or subcellular structure-specific antibodies that are capable of binding to protein markers that are preferentially expressed in certain tissues, cell types, or subcellular structures.

[0459] Altered expression of genes associated with a signaling biochemical pathway can also be determined by examining changes in activity of the gene products relative to control cells. The determination of agent-induced changes in activity of proteins associated with a signaling biochemical pathway will depend on the biological activity and / or signaling pathway under investigation. For example, where the protein is a kinase, changes in its ability to phosphorylate one or more downstream substrates can be determined by a variety of assays known in the art. Representative assays include, but are not limited to, immunoblotting and immunoprecipitation with antibodies, such as anti-phosphotyrosine antibodies that recognize phosphorylated proteins. In addition, kinase activity can be detected by high-throughput chemiluminescent assays, such as AlphaScreen TM (available from PerkinElmer) and eTag TM Assay (Chan-Hui et al. (2003) Clinical Immunology 111: 162-174).

[0460] In the case where the protein associated with the signal transduction biochemical pathway is a part of the signal transduction cascade that makes the intracellular pH condition fluctuate, a pH-sensitive molecule (such as a fluorescent pH dye) can be used as a reporter molecule. In another example where the protein associated with the signal transduction biochemical pathway is a kind of ion channel, the fluctuation of membrane potential and / or intracellular ion concentration can be monitored. Various commercial kits and high-throughput devices are particularly suitable for fast and robust screening of ion channel modulators. Representative instruments include FLIPRTM (Molecular Devices, Inc.) and VIPR (Aurora Biosciences). These instruments can simultaneously detect the reaction in more than 1000 sample wells of microplates, and can provide real-time measurement and functional data in one second or even one millisecond.

[0461] In practicing any of the methods disclosed herein, suitable vectors can be introduced into cells or embryos via one or more methods known in the art, including but not limited to microinjection, electroporation, sonoporation, gene gun, calcium phosphate-mediated transfection, cationic transfection, liposome transfection, dendrimer transfection, heat shock transfection, nuclear transfection, magnetofection, lipofection, impalefection, optical transfection, nucleic acid uptake enhanced by proprietary agents, and delivery via liposomes, immunoliposomes, viral particles, or artificial virions. In some methods, the vector is introduced into the embryo by microinjection. The vector or vectors can be microinjected into the nucleus or cytoplasm of the embryo. In some methods, the vector or vectors are introduced into the cell by nuclear transfection.

[0462] The target polynucleotide of the CRISPR complex can be any polynucleotide endogenous or exogenous to a eukaryotic cell. For example, the target polynucleotide can be a polynucleotide that resides in the nucleus of a eukaryotic cell. The target polynucleotide can be a sequence encoding a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulatory polynucleotide or a useless DNA).

[0463] Examples of target polynucleotides include sequences associated with signal transduction biochemical pathways, such as signal transduction biochemical pathway-related genes or polynucleotides. Examples of target polynucleotides include disease-related genes or polynucleotides. "Disease-related" genes or polynucleotides refer to any genes or polynucleotides that produce transcription or translation products at abnormal levels or in abnormal forms in cells derived from disease-affected tissues compared to tissues or cells of non-disease controls. In the case where the altered expression is associated with the appearance and / or progression of the disease, it can be a gene expressed at an abnormally high level; it can be a gene expressed at an abnormally low level. Disease-related genes also refer to genes with one or more mutations or genetic variations that are directly responsible for or are disequilibrium with one or more genes responsible for the etiology of the disease. The transcribed or translated products can be known or unknown and can be at normal or abnormal levels.

[0464] The target polynucleotide of the CRISPR complex can be any polynucleotide endogenous or exogenous to a eukaryotic cell. For example, the target polynucleotide can be a polynucleotide that resides in the nucleus of a eukaryotic cell. The target polynucleotide can be a sequence encoding a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulatory polynucleotide or a useless DNA).

[0465] The target polynucleotides of the CRISPR complex can include a plurality of disease-associated genes and polynucleotides and signaling biochemical pathway-associated genes and polynucleotides, as listed in U.S. Provisional Patent Applications 61 / 736,527 and 61 / 748,427, filed on December 12, 2012 and January 2, 2013, respectively, both entitled SYSTEMS METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION, with Broad Reference Nos. BI-2011 / 008 / WSGR Docket No. 44063-701.101 and BI-2011 / 008 / WSGR Docket No. 44063-701.102, the contents of all of which are incorporated herein by reference in their entirety.

[0466] Examples of target polynucleotides include sequences associated with signal transduction biochemical pathways, such as signal transduction biochemical pathway-related genes or polynucleotides. Examples of target polynucleotides include disease-related genes or polynucleotides. "Disease-related" genes or polynucleotides refer to any genes or polynucleotides that produce transcription or translation products at abnormal levels or in abnormal forms in cells derived from disease-affected tissues compared to tissues or cells of non-disease controls. In the case where the altered expression is associated with the appearance and / or progression of the disease, it can be a gene expressed at an abnormally high level; it can be a gene expressed at an abnormally low level. Disease-related genes also refer to genes with one or more mutations or genetic variations that are directly responsible for or are disequilibrium with one or more genes responsible for the etiology of the disease. The transcribed or translated products can be known or unknown and can be at normal or abnormal levels.

[0467] Examples of disease-associated genes and polynucleotides are available from the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, Maryland) and the National Center for Biotechnology Information, National Library of Medicine (Bethesda, Maryland).

[0468] Examples of disease-associated genes and polynucleotides are listed in Tables A and B. Disease-specific information available on the World Wide Web can be obtained from the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, Maryland) and the National Center for Biotechnology Information, National Library of Medicine (Bethesda, Maryland). Examples of signal transduction biochemical pathway-related genes and polynucleotides are listed in Table C.

[0469] Mutations in these genes and pathways can result in the production of inappropriate proteins or proteins that affect function in inappropriate amounts. Additional examples of genes, diseases, and proteins from U.S. Provisional Applications 61 / 736,527, filed December 12, 2012, and 61 / 748,427, filed January 2, 2013, are hereby incorporated by reference. Such genes, proteins, and pathways can be target polynucleotides for CRISPR complexes.

[0470] Table A

[0471]

[0472]

[0473] Table B:

[0474]

[0475]

[0476]

[0477]

[0478] Table C:

[0479]

[0480]

[0481]

[0482]

[0483]

[0484]

[0485]

[0486]

[0487]

[0488]

[0489]

[0490]

[0491]

[0492] Embodiments of the present invention also relate to methods and compositions for knocking out genes, amplifying genes, and repairing specific mutations associated with DNA repeat instability and neurological disorders (Robert D. Wells, Tetsuo Ashizawa, Genetic Instabilities and Neurological Diseases, 2nd ed., Academic Press, October 13, 2011 - Medical). Specific aspects of tandem repeat sequences have been found to be responsible for more than twenty human diseases (New insights into repeat instability: role of RNA·DNA hybrids. McIvor EI, Polak U, Napierala M. RNA Biol. 2010 Sep-Oct; 7(5):551-8). CRISPR-Cas systems can be used to correct genomic instability defects.

[0493] Another aspect of the present invention relates to the use of CRISPR-Cas systems to correct EMP2A and EMP2B Gene defects, which have been identified as being associated with Lafora disease. Lafora disease is an autosomal recessive disorder characterized by progressive myoclonic epilepsy that can begin as a seizure in adolescence. A few cases of the disease can be caused by mutations in genes that have not yet been identified. The disease causes seizures, muscle spasms, difficulty walking, dementia, and ultimately causes death. Currently no therapy has been shown to be effective against disease progression. Other genetic abnormalities associated with epilepsy can also target the CRISPR-Cas system and basic genetics are further described in Genetics of Epilepsy and Genetic Epilepsies, edited by Giuliano Avanzini and Jeffrey L. Noebels, Mariani Foundation Paediatric Neurology: 20; 2009).

[0494] In yet another aspect of the invention, the CRISPR-Cas system can be used to correct eye defects caused by several genetic mutations, which are further described in Genetic Diseases of the Eye, 2nd ed., edited by Elias I. Traboulsi, Oxford University Press, 2012.

[0495] Several additional aspects of the invention relate to correcting defects associated with a wide range of genetic diseases, which are further described on the website of the National Institutes of Health under the topical subsection Genetic Disorders (at health.nih.gov / topic / GeneticDisorders). Genetic brain diseases can include, but are not limited to, adrenoleukodystrophy, corpus callosum dysgenesis, Aicardi Syndrome, Alpers' Disease, Alzheimer's Disease, Barth Syndrome, Batten Disease, CADASIL, cerebellar degeneration, Fabry's Disease, Gerstmann-Straussler-Scheinker Disease, Huntington's disease and other triplet repeat disorders, Leigh's Disease, Lesch-Nyne Syndrome, Menkes Disease, mitochondrial myopathy, and NINDS Colpocephaly. These disorders are further described on the National Institutes of Health website under the section Genetic Brain Disorders.

[0496] In some embodiments, the disease can be a neoplasia. In some embodiments, in the case where the disease is a neoplasia, the gene to be targeted is any one of those genes listed in Table A (PTEN, etc. in this case). In some embodiments, the disease can be age-related macular degeneration. In some embodiments, the disease can be a schizophrenia disorder. In some embodiments, the disease can be a trinucleotide repeat disorder. In some embodiments, the disease can be fragile X syndrome. In some embodiments, the disease can be a secretase-related disorder. In some embodiments, the disease can be a prion-related disorder. In some embodiments, the disease can be ALS. In some embodiments, the disease can be a drug addiction. In some embodiments, the disease can be autism. In some embodiments, the disease can be Alzheimer's disease. In some embodiments, the disease can be inflammation. In some embodiments, The disease can be Parkinson's disease.

[0497] Examples of proteins associated with Parkinson's disease include, but are not limited to, α-synuclein, DJ-1, LRRK2, PINK1, Parkin, UCHL1, Synphilin-1, and NURR1.

[0498] Examples of addiction-related proteins may include, for example, ABAT.

[0499] Examples of inflammation-related proteins may include, for example, monocyte chemoattractant protein-1 (MCP1) encoded by the Ccr2 gene, CC chemokine receptor type 5 (CCR5) encoded by the Ccr5 gene, IgG receptor IIB (FCGR2b, also known as CD32) encoded by the Fcgr2b gene, or FcεR1g (FCER1g) protein encoded by the Fcer1g gene.

[0500] Examples of cardiovascular disease-related proteins may include, for example, IL1B (interleukin 1, beta), XDH (xanthine dehydrogenase), TP53 (tumor protein p53), PTGIS (prostaglandin I2 (prostacyclin) synthase), MB (myoglobin), IL4 (interleukin 4), ANGPT1 (angiopoietin 1), ABCG8 (ATP-binding cassette, subfamily G (WHITE), member 8) or CTSK (cathepsin K).

[0501] Examples of Alzheimer's disease-associated proteins may include, for example, very low density lipoprotein receptor protein (VLDLR) encoded by the VLDLR gene, ubiquitin-like modifier activating enzyme 1 (UBA1) encoded by the UBA1 gene, or NEDD8-activating enzyme E1 catalytic subunit protein (UBE1C) encoded by the UBA3 gene.

[0502] Examples of autism spectrum disorder-related proteins may include, for example, benzodiazepine receptor (peripheral)-associated protein 1 (BZRAP1) encoded by the BZRAP1 gene, AF4 / FMR2 family member 2 protein (AFF2) (also known as MFR2) encoded by the AFF2 gene, fragile X mental retardation autosomal homolog 1 protein (FXR1) encoded by the FXR1 gene, or fragile X mental retardation autosomal homolog 2 protein (FXR2) encoded by the FXR2 gene.

[0503] Examples of macular degeneration-related proteins may include, for example, the ATP-binding cassette, subfamily A (ABC1) member 4 protein (ABCA4) encoded by the ABCR gene, the apolipoprotein E protein (APOE) encoded by the APOE gene, or the chemokine (CC motif) ligand 2 protein (CCL2) encoded by the CCL2 gene.

[0504] Examples of schizophrenia-related proteins may include NRG1, ErbB4, CPLX1, TPH1, TPH2, NRXN1, GSK3A, BDNF, DISC1, GSK3B, and combinations thereof.

[0505] Examples of proteins involved in tumor suppression can include, for example, ATM (ataxia telangiectasia mutated), ATR (ataxia telangiectasia and Rad3 related), EGFR (epidermal growth factor receptor), ERBB2 (v-erb-b2 erythroleukemia viral oncogene homolog 2), ERBB3 (v-erb-b2 erythroleukemia viral oncogene homolog 3), ERBB4 (v-erb-b2 erythroleukemia viral oncogene homolog 4), Notch 1, Notch2, Notch 3 or Notch 4.

[0506] Examples of proteins associated with secretase disorders may include, for example, PSENEN (presenilin enhancer 2 homolog (Caenorhabditis elegans)), CTSB (cathepsin B), PSEN1 (presenilin 1), APP (amyloid beta (A4) precursor protein), APH1B (anterior pharyngeal defect 1 homolog B (Caenorhabditis elegans)), PSEN2 (presenilin 2 (Alzheimer's disease 4)), or BACE1 (beta-site APP-cleaving enzyme 1).

[0507] Examples of proteins associated with amyotrophic lateral sclerosis may include SOD1 (superoxide dismutase 1), ALS2 (amyotrophic lateral sclerosis 2), FUS (fused in sarcoma), TARDBP (TAR DNA binding protein), VAGFA (vascular endothelial growth factor A), VAGFB (vascular endothelial growth factor B) and VAGFC (vascular endothelial growth factor C) and any combination thereof.

[0508] Examples of proteins associated with prion diseases may include SOD1 (superoxide dismutase 1), ALS2 (amyotrophic lateral sclerosis 2), FUS (fused in sarcoma), TARDBP (TAR DNA binding protein), VAGFA (vascular endothelial growth factor A), VAGFB (vascular endothelial growth factor B), and VAGFC (vascular endothelial growth factor C), and any combination thereof.

[0509] Examples of proteins associated with neurodegenerative diseases in prion disorders may include, for example, A2M (alpha-2-macroglobulin), AATF (apoptosis-antagonizing transcription factor), ACPP (acid phosphatase of the prostate), ACTA2 (actin alpha 2 smooth muscle aorta), ADAM22 (ADAM metallopeptidase domain), ADORA3 (adenosine A3 receptor) or ADRA1D (Alpha-1D adrenergic receptor or Alpha-1D adrenoreceptor).

[0510] Examples of proteins associated with immunodeficiency may include, for example, A2M [alpha-2-macroglobulin]; AANAT [arylalkylamine N-acetyltransferase]; ABCA1 [ATP-binding cassette, subfamily A (ABC1), member 1]; ABCA2 [ATP-binding cassette, subfamily A (ABC1), member 2]; or ABCA3 [ATP-binding cassette, subfamily A (ABC1), member 3].

[0511] Examples of proteins associated with trinucleotide repeat disorders include, for example, AR (androgen receptor), FMR1 (fragile X mental retardation 1), HTT (huntingtin) or DMPK (myotonic dystrophy protein kinase), FXN (frataxin), ATXN2 (ataxin 2).

[0512] Examples of proteins associated with neurotransmission disorders include, for example, SST (somatostatin), NOS1 (nitric oxide synthase 1 (neuronal)), ADRA2A (adrenergic, alpha-2A-, receptor), ADRA2C (adrenergic, alpha-2C-, receptor), TACR1 (tachykinin receptor 1), or HTR2c (5-hydroxytryptamine (serotonin) receptor 2C).

[0513] Examples of neurodevelopment-associated sequences include, for example, A2BP1 [ataxin 2-binding protein 1], AADAT [aminoadipate aminotransferase], AANAT [arylalkylamine N-acetyltransferase], ABAT [4-aminobutyrate aminotransferase], ABCA1 [ATP-binding cassette, subfamily A (ABC1), member 1] or ABCA13 [ATP-binding cassette, subfamily A (ABC1), member 13].

[0514] Additional examples of preferred disorders that can be treated with the system of the present invention can be selected from: Aicardi-Goutières Syndrome; Alexander disease; Allan-Herndon-Dudley Syndrome; POLG-related disorders; α-mannosidosis (types II and III); Alström's syndrome ( Syndrome; Angelman; Syndrome; Ataxia- Telangiectasia; Neuronal ceroid-lipofuscinosis; Beta-thalassemia; Bilateral optic atrophy and type 1 (infantile) optic atrophy; Retinoblastoma (bilateral); Canavan Disease; Cerebro-oculofacioskeletal Syndrome 1 [COFS1]; Cerebrotendinous xanthomatosis; Cornelia de Lange Syndrome; MAPT-related disorders; Hereditary prion diseases; Dravet Syndrome; Early-onset familial Alzheimer's disease; Friedreich's ataxia [FRDA]; Multiple malformations; Fucosidosis; Fukuyama congenital muscular dystrophy; Galactosialidosis; Gaucher Disease; Organic acidemias; Hemophagocytic lymphohistiocytosis; Progeria; Mucolipidosis II; Infantile free sialic acid storage disease; PLA2G6-related neurodegeneration; Jervell and Lange-Nielsen Syndrome; Conjunctive epidermolysis bullosa; Huntington disease; Krabbe disease (infantile); Mitochondrial DNA-Associated Leigh Syndrome and NARP; Lesch-Nyhan syndrome; LIS1-related lissencephaly; Lowe syndrome; Maple syrup urine disease; MECP2 duplication syndrome; ATP7A-related copper transport disorder; LAMA2-related muscular dystrophy; Arylsulfatase A deficiency; Mucopolysaccharidosis type I, II, or III; Peroxisome biogenesis disorders, Zellweger spectrum syndrome Syndrome Spectrum; Neurodegeneration with brain iron accumulation disorder; Acid sphingomyelinase deficiency; Niemann-Pick disease type C; Glycine encephalopathy; ARX-related disorders; Urea cycle disorders; COL1A1 / 2-related osteogenesis imperfecta; Mitochondrial DNA deletion syndrome; PLP1-related disorders; Perry Syndrome; Phelan-McDermid Syndrome; Glycogen storage disease type II (Pompe disease) (infantile); MAPT-related disorders; MECP2-related disorders; Rhizomelic Chondrodysplasia Punctata Type 1;Roberts Syndrome; Sandhoff Disease; Schindler Disease Type 1; Adenosine Deaminase Deficiency; Stevens-Lemme-Ossen Syndrome; Spinal Muscular Atrophy; Infantile-Onset Spinocerebellar Ataxia; Hexosaminidase A Deficiency; Thanatosyl dysplasia Type 1; Collagen Type VI-Related Disorders; Usher Syndrome Type 1; Congenital Muscular Dystrophy; Wolf-Hirschhorn Syndrome; Lysosomal Acid Lipase Deficiency; and Xeroderma Pigmentosum.

[0515] As will be apparent, it is envisioned that any interested polynucleotide sequence can be targeted using the system of the present invention. Some examples of disorders or diseases that may be useful for treatment using the system of the present invention are included in the above table and examples of genes currently associated with those disorders are also provided herein. However, the genes of the examples are not exhaustive.

[0516] Examples

[0517] The following examples are given for the purpose of illustrating different embodiments of the present invention and are not intended to limit the present invention in any way. The present examples, together with the methods described herein, currently represent preferred embodiments, are exemplary, and are not intended to limit the scope of the present invention. Variations herein and other uses encompassed within the spirit of the present invention as defined by the scope of the claims are within the purview of those of ordinary skill in the art.

[0518] Example 1: Improvement of the Cas9 system for in vivo applications

[0519] Applicants performed a metagenomic search for Cas9 with small molecular weights. Most Cas9 orthologs are quite large. Many known Cas9 orthologs are large and contain more than 1300 amino acids. For example, SpCas9 is around 1368aa in length, which is too large to be easily packaged into a viral vector for delivery. An image showing the length distribution of Cas9 homologs is shown in Figure 6 Middle: This image was generated from sequences deposited in GenBank. Some sequences may have been misannotated and so the exact frequency of each length is not necessarily precise. Nevertheless, it provides a vague idea of ​​the distribution of the Cas9 protein and suggests that shorter Cas9 homologs exist.

[0520] Through computational analysis, the applicant discovered that in the bacterial strain Campylobacter, there are two Cas9 proteins with less than 1000 amino acids. The sequence of a Cas9 from Campylobacter jejuni is presented below. With this length, CjCas9 can be easily packaged into AAV, lentivirus, adenovirus, and other viral vectors for robust delivery into primary cells and into animal models. In a preferred embodiment of the present invention, a Cas9 protein from Staphylococcus aureus is used.

[0521] Campylobacter jejuni Cas9 (CjCas9)

[0522] MARILAFDIGISSIWAFSENDELKDCGVRIFTKVENPKTGESLALPRRRLARSARK RLARRKARLNHLKHLIANEFKLNYEDYQSFDESLAKAYKGSLISPYELRFRALN ELLSKQDFARVILHIAKRRGYDDIKNSDDKEKGAILKAIKQNEEKLANYQSVGEYLYKEYFQKFKENSKEFTNVRNKKESYERCIAQSFLKDELKLIFKKQREGFSFSKKFEEVLSVAFYKRALKDFSHLVGNCSFFTDEKRAPKNSPLAFMFVALTRIINL LNNLKNTEGILYTKDDLNALLNEVLKNGTLTYKQTKKLLGLSDDYEFKGEKGTYFIEFKKYKEFIKALGEHNLSQDDLNNEIAKDITLIKDEIKLKKALAKYDLNQNQID SLSKLEFKDHLNISFKALKLVTPLMEGKKYDEACNELNLKVAINEDKKDFLPAFNETYYKDEVTNPVLRAIKEYRKVLNALLKKYGKVHKINIELAREVGKNHSQ RAKIEKEQNENYKAKKDAELECEKLGLKKINSKNILKLRLFKEQKEFCAYSGEKIKISDLQDEKMLEIDHIYPYSRSFDDSYMNKVLVFTKQNQEKLNQTPFEAFGNDSA KWQKIEVLAKNLPTKKQKRILDKNYKDKEQKNFKDRNLNDTRYIARLVLNYTK DYLDFLPLPSDDENTKLNDTQKGSKVHVEAKSGMLTSALRHTWGFSAKDRNNHLHHAIDAVIIAYNNSIVKAFSDFKKEQESNSAELYAKKISELDYKNKRKFFEPFS GFRQKVLDKIDEIFVSKPERKKPSGALHEETFRKEEFYQSYGGKEGVLKALELGKIRKVNGKIVKNGDMFRVDIFKHKKTNKFYAVPIYTMDFALKVLPNKAVARSK KGEIKDWILMDENYEFCFSLYKDSLILIQTKDMQEPEFVYYNAFTSSTVSLIVSK HDNKFETLSKNQKILFKNANEKEVIAKSIGIQNLKVFEKYIVSALGEVTKAEFRQ REDFKK.

[0523] The putative tracrRNA elements of this CjCas9 are:

[0524] TATAATCTCATAAGAAATTTAAAAAGGGACTAAAATAAAGAGTTTGCGGGA CTCTGCGGGGTTACAATCCCCTAAAACCGCTTTTAAAATT

[0525] The direct repeat sequences are:

[0526] GTTTTAGTCCCTTTTAAATTTCTTTATGGTAAAAT

[0527] An example of a chimeric guide RNA for CjCas9 is:

[0528] NNNNNNNNNNNNNNNNNNGUUUUAGUCCCGAAAGGGACUAAAAUAAA GAGUUUGCGGGACUCUGCGGGGUUACAAUCCCCUAAAACCGCUUUU

[0529] Example 2: Cas9 diversity and chimeric RNA

[0530] The wild-type CRISPR-Cas system is an acquired immune mechanism against invasive foreign DNA that is utilized by different species across bacteria and archaea. The type II CRISPR-Cas system consists of a set of genes encoding proteins responsible for "capturing" foreign DNA into the CRISPR locus and a set of genes encoding proteins responsible for "executing" the DNA cutting mechanism; these include DNA nucleases (Cas9), non-coding trans-activating cr-RNAs (tracrRNAs), and exogenous DNA-derived spacer arrays (crRNAs) flanked by direct repeats. When matured by Cas9, the tracRNA and crRNA duplexes guide the Cas9 nuclease to the target DNA sequence specified by the spacer guide sequence, and mediate double-strand breaks in the DNA near a short sequence motif in the target DNA, which is required for cutting and is specific to each CRISPR-Cas system. Type II CRISPR-Cas systems are found throughout the bacterial kingdom and are highly diverse in terms of Cas9 protein sequence and size, tracrRNA and crRNA direct repeat sequences, genomic organization of these elements, and motif requirements for target cutting. A species can have multiple distinct CRISPR-Cas systems.

[0531] Applicants evaluated 207 putative Cas9s from bacterial species identified based on sequence homology to known Cas9s and structures orthologous to known subdomains, including HNH endonuclease domains and RuvC endonuclease domains [information from Eugene Koonin and Kira Makarova]. Phylogenetic analysis based on this set of protein sequence conservation revealed five Cas9 families, including three groups of large Cas9s (about 1400 amino acids) and two groups of small Cas9s (about 1100 amino acids) (see Figures 4 and 5A-F).

[0532] In some embodiments, the tracr mate sequences or the direct repeats are downloaded from the CRISPR database or identified in silico by searching for repeat motifs that are 1. found in a 2 kb window of the genomic sequence flanking the type II CRISPR locus, 2. spanning 20 to 50 bp, and 3. spaced apart by 20 to 50 bp. In some embodiments, 2 of these criteria may be used, such as 1 and 2, 2 and 3, or 1 and 3. In some embodiments, all 3 criteria may be used. In some embodiments, candidate tracrRNAs are subsequently predicted by: 1. sequence homology to direct repeats (motif search with up to 18-bp mismatches in Geneious), 2. the presence of a predicted Rho-independent transcription terminator in the transcription direction, and 3. a stable hairpin secondary structure between tracrRNA and direct repeats. In some embodiments, 2 of these criteria may be used, such as 1 and 2, 2 and 3, or 1 and 3. In some embodiments, all 3 criteria may be used. In some embodiments, the chimeric synthetic guide RNA (sgRNA) design incorporates at least 12 bp of duplex structure between the direct repeat and the tracrRNA.

[0533] Fig. 9A -O provides a way to Fig. 8A -J. Applicants have also shown that these Cas9 orthologs can cleave their targets in in vitro cleavage assays ( Fig.16 ). The CRISPR loci in some of these families are described in Fig.11 The corresponding guide RNA sequence is in Fig.12Shown in. The applicant systematically analyzed the genomic DNA sequence within about 2kb of the Cas9 protein using a custom computer analysis code, and identified the same direction repeats ranging from 35bp to 50bp, with an intervening spacer ranging from 29bp to 35bp. Based on the same direction repeat sequence, the applicant calculated and searched for tracrRNA candidate sequences according to the following standards: outside the crRNA array but with the same direction repeat containing a high degree of homology (such as for the same direction repeat: tracrRNA base pairing required; custom calculation analysis), outside the coding region of these protein components, about 60bp-120bp downstream of the region with homology to the same direction repeat contains a transcription termination signal that does not rely on Rho, and co-folds with the same direction repeat to form a duplex, and then forms two or more hairpin structures at the far end of the tracrRNA sequence. Based on these prediction criteria, the applicant selects an initial set of 18 kinds of Cas9 proteins, and uniquely related same direction repeats and tracrRNAs are distributed across all five Cas9 families. Applicants further generated a set of 18 chimeric RNA structures that retain the sequence and secondary structure of the natural direct repeat:tracrRNA duplex while shortening the base pairing region and fusing the two RNA elements through an artificial loop ( Fig. 8A -J).

[0534] Example 3: Cas9 orthologs

[0535] Applicants have generated codon-optimized Cas9 orthologs to facilitate expression in eukaryotic cells.

[0536] Examples of human codon optimized sequences (i.e., optimized for expression in humans) sequences are provided below for SaCas9:

[0537] ACCGGTGCCACCATGTACCCATACGATGTTCCAGATTACGCTTCGCCGAAGA AAAAGCGCAAGGTCGAAGCGTCCATGAAAAGGAACTACATTCTGGGGCTGGACATCGGGATTACAAGCGTGGGGTATGGGATTATTGACTATGAAACAAGGG ACGTGATCGACGCAGGCGTCAGACTGTTCAAGGAGGCCAACGTGGAAAACA ATGAGGGACGGAGAAGCAAGAGGGGAGCCAGGCGCCTGAAACGACGGAGAAGGCACAGAATCCAGAGGGTGAAGAAACTGCTGTTCGATTACAACCTGCTG ACCGACCATTCTGAGCTGAGTGGAATTAATCCTTATGAAGCCAGGGTGAAAGGCCTGAGTCAGAAGCTGTCAGAGGAAGAGTTTTCCGCAGCTCTGCTGCACC TGGCTAAGCGCCGAGGAGTGCATAACGTCAATGAGGTGGAAGAGGACACCG GCAACGAGCTGTCTACAAAGGAACAGATCTCACGCAATAGCAAAGCTCTGGAAGAGAAGTATGTCGCAGAGCTGCAGCTGGAACGGCTGAAGAAAGATGGCG AGGTGAGAGGGTCAATTAATAGGTTCAAGACAAGCGACTACGTCAAAGAAGCCAAGCAGCTGCTGAAAGTGCAGAAGGCTTACCACCAGCTGGATCAGAGCT TCATCGATACTTATATCGACCTGCTGGAGACTCGGAGAACCTACTATGAGGG ACCAGGAGAAGGGAGCCCCTTCGGATGGAAAGACATCAAGGAATGGTACGAGATGCTGATGGGACATTGCACCTATTTTCCAGAAGAGCTGAGAAGCGTCAAGTACGCTTATAACGCAGATCTGTACAACGCCCTGAATGACCTGAACAACCTGGTCATCACCAGGGATGAAAACGAGAAACTGGAATACTATGAGAAGTTCCAG ATCATCGAAAACGTGTTTAAGCAGAAGAAAAAGCCTACACTGAAACAGATTGCTAAGGAGATCCTGGTCAACGAAGAGGACATCAAGGGCTACCGGGTGACAAGCACTGGAAAACCAGAGTTCACCAATCTGAAAGTGTATCACGATATTAAG GACATCACAGCACGGAAAGAAATCATTGAGAACGCCGAACTGCTGGATCAGATTGCTAAGATCCTGACTATCTACCAGAGCTCCGAGGACATCCAGGAAGAG CTGACTAACCTGAACAGCGAGCTGACCCAGGAAGAGATCGAACAGATTAGT AATCTGAAGGGGTACACCGGAACACACAACCTGTCCCTGAAAGCTATCAATCTGATTCTGGATGAGCTGTGGCATACAAACGACAATCAGATTGCAATCTTTA ACCGGCTGAAGCTGGTCCCAAAAAAGGTGGACCTGAGTCAGCAGAAAGAGATCCCAACCACACTGGTGGACGATTTCATTCTGTCACCCGTGGTCAAGCGGAG CTTCATCCAGAGCATCAAAGTGATCAACGCCATCATCAAGAAGTACGGCCTGCCCAATGATATCATTATCGAGCTGGCTAGGGAGAAGAACAGCAAGGACGCA CAGAAGATGATCAATGAGATGCAGAAACGAAACCGGCAGACCAATGAACGCATTGAAGAGATTATCCGAACTACCGGGAAAGAGAACGCAAAGTACCTGAT TGAAAAAATCAAGCTGCACGATATGCAGGAGGGAAAGTGTCTGTATTCTCTGGAGGCCATCCCCCTGGAGGACCTGCTGAACAATCCATTCAACTACGAGGTC GATCATATTATCCCCAGAAGCGTGTCCTTCGACAATTCCTTTAACAACAAGGTGCTGGTCAAGCAGGAAGAGAACTCTAAAAAGGGCAATAGGACTCCTTTCCAGTACCTGTCTAGTTCAGATTCCAAGATCTCTTACGAAACCTTTAAAAAGCACATTCTGAATCTGGCCAAAGGAAAGGGCCGCATCAGCAAGACCAAAAAGGAGTACCTGCTGGAAGAGCGGGACATCAACAGATTCTCCGTCCAGAAGGATTTTATTAACCGGAATCTGGTGGACACAAGATACGCTACTCGCGGCCTGATGAATC TGCTGCGATCCTATTTCCGGGTGAACAATCTGGATGTGAAAGTCAAGTCCATCAACGGCGGGTTCACATCTTTTCTGAGGCGCAAATGGAAGTTTAAAAAGGA GCGCAACAAAGGGTACAAGCACCATGCCGAAGATGCTCTGATTATCGCAAA TGCCGACTTCATCTTTAAGGAGTGGAAAAAGCTGGACAAAGCCAAGAAAGTGATGGAGAACCAGATGTTCGAAGAGAAGCAGGCCGAATCTATGCCCGAAAT CGAGACAGAACAGGAGTACAAGGAGATTTTCATCACTCCTCACCAGATCAAGCATATCAAGGATTTCAAGGACTACAAGTACTCTCACCGGGTGGATAAAAA GCCCAACAGAGAGCTGATCAATGACACCCTGTATAGTACAAGAAAAGACGA TAAGGGGAATACCCTGATTGTGAACAATCTGAACGGACTGTACGACAAAGATAATGACAAGCTGAAAAAGCTGATCAACAAAAGTCCCGAGAAGCTGCTGAT GTACCACCATGATCCTCAGACATATCAGAAACTGAAGCTGATTATGGAGCAGTACGGCGACGAGAAGAACCCACTGTATAAGTACTATGAAGAGACTGGGAA CTACCTGACCAAGTATAGCAAAAAGGATAATGGCCCCGTGATCAAGAAGAT CAAGTACTATGGGAACAAGCTGAATGCCCATCTGGACATCACAGACGATTACCCTAACAGTCGCAACAAGGTGGTCAAGCTGTCACTGAAGCCATACAGATTCGATGTCTATCTGGACAACGGCGTGTATAAATTTGTGACTGTCAAGAATCTGGATGTCATCAAAAAGGAGAACTACTATGAAGTGAATAGCAAGTGCTACGAAG AGGCTAAAAAGCTGAAAAAGATTAGCAACCAGGCAGAGTTCATCGCCTCCT TTTACAACAACGACCTGATTAAGATCAATGGCGAACTGTATAGGGTCATCGGGGTGAACAATGATCTGCTGAACCGCATTGAAGTGAATATGATTGACATCACTTACCGAGAGTATCTGGAAAACATGAATGATAAGCGCCCCCCTCGAATTATCAAAACAATTGCCTCTAAGACTCAGAGTATCAAAAAGTACTCAACCGACATTCT GGGAAACCTGTATGAGGTGAAGAGCAAAAAGCACCTCAGATTATCAAAAA GGGCTAAGAATTC

[0538] Applicants analyzed Cas9 orthologs to identify relevant PAM sequences and corresponding chimeric guide RNAs, as described in Fig.13A -II. This expanded set of PAMs provides broader targeting across the genome and also significantly increases the number of unique target sites and provides the potential to identify novel Cas9s with increased levels of specificity in the genome. Applicants determined that the PAM of Staphylococcus aureus subspecies aureus Cas9 is NNGRR ( Fig.14 ). Staphylococcus aureus subsp. aureus Cas9 is also known as SaCas9. Fig.15 ad provides SaCas9 single or multiple vector designs.

[0539] Figure 7 Sequence icon showing the inferred PAM, as indicated by the reverse complement sequence. Cas9 orthologs and their respective sgRNAs were used to cleave a library of targets with a randomized PAM (7-bp sequence just 3' of the target sequence). The cleaved products were isolated and deep sequenced to generate 7-bp candidate sequences that allowed cleavage for each Cas9 ortholog. For each Cas9 ortholog, the consensus PAM was determined by aligning all 7-bp candidate sequences. ( Figure 7 and 21 ).

[0540] Further work examining the thermodynamics and in vivo stability of sgRNA-DNA duplexes is likely to yield additional predictive power for off-target activity, while exploration of SpCas9 mutants and orthologs may yield novel variants with improved specificity. The specificity of Cas9 orthologs can be further evaluated by testing the ability of each Cas9 to tolerate mismatches between the guide RNA and its DNA target.

[0541] Example 4: Cas9 mutation

[0542] In this example, Applicants show that the following mutations can convert SpCas9 into a nickase: D10A, E762A, H840A, N854A, N863A, D986A.

[0543] Applicants provide sequences showing where the sequence mutation points are located within the SpCas9 gene ( Fig. 10A -M). Applicants also showed that these nickases are still able to mediate homologous recombination. In addition, SpCas9 with these mutations (individually) reduces the level of double-strand breaks. All Cas9 orthologs share a common structure of 3-4 RuvC domains and one HNH domain (Figure 19). The 5' most RuvC domain cuts the non-complementary strand, while the HNH domain cuts the complementary strand. All symbols are with respect to the guide sequence.

[0544] The catalytic residues in the 5'RuvC domain were identified by homology comparison of the Cas9 of interest with other Cas9 orthologs (from S. pyogenes type II CRISPR loci, S. thermophilus CRISPR loci 1, S. thermophilus CRISPR loci 3, and Franciscilla novicida type II CRISPR loci), and the conserved Asp residues were mutated to alanine to convert Cas9 into a complementary strand nicking enzyme. Similarly, the conserved His and Asn residues in the HNH domain were mutated to alanine to convert Cas9 into a non-complementary strand nicking enzyme.

[0545] Example 5: Cas9 function optimization

[0546] For enhanced functions or for developing new functions, Applicants generated chimeric Cas9 proteins by combining fragments from different Cas9 orthologs.

[0547] For example, Applicants fused the N-terminus of St1Cas9 (the fragment from this protein is in bold) to the N-terminus of SpCas9 (the fragment from this protein is underlined).

[0548] >St1(N)Sp(C)Cas9

[0549]

[0550]

[0551] Applicants have also generated Sp_St3 chimeric proteins and have shown in vitro cleavage by SpCas9, St3Cas9, Sp_St3 chimeras, and St3_Sp chimeras ( Fig.17 ).

[0552] Benefits of creating a chimeric Cas9 include:

[0553] a. Reduce toxicity

[0554] b. Improved expression in eukaryotic cells

[0555] c. Enhanced specificity

[0556] d. Reduce the molecular weight of the protein by combining minimal domains from different Cas9 homologs to make the protein smaller.

[0557] e. Change PAM sequence requirements

[0558] Example 6: In vivo delivery of Cas9 using AAV particles or vectors

[0559] In vivo delivery – AAV approach

[0560] AAV is advantageous over other viral vectors for two reasons:

[0561] o Low toxicity (this may be due to the purification method not requiring ultracentrifugation of cell particles, which may activate immune responses)

[0562] o Low probability of causing insertional mutagenesis because it is not integrated into the host genome.

[0563] While some current AAV vectors can accommodate insert DNA of up to 4300 bases, AAV can have 4.5 or 4.75KB insert DNA because of the upper limit or packaging limitations. This means that the DNA encoding the Cas9 enzyme as well as the promoter and transcription terminator must all be fitted into the same viral vector. Constructs larger than 4.5 or 4.75KB will result in a significant reduction in viral production. SpCas9 is quite large, with the gene itself exceeding 4.1kb, making it difficult to package into AAV. Therefore, embodiments of the present invention include the use of shorter Cas9 orthologs. For example:

[0564]

[0565]

[0566] Figure 3 A schematic representation of an AAV vector useful in the methods and compositions of the invention is provided.Packaging is discussed above.

[0567] Example 7: Engineering microalgae using Cas9

[0568] Methods of delivering Cas9

[0569] Method 1: Applicants delivered Cas9 and guide RNA using a vector that expresses Cas9 under the control of a constitutive promoter (such as Hsp70A-Rbc S2 or β2-tubulin).

[0570] Method 2: Applicants deliver Cas9 and T7 polymerase using a vector that expresses Cas9 and T7 polymerase under the control of a constitutive promoter such as Hsp70A-Rbc S2 or β2-tubulin. The guide RNA will be delivered using a vector containing a T7 promoter driving the guide RNA.

[0571] Method 3: Applicants deliver Cas9 mRNA and in vitro transcribed guide RNA into algae cells. RNA can be transcribed in vitro. Cas9 mRNA will consist of the coding region of Cas9 and the 3'UTR from Cop1 to ensure the stability of Cas9 mRNA.

[0572] For homologous recombination, applicants provide an additional homology-directed repair template.

[0573] The sequence of the cassette driving the expression of Cas9 under the control of the β-2 tubulin promoter is located after the 3'UTR of Cop1.

[0574] TCTTTCTTGCGCTATGACACTTCCAGCAAAAGGTAGGGCGGGCTGCGAGACG GCTTCCCGGCGCTGCATGCAACACCGATGATGCTTCGACCCCCCGAAGCTCCTTCGGGGCTGCATGGGCGCTCCGATGCCGCTCCAGGGCGAGCGCTGTTTAAA TAGCCAGGCCCCCGATTGCAAAGACATTATAGCGAGCTACCAAAGCCATATTCAAACACCTAGATCACTACCACTTCTACACAGGCCACTCGAGCTTGTGATCG CACTCCGCTAAGGGGGCGCCTCTTCCTCTTCGTTTCAGTCACAACCCGCAAA CATGTACCCATACGATGTTCCAGATTACGCTTCGCCGAAGAAAAAGCGCAAGGTCGAAGCGTCCGACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAA CTCTGTGGGCTGGGCCGTGATCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACCGGCACAGCATCAAGAAGAACCTGAT CGGAGCCCTGCTGTTCGACAGCGGCGAAACAGCCGAGGCCACCCGGCTGAA GAGAACCGCCAGAAGAAGATACACCAGACGGAAGAACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACGAGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCC ACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGAC CTGCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATCGAGGGCGACCTGAACCCCGACAACAGCGACGTGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATCAACGCCAGCGGCGTGGACGCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAG CAGACGGCTGGAAAATCTGATCGCCCAGCTGCCCGGCGAGAAGAAGAATGG CCTGTTCGGCAACCTGATTGCCCTGAGCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGATGCCAAACTGCAGCTGAGCAAGGACACC TACGACGACGACCTGGACAACCTGCTGGCCCAGATCGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCGACGCCATCCTGCTGAGCGACA TCCTGAGAGTGAACACCGAGATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTCGT GCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTA CAAGTTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAACAGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAA CGGCAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATTCCTGAAGGACAACCGGGAAAAGATCGAG AAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGACTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCCCTTCCTGAGCGGCGAGCA GAAAAAGGCCATCGTGGACCTGCTCTTTCAAGACCAACCGGAAGTGACCGTGAAGCAGCTGAAGAGAGGACTACTTCCAAGAAAATCGAGTGCTTCGACTCCGT GGAAATCTCGGCGTGGAAGATCGGGTGGAAGATCGGGTCTCCCTGGGCACATACCACGATCTGTCGGAAAATTATCAAGGACAAGGACTTCCTGGACAATGGATGAGCAGCTGAGCGAGATACACCGGCTGGCAGCTGGAGC CGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGGCAAGACAATCCTGGATTTCCTGAAGTCCCGAGGCTTCGCCAACAGAAACTTCATGCAGCTATCC ACGACGACAGCCTGGACCTTTAAAAGGACATCCAGCAAGCCCAAGCCAGTGTCCG GCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCGGCAGCCCCGCCATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGA AAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGACCACCAGAAGGGACAGAAAGACAGCCGCGAGAGAATGAAG CGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCGAATCCTGAAAAACAC CCCGTGGAAAACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGAACTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCTTTCTGAAGGACGACT CCATCGACAACAAGGTGCTGACCAGAAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGG CAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTG GACTCCCGGATGAACACTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATT TCCAGTTTTACAAAGTGCGCGAGATCAACAACTACCACCACGCCCACGACGC CTACCTGAACGCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTACAAGGTGTACGACGTGCGGAAGATG ATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCGAGATTACCCTGGCCAACGGCG AGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGAGATCG TGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCA AAGAGTCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTTCG AGAAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAGTACTCCCTGTTCGAGCTGGAAAACGG CCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCTGGCCAGCCACTATGAG AAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCAC CTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCA CCCTGATCCACCAGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAGGCGACAGCCCCAAGAAGAAGAGAAAGGTGGAGGCCAGCT AAGGATCCGGCAAGACTGGCCCCGCTTGGCAACGCAACAGTGAGCCCCTCCCTAGTGTGTTTGGGGATGTGACTATGTATTCGTGTGTTGGCCAACGGGTCAA CCCGAACAGATTGATACCCGCCTTGGCATTTCCTGTCAGAATGTAACGTCAG TTGATGGTACT

[0575] The sequence of a cassette that drives the expression of T7 polymerase under the control of the β-2 tubulin promoter located after the 3’ UTR of Cop1:

[0576] TCTTTCTTGCGCTATGACACTTCCAGCAAAAGGTAGGGCGGGCTGCGAGACG GCTTCCCGGCGCTGCATGCAACACCGATGATGCTTCGACCCCCCGAAGCTCCTTCGGGGCTGCATGGGCGCTCCGATGCCGCTCCAGGGCGAGCGCTGTTTAAA TAGCCAGGCCCCCGATTGCAAAGACATTATAGCGAGCTACCAAAGCCATATTCAAACACCTAGATCACTACCACTTCTACACAGGCCACTCGAGCTTGTGATCG CACTCCGCTAAGGGGGCGCCTCTTCCTCTTCGTTTCAGTCACAACCCGCAAACatgcctaagaagaagaggaaggttaacacgattaacatcgctaagaacgacttctctgacatcgaactggctgctatcccgtt caacactctggctgaccattacggtgagcgtttagctcgcgaacagttggcccttgagcatgagtcttacgagatgggtgaagcacgcttccgcaagatgtttgagcgtcaacttaaagctggtgaggttgcggataacgctgccgccaagcctctcatcactacccta ctccctaagatgattgcacgcatcaacgactggtttgaggaagtgaaagctaagcgcggcaagcgcccgacagccttccagttcctgcaagaaatcaagccggaagccgtagcgtacatcaccattaagaccactctggcttgcctaaccagtgctgacaatacaaccgttcaggctgtagcaagcgcaatcggtcgggccattgaggacgaggctcgcttcggtcgtatccgtgaccttgaagctaagcacttcaagaaaaacgttgaggaacaactcaacaagcgcgtagggcacgtctacaagaaagcatttatgcaagttgtcgaggctgacatgctctctaagggtctactcggtggcgaggcgtggtcttcgtggcataaggaagactctattcatgtaggagtacgctgcatcgagatgctcattgagtcaaccggaatggttagcttacaccgccaaaatgctggcgtagtaggtcaagactctgagactatcga actcgcacctgaatacgctgaggctatcgcaacccgtgcaggtgcgctggctggcatctctccgatgttccaaccttgcgtagttcctcctaagccgtggactggcattactggtggtggctattgggctaacggtcgtcgtcctctggcgctggtgcgtactcacagta agaaagcactgatgcgctacgaagacgtttacatgcctgaggtgtacaaagcgattaacattgcgcaaaacaccgcatggaaaatcaacaagaaagtcctagcggtcgccaacgtaatcaccaagtggaagcattgtccggtcgaggacatccctgcgattgagcg tgaagaactcccgatgaaaccggaagacatcgacatgaatcctgaggctctcaccgcgtggaaacgtgctgccgctgctgtgtaccgcaaggacaaggctcgcaagtctcgccgtatcagccttgagttcatgcttgagcaagccaataagtttgctaaccataaggccatctggttcccttacaacatggactggcgcggtcgtgtttacgctgtgtcaatgttcaacccgcaaggtaacgatatgaccaaaggactgcttacgctggcgaaaggtaaaccaatcggtaaggaaggttactactggctgaaaatccacggtgcaaactgtgcggg tgtcgacaaggttccgttccctgagcgcatcaagttcattgaggaaaaccacgagaacatcatggcttgcgctaagtctccactggagaacacttggtgggctgagcaagattctccgttctgcttccttgcgttctgctttgagtacgctggggtacagcaccacggcct gagctataactgctcccttccgctggcgtttgacgggtcttgctctggcatccagcacttctccgcgatgctccgagatgaggtaggtggtcgcgcggttaacttgcttcctagtgaaaccgttcaggacatctacgggattgttgctaagaaagtcaacgagattctacaa gcagacgcaatcaatgggaccgataacgaagtagttaccgtgaccgatgagaacactggtgaaatctctgagaaagtcaagctgggcactaaggcactggctggtcaatggctggcttacggtgttactcgcagtgtgactaagcgttcagtcatgacgctggcttac gggtccaaagagttcggcttccgtcaacaagtgctggaagataccattcagccagctattgattccggcaagggtctgatgttcactcagccgaatcaggctgctggatacatggctaagctgatttgggaatctgtgagcgtgacggtggtagctgcggttgaagcaatgaactggcttaagtctgctgctaagctgctggctgctgaggtcaaagataagaagactggagagattcttcgcaagcgttgcgctgtgcattgggtaactcctgatggtttccctgtgtggcaggaatacaagaagcctattcagacgcgcttgaacctgatgttcctcg gtcagttccgcttacagcctaccattaacaccaacaaagatagcgagattgatgcacacaaacaggagtctggtatcgctcctaactttgtacacagccaagacggtagccaccttcgtaagactgtagtgtgggcacacgagaagtacggaatcgaatcttttgcactg attcacgactccttcggtacgattccggctgacgctgcgaacctgttcaaagcagtgcgcgaaactatggttgacacatatgagtcttgtgatgtactggctgatttctacgaccagttcgctgaccagttgcacgagtctcaattggacaaaatgccagcacttccggcta aaggtaacttgaacctccgtgacatcttagagtcggacttcgcgttcgcgtaaGGATCCGGCAAGACTGGCCCCGCTTGGCAACGCAACAGTGAGCCCCTCCCTAGTGTGTTTGGGGATGTGAC TATGTATTCGTGTGTTGGCCAACGGGTCAACCCGAACAGATTGATACCCGCCTTGGCATTTCCTGTCAGAATGTAACGTCAGTTGATGGTACT

[0577] Sequence of the guide RNA driven by the T7 promoter (T7 promoter, N represents the targeting sequence):

[0578]

[0579] Gene delivery:

[0580] Chlamydomonas reinhardtii strains CC-124 and CC-125 from the Chlamydomonas Resource Center will be used for electroporation. The electroporation protocol follows the standard recommended protocol from the GeneArt Chlamydomonas Engineering Kit (website information at tools.invitrogen.com / content / sfs / manuals / geneart_chlamy_kits_man.pdf).

[0581] Moreover, the applicant generates a Chlamydomonas reinhardtii line that constitutively expresses Cas9. This can be accomplished by using pChlamy1 (linearized using PvuI) and selecting hygromycin-resistant colonies. The following is the sequence of pChlamy1 containing Cas9. To achieve gene knockout in this way, it is simply necessary to deliver the RNA of the guide RNA. For homologous recombination, the applicant delivered the guide RNA and the linearized homologous recombination template.

[0582] pChlamy1-Cas9:

[0583] TGCGGTATTTCACACCGCATCAGGTGGCACTTTTCGGGGAAATGTGCGCGGA ACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTT AAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCT TAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTG GCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGC AACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCA TCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCT CCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGA TGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCC ACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGA GCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATC AGGGTTATTGTCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGA GCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGT TTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCC ACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCT GTTACCAGTGGCTGTTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGT TCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCG GACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGA GCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGTCGCTGAGGCTTGACATGATTGGTG CGTATGTTTGTATGAAGCTACAGGACTGATTTGGCGGGCTATGAGGGCGGGGGAAGCTCTGGAAGGGCCGCGATGGGGCGCGCGGCGTCCAGAAGGCGCCATA CGGCCCGCTGGCGGCACCCATCCGGTATAAAAGCCCGCGACCCCGAACGGTGACCTCCACTTTCAGCGACAAACGAGCACTTATACATACGCGACTATTCTGC CGCTATACATAACCACTCAGCTAGCTTAAGATCCCATCAAGCTTGCATGCCGGGCGCGCCAGAAGGAGCGCAGCCAAACCAGGATGATGTTTGATGGGGTATT TGAGCACTTGCAACCCTTATCCGGAAGCCCCCTGGCCCACAAAGGCTAGGCG CCAATGCAAGCAGTTCGCATGCAGCCCCTGGAGCGGTGCCCTCCTGATAAACCGGCCAGGGGGCCTATGTTCTTTACTTTTTTACAAGAGAAGTCACTCAACAT CTTAAAATGGCCAGGTGAGTCGACGAGCAAGCCCGGCGGATCAGGCAGCGTGCTTGCAGATTTGACTTGCAACGCCCGCATTGTGTCGACGAAGGCTTTTGGC TCCTCTGTCGCTGTCTCAAGCAGCATCTAACCCTGCGTCGCCGTTTCCATTTGCAGGAGATTCGAGGTACCATGTACCCATACGATGTTCCAGATTACGCTTCGC CGAAGAAAAAGCGCAAGGTCGAAGCGTCCGACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGATCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACCGGCACAGC ATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAACAGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAA GAACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGT GGACGACAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACGAGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGC CTACCACGAGAAGTACCCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCTGCGGCTGATCTATCTGGCCCTGGCCCACATG ATCAAGTTCCGGGGCCACTTCCTGATCGAGGGCGACCTGAACCCCGACAAC AGCGACGTGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATCAACGCCAGCGGCGTGGACGCCAAGGCCATCCTGT CTGCCAGACTGAGCAAGAGCAGACGGCTGGAAAATCTGATCGCCCAGCTGCCCGGCGAGAAGAAGAATGGCCTGTTCGGCAACCTGATTGCCCTGAGCCTGG GCCTGACCCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGATGCCAAACT GCAGCTGAGCAAGGACACCTACGACGACGACCTGGACAACCTGCTGGCCCAGATCGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCGACGCCATCCTGCTGAGCGACATCCTGAGAGTGAACACCGAGATCACCAAGGCC CCCCTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTACATTGACGGCGGA GCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAACAGAGAGGACCTGCTGCGG AAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCAGATCCACCTGGGA GAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATTCCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGT GGGCCCTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGC TTCCGCCCAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGT ATAACGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAGA CCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAACGC CTCCCTGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTG ACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCCACCTGTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAG TCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACATCCA GAAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATTAAGAAGGGCATCCTGCAGACAGTGAAGGT GGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGACCACCCAGAAGGGACAGAAGAACA GCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGCTGCAGAACGAGAAG CTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGAA CTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACA AGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGA AAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGAT AAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAGTACGACGAGAAT GACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTGAT CAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGG CTACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCGAGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAA CGGCGAAACCGGGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGT GCGGAAAGTGCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAGGAACAGCGA TAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAA GGGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCAT CATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAGTACTC CCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAG CAGAAACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTACCCTGACCAATCTGGGAGCCCCTG CCGCCTTCAAGTACTTTGACACCACCATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCACCGGCCTGTA CGAGACACGGATCGACCTGTCTCAGCTGGGAGGCGACAGCCCCAAGAAGAA GAGAAAGGTGGAGGCCAGCTAA

[0584] CATATGATTCGAATGTCTTTCTTGCGCTATGACACTTCCAGCAAAAGGTAGG GCGGGCTGCGAGACGGCTTCCCGGCGCTGCATGCAACACCGATGATGCTTCG ACCCCCCGAAGCTCCTTCGGGGCTGCATGGGCGCTCCGATGCCGCTCCAGGGCGAGCGCTGTTTAAATAGCCAGGCCCCCGATTGCAAAGACATTATAGCGAG CTACCAAAGCCATATTCAAACACCTAGATCACTACCACTTCTACACAGGCCA CTCGAGCTTGTGATCGCACTCCGCTAAGGGGGCGCCTCTTCCTCTTCGTTTCAGTCACAACCCGCAAACATGACACAAGAATCCCTGTTACTTCTCGACCGTATT GATTCGGATGATTCCTACGCGAGCCTGCGGAACGACCAGGAATTCTGGGAG GTGAGTCGACGAGCAAGCCCGGCGGATCAGGCAGCGTGCTTGCAGATTTGACTTGCAACGCCCGCATTGTGTCGACGAAGGCTTTTGGCTCCTCTGTCGCTGTCTCAAGCAGCATCTAACCCTGCGTCGCCGTTTCCATTTGCAGCCGCTGGCCCGCCGAGCCCTGGAGGAGCTCGGGCTGCCGGTGCCGCCGGTGCTGCGGGTGCC CGGCGAGAGCACCAACCCCGTACTGGTCGGCGAGCCCGGCCCGGTGATCAAGCTGTTCGGCGAGCACTGGTGCGGTCCGGAGAGCCTCGCGTCGGAGTCGGA GGCGTACGCGGTCCTGGCGGACGCCCCGGTGCCGGTGCCCCGCCTCCTCGGCCGCGGCGAGCTGCGGCCCGGCACCGGAGCCTGGCCGTGGCCCTACCTGGTG ATGAGCCGGATGACCGGCACCACCTGGCGGTCCGCGATGGACGGCACGACCGACCGGAACGCGCTGCTCGCCCTGGCCCGCGAACTCGGCCGGGTGCTCGGCCGGCTGCACAGGGTGCCGCTGACCGGGAACACCGTGCTCACCCCCCATTCCGAGGTCTTCCCGGAACTGCTGCGGGAACGCCGCGCGGCGACCGTCGAGGACC ACCGCGGGTGGGGCTACCTCTCGCCCCGGCTGCTGGACCGCCTGGAGGACTGGCTGCCGGACGTGGACACGCTGCTGCCCGGCCGAACCCCGGTTCGTCCAC GGCGACCTGCACGGGACCAACATCTTCGTGGACCTGGCCGCGACCGAGGTCACCGGGATCGTCGACTTCACCGACGTCTATGCGGGAGACTCCCGCTACAGCC TGGTGCAACTGCATCTCAACGCCTTCCGGGGCGACCGCGAGATCCTGGCCGCGCTGCTCGACGGGGCGCAGTGGAAGCGGACCGAGGACTTCGCCCGCGAACT GCTCGCCTTCACCTTCCTGCACGACTTCGAGGTGTTCGAGGAGACCCCGCTGGATCTCTCCGGCTTCACCGATCCGGAGGAACTGGCGCAGTTCCTCTGGGGGC CGCCGGACACCGCCCCCGGCGCCTGATAAGGATCCGGCAAGACTGGCCCCGCTTGGCAACGCAACAGTGAGCCCCTCCCTAGTGTGTTTGGGGATGTGACTAT GTATTCGTGTGTTGGCCAACGGGTCAACCCGAACAGATTGATACCCGCCTTG GCATTTCCTGTCAGAATGTAACGTCAGTTGATGGTACT

[0585] For all modified C. reinhardtii cells, Applicants used PCR, SURVEYOR nuclease assay, and DNA sequencing to verify successful modification.

[0586] Example 8: SaCas9 and PAM recognition for in vivo applications

[0587] This project began because after identifying the Streptococcus pyogenes (Sp) and Streptococcus thermophilus (St) CRISPR / Cas systems as functional genome engineering tools in mammalian cells, the applicants wanted to further explore the diversity of type II CRISPR / Cas systems.

[0588] By defining new functional Type II CRISPR / Cas systems for application in mammalian cells, applicants will potentially be able to discover:

[0589] (1) CRISPR / Cas systems with higher efficiency and / or specificity

[0590] (2) CRISPR / Cas systems with different protospacer adjacent motifs (PAMs) that allow targeting of a wider range of genomic loci

[0591] (3) CRISPR / Cas systems with smaller size, so that applicants can deliver them in vivo in a single vector using mammalian viral delivery systems such as adenovirus-associated virus (AAV) vectors that have packaging size limitations (current Sp or St systems exceed this 4.7 kb limit)

[0592] and other desirable traits.

[0593] Identification and design of Sa CRISPR / Cas systems for in vivo applications. The applicant tested a new type II CRISPR / Cas system in Staphylococcus aureus (Sa), which worked in vitro in a dsDNA cleavage assay and identified the inferred PAM of NNGRRT. The components of this system are a Cas9 protein from Sa, a guide CRISPR RNA with a direct repeat (DR) from Sa, which will form a functional guide RNA complex with tracrRNA from Sa. This three-component system is similar to all other type II CRISPR / Cas systems. Therefore, the applicant designs a two-component system in which the applicant fuses the Sa tracrRNA to the Sa guide CRISPR RNA through a short stem loop to form a chimeric guide RNA, as the applicant uses the Streptococcus pyogenes (Sp) CRISPR / Cas system accurately. This chimeric guide RNA can support in vitro cutting of dsDNA. Therefore, the applicant decided to clone the complete two-component system: cas9 and the chimeric guide RNA into an AAV vector to test its functionality in a biological organism.

[0594] Applicants chose the AAV system because it is a non-integrating, ssDNA-based, non-immunogenic mammalian virus that has a broad tropism in different tissues / organs depending on the serotype, has been shown to be safe for in vivo applications, and also supports long-term expression of transgenes in living organisms.

[0595] The design of the initial AAV vector had (1) a CMV promoter driving the SaCas9 protein with a single NLS and an HA epitope tag. (2) A human U6 promoter driving the chimeric RNA. These were placed between two inverted terminal repeats (ITRs) from the best-studied AAV serotype 2, which act as viral packaging signals.

[0596] PAM sequence testing on endogenous mammalian genomes is as follows: SaCas9 target spacers are selected across multiple genes to cover different potential PAM sequences. Different spacers are cloned into U6-sgRNA (single-guide RNA) expression dsDNA boxes, which are co-transfected into mammalian cell lines (293FT for human targets and N2a and Hepa for mouse targets). 72 hours after transfection, all genomic DNA is extracted and subjected to surveyor nuclease assay. Run gel on TBE Page gel to detect genomic cleavage. Quantify genomic DNA cleavage efficiency and plot.

[0597] Summary of genomic cleavage efficiency and other statistics for all targets tested

[0598]

[0599] Summary of genomic cleavage efficiencies and other statistics for all tested targets (curated)

[0600]

[0601] The results from this PAM test are shown in Figure 22-27 Comprehensive testing on 100 targets identified a PAM for SaCas9 that can be described as NNGRR (rather than NNGRRT as previously indicated).

[0602] Summary of PAM testing: (1) NNGRR, the universal PAM for SaCas9 - helps design new targets, (2) testing double nickases with new targets, (3) NNGRG can be a more potent PAM.

[0603] References

[0604] 1. Cong, L. et al. Multiplex genome engineering using CRISPR / Cas systems. Science 339, 819-823 (2013).

[0605] 2. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013).

[0606] 3. Jinek, M. et al. RNA-programmed genome editing in human cells. eLife 2, e00471 (2013).

[0607] 4. Cho, SW, Kim, S., Kim, JM & Kim, JS. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 31, 230-232 (2013).

[0608] 5. Deltcheva, E. et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471, 602-607 (2011).

[0609] 6. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 337, 816-821 (2012).

[0610] 7. Wang, H. et al. One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR-Cas-Mediated Genome Engineering. Cell 153, 910-918 (2013).

[0611] 8. Guschin, DY et al. A rapid and general assay for monitoring endogenous gene modification. Methods Mol Biol 649, 247-256 (2010).

[0612] 9. Bogenhagen, DF & Brown, DD. Nucleotide sequences in Xenopus 5S DNA required for transcription termination. Cell, 24, 261-270 (1981).

[0613] 10. Hwang, WY et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol 31, 227-229 (2013).

[0614] 11. Bultmann, S. et al. Targeted transcriptional activation of silent oct4 pluripotency gene by combining designer TALEs and inhibition of epigenetic modifiers. Nucleic Acids Res 40, 5368-5377 (2012).

[0615] 12. Valton, J. et al. Overcoming transcription activator-like effector (TALE) DNA binding domain sensitivity to cytosine methylation. J Biol Chem 287, 38427-38432 (2012).

[0616] 13. Christian, M. et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics, 186, 757-761 (2010).

[0617] 14. Miller, JC et al. TALE nuclease architecture for efficient genome editing. Nat Biotechnol 29, 143-148 (2011).

[0618] 15. Mussolino, C. et al. A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic acids research 39, 9283-9293 (2011).

[0619] 16. Hsu, PD & Zhang, F. Dissecting neural function using targeted genome engineering technologies. ACS Chem Neurosci 3, 603-610 (2012).

[0620] 17. Sanjana, NE et al. A transcription activator-like effector toolbox for genome engineering. Nat Protoc 7, 171-192 (2012).

[0621] 18. Porteus, MH & Baltimore, D. Chimeric nucleases stimulate gene targeting in human cells. Science 300, 763 (2003).

[0622] 19. Miller, JC et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol 25, 778-785 (2007).

[0623] 20. Sander, JD et al. Selection-free zinc-finger-nuclease engineering by context-dependent assembly (CoDA). Nat Methods 8, 67-69 (2011).

[0624] 21. Wood, AJ et al. Targeted genome editing across species using ZFNs and TALENs. Science 333, 307 (2011).

[0625] 22. Bobis-Wozowicz, S., Osiak, A., Rahman, SH & Cathomen, T. Targeted genome editing in pluripotent stem cells using zinc-fingernucleases. Methods 53, 339-346 (2011).

[0626] 23. Jiang, W., Bikard, D., Cox, D., Zhang, F. & Marraffini, LA. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol 31, 233-239 (2013).

[0627] 24. Qi, LS et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152, 1173-1183 (2013).

[0628] 25. Michaelis, LM, Maud "Die kinetik derinvertinwirkung." Biochem.z (1913).

[0629] 26. Mahfouz, MM et al. De novo-engineered transcription activator-like effector (TALE) hybrid nuclease with novel DNA binding specificity creates double-strand breaks. Proc Natl Acad Sci USA 108, 2623-2628 (2011).

[0630] 27. Wilson, EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 22, 209-212 (1927).

[0631] 28. Ding, Q. et al. A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell 12, 238-251 (2013).

[0632] 29. Soldner, F. et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 146, 318-331 (2011).

[0633] 30. Carlson, DF et al. Efficient TALEN-mediated gene knockout in livestock. Proc Natl Acad Sci USA 109, 17382-17387 (2012).

[0634] 31. Geurts, AM et al. Knockout Rats via Embryo Microinjection of Zinc-Finger Nucleases. Science, 325, 433-433 (2009).

[0635] 32. Takasu, Y. et al. Targeted mutagenesis in the silkworm Bombyx mori using zinc finger nuclease mRNA injection. Insect Biochem Molec 40, 759-765 (2010).

[0636] 33. Watanabe, T. et al. Non-transgenic genome modifications in a hemimetabolous insect using zinc-finger and TAL effector nucleases. Nat Commun 3 (2012).

[0637] 34. Reyon, D. et al. FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol 30, 460-465 (2012).

[0638] 35. Boch, J. et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science, 326, 1509-1512 (2009).

[0639] 36. Moscow, MJ & Bogdanove, AJ. A simple cipher governs DNA recognition by TAL effectors. Science, 326, 1501 (2009).

[0640] 37. Deveau, H., Garneau, J.E. & Moineau, S. CRISPR-Cas system and its role in phage-bacteria interactions. Annu Rev Microbiol 64, 475-493 (2010).

[0641] 38. Horvath, P. & Barrangou, R. CRISPR-Cas, the immune system of bacteria and archaea. Science, 327, 167-170 (2010).

[0642] 39. Makarova, KS et al. Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol 9, 467-477 (2011).

[0643] 40. Bhaya, D., Davison, M. & Barrangou, R. CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. Annu Rev Genet 45, 273-297 (2011).

[0644] 41. Garneau, JE et al. The CRISPR-Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468, 67-71 (2010).

[0645] 42. Gasiunas, G., Barrangou, R., Horvath, P. & Siksnys, V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci USA 109, E2579-2586 (2012).

[0646] 43. Urnov, FD, Rebar, EJ, Holmes, MC, Zhang, HS & Gregory, PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet 11, 636-646 (2010).

[0647] 44. Perez, EE et al. Establishment of HIV-1 resistance in CD4(+) T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26, 808-816 (2008).

[0648] 45. Chen, FQ et al. High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases. Nat Methods 8, 753-1796 (2011).

[0649] 46. ​​Bedell, VM et al. In vivo genome editing using a high-efficiency TALEN system. Nature 491, 114-U133 (2012).

[0650] 47. Saleh-Gohari, N. & Helleday, T. Conservative homologous recombination preferentially repairs DNA double-strand breaks in the S phase of the cell cycle in human cells. Nucleic Acids Res 32, 3683-3688 (2004).

[0651] 48. Sapranauskas, R. et al. The Streptococcus thermophilus CRISPR / Cas system provides immunity in Escherichia coli. Nucleic Acids Res 39, 9275-9282 (2011).

[0652] 49. Shen, B. et al. Generation of gene-modified mice via Cas9 / RNA-mediated gene targeting. Cell Res 23, 720-723 (2013).

[0653] 50. Tuschl, T. Expanding small RNA interference. Nat Biotechnol 20, 446-448 (2002).

[0654] 51. Smithies, O., Gregg, RG, Boggs, SS, Koralewski, MA & Kucherlapati, RS. Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination. Nature, 317, 230-234 (1985).

[0655] 52. Thomas, KR, Folger, KR & Capecchi, MR. High frequency targeting of genes to specific sites in the mammalian genome. Cell, 44, 419-428 (1986).

[0656] 53. Hasty, P., Rivera-Perez, J. & Bradley, A. The length of homology required for gene targeting in embryonic stem cells. Mol Cell Biol, 11, 5586-5591 (1991).

[0657] 54. Wu, S., Ying, GX, Wu, Q. & Capecchi, MR. A protocol for constructing gene targeting vectors: generating knockout mice for the cadherin family and beyond. Nat Protoc 3, 1056-1076 (2008).

[0658] 55. Oliveira, TY et al. Translocation capture sequencing: a method for high throughput mapping of chromosomal rearrangements. J Immunol Methods 375, 176-181 (2012).

[0659] 56. Tremblay et al. Transcription Activator-Like Effector Proteins Induce the Expression of the Frataxin Gene. Human Gene Therapy. 2012 Aug; 23(8): 883-890.

[0660] 57. Shalek et al. Nanowire-mediated delivery enables functional interrogation of primary immune cells: application to the analysis of chronic lymphocytic leukemia. Nano Letters. 2012 Dec 12;12(12):6498-504.

[0661] 58. Pardridge et al. Preparation of Trojan horse liposomes (THLs) for gene transfer across the blood-brain barrier. Cold Spring Harb Protoc; 2010; Apr; 2010 (4).

[0662] 59. Plosker GL et al. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia. Drugs 1996, 51(3): 433-459.

[0663] 60. Trapani et al. Potential role of nonstatin cholesterol lowering agents. IUBMB Life, Vol. 63, No. 11, pp. 964–971, November 2011.

[0664] 61. Birch AM et al. DGAT1 inhibitors as anti-obesity and anti-diabetic agents. Current Opinion in Drug Discovery & Development, 2010, 13(4): 489-496.

[0665] 62. Fuchs, K. Killing of leukemic cells with a BCR / ABL fusion gene by RNA interference (RNAi), Oncogene, 2002, 21(37): 5716-5724.

[0666] 63. McManaman JL et al. Perilipin-2 Null Mice are Protected Against Diet-Induced Obesity, Adipose Inflammation and Fatty Liver Disease. The Journal of Lipid Research, jlr. M035063. First published February 12, 2013.

[0667] 64. Tang J et al. Inhibition of SREBP by a Small Molecule, Betulin, Improves Hyperlipidemia and Insulin Resistance and Reduces Atherosclerotic Plaques; Cell Metabolism, Vol. 13, No. 1, 44-56, January 5, 2011.

[0668] 65. Dumitrache et al. Trex2 enables spontaneous sister chromatid exchanges without facilitating DNA double-strand break repair. Genetics. 2011 Aug;188(4):787–797.

[0669] ***

[0670] Although preferred embodiments of the present invention have been shown and described herein, it should be apparent to those of ordinary skill in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those of ordinary skill in the art without departing from the present invention. It should be understood that different alternatives to the embodiments of the present invention described herein may be employed in practicing the present invention.

Claims

1. An engineered, non-naturally occurring CRISPR-Cas system for genome editing in eukaryotic cells, include: (a) a Cas9 protein or a polynucleotide encoding the Cas9 protein, wherein the Cas9 protein is Streptococcus pyogenes Cas9, Streptococcus thermophilus Cas9, Staphylococcus aureus Cas9 or Campylobacter jejuni Cas9; (b) A CRISPR-Cas system chimeric RNA comprising a guide sequence capable of hybridizing to a target sequence adjacent to a protospacer adjacent motif (PAM) in a nucleus of a eukaryotic cell and directing the CRISPR-Cas complex to sequence-specifically bind to the target sequence, a tracr mate sequence capable of hybridizing to a tracr sequence, and a tracr sequence.

2. An engineered, non-naturally occurring CRISPR-Cas system for genome editing in eukaryotic cells, include: (a) a Cas9 protein or a polynucleotide encoding the Cas9 protein, wherein the Cas9 protein is Streptococcus pyogenes Cas9, Streptococcus thermophilus Cas9, Staphylococcus aureus Cas9 or Campylobacter jejuni Cas9; (b) a CRISPR-Cas system crRNA comprising a guide sequence capable of hybridizing to a target sequence adjacent to a protospacer adjacent motif (PAM) in a nucleus of a eukaryotic cell and directing the CRISPR-Cas complex to sequence-specifically bind to the target sequence and a tracr mate sequence capable of hybridizing to a tracr sequence; and (c) tracrRNA comprising a tracr sequence.

3. An engineered, non-naturally occurring CRISPR-Cas vector system for genome editing in eukaryotic cells, comprising one or more vectors comprising: (a) a polynucleotide encoding a Cas9 protein, wherein the Cas9 protein is Streptococcus pyogenes Cas9, Streptococcus thermophilus Cas9, Staphylococcus aureus Cas9 or Campylobacter jejuni Cas9; (b) a polynucleotide encoding a CRISPR-Cas system chimeric RNA, wherein the chimeric RNA comprises a guide sequence capable of hybridizing to a target sequence adjacent to a protospacer adjacent motif (PAM) in a nucleus of a eukaryotic cell and directing the CRISPR-Cas complex to sequence-specifically bind to the target sequence, a tracr mate sequence capable of hybridizing to a tracr sequence, and a tracr sequence.

4. An engineered, non-naturally occurring CRISPR-Cas vector system for genome editing in eukaryotic cells, comprising one or more vectors comprising: (a) a polynucleotide encoding a Cas9 protein, wherein the Cas9 protein is Streptococcus pyogenes Cas9, Streptococcus thermophilus Cas9, Staphylococcus aureus Cas9 or Campylobacter jejuni Cas9; (b) a polynucleotide encoding a CRISPR-Cas system crRNA, wherein the crRNA comprises a guide sequence capable of hybridizing to a target sequence adjacent to a protospacer adjacent motif (PAM) in a eukaryotic cell nucleus and directing the CRISPR-Cas complex to sequence-specifically bind to the target sequence, and a tracr pairing sequence capable of hybridizing to a tracr sequence; and (c) a polynucleotide encoding a tracrRNA, wherein the tracrRNA comprises a tracr sequence.

5. The system of claim 1, 2, 3 or 4, wherein the Cas9 protein is Streptococcus pyogenes Cas9.

6. The system of claim 1, 2, 3 or 4, wherein the Cas9 protein is Streptococcus thermophilus Cas9.

7. The system of claim 1, 2, 3 or 4, wherein the Cas9 protein is Staphylococcus aureus Cas9.

8. The system of claim 1, 2, 3 or 4, wherein the Cas9 protein is Campylobacter jejuni Cas9.

9. The system of claim 1, 2, 3 or 4, wherein the tracr sequence is at least 30 nucleotides in length.

10. The system of claim 1, 2, 3 or 4, wherein the tracr sequence is at least 40 nucleotides in length.

11. The system of claim 1, 2, 3 or 4, wherein the tracr sequence is at least 50 nucleotides in length.

12. The system of claim 1, 2, 3 or 4, wherein the guide sequence is 15-30 nucleotides in length.

13. The system of claim 1, 2, 3 or 4, wherein the Cas9 protein is a nuclease capable of cleaving both DNA strands.

14. The system of claim 1, 2, 3 or 4, wherein at least one catalytic domain of the Cas9 protein is mutated such that the Cas9 protein is a nickase lacking the ability to cleave one DNA strand.

15. The system of claim 13, wherein the Cas9 protein comprises a mutation corresponding to D10A, H840A, N854A or N863A of Streptococcus pyogenes Cas9.

16. The system of claim 1, 2, 3 or 4, wherein at least two catalytic domains of the Cas9 protein are mutated such that the Cas9 protein lacks DNA cleavage activity.

17. The system of claim 15, wherein the Cas9 protein comprises a mutation corresponding to D10A of Streptococcus pyogenes Cas9 and a mutation corresponding to H840A, N854A or N863A of Streptococcus pyogenes Cas9.

18. The system of claim 1, 2, 3 or 4, wherein the Cas9 protein is linked to at least one nuclear localization signal (NLS).

19. The system of claim 1, 2, 3 or 4, wherein the Cas9 protein is linked to at least two NLSs.

20. The system of claim 1, 2, 3 or 4, wherein the Cas9 protein is linked to at least one N-terminal NLS and at least one C-terminal NLS.

21. The system of claim 1, 2, 3 or 4, wherein the Cas9 protein is linked to at least one heterologous protein domain.

22. The system of claim 21, wherein the heterologous protein domain has one or more of the following activities: methylase activity, demethylase activity, transcriptional activation activity, transcriptional repression activity, transcriptional release factor activity, histone modification activity, RNA cleavage activity, and nucleic acid binding activity.

23. The system of claim 1, 2, 3 or 4, wherein the polynucleotide encoding the Cas9 protein is codon optimized for expression in mammalian cells or human cells.

24. The system of claim 1 or 2, wherein the system comprises mRNA encoding the Cas9 protein.

25. The system of claim 3 or 4, wherein the one or more vectors are viral vectors, wherein components (a) and (b) are located on the same vector.

26. The system of claim 25, wherein the one or more vectors are adeno-associated viral (AAV) vectors.

27. Use of the system according to claim 1, 2, 3 or 4 in the manufacture of a medicament for gene therapy.

28. Use of the system according to claim 1, 2, 3 or 4 for modifying eukaryotic cells ex vivo or in vitro.

29. An isolated animal cell comprising the system of claim 1, 2, 3 or 4.

30. An ex vivo or in vitro method for producing a modified eukaryotic cell comprising introducing an engineered, non-naturally occurring CRISPR-Cas system into a eukaryotic cell, the system include: (a) a Cas9 protein or a polynucleotide encoding the Cas9 protein, wherein the Cas9 protein is Streptococcus pyogenes Cas9, Streptococcus thermophilus Cas9, Staphylococcus aureus Cas9 or Campylobacter jejuni Cas9; (b) a CRISPR-Cas system chimeric RNA comprising a guide sequence capable of hybridizing to a target sequence adjacent to a protospacer adjacent motif (PAM) in a nucleus of a eukaryotic cell and directing a CRISPR-Cas complex to sequence-specifically bind to the target sequence, a tracr mate sequence capable of hybridizing to a tracr sequence, and a tracr sequence, Thereby a modified eukaryotic cell is obtained, wherein the eukaryotic cell is not a human germ cell.

31. An ex vivo or in vitro method for producing a modified eukaryotic cell comprising introducing an engineered, non-naturally occurring CRISPR-Cas system into a eukaryotic cell, the system include: (a) a Cas9 protein or a polynucleotide encoding the Cas9 protein, wherein the Cas9 protein is Streptococcus pyogenes Cas9, Streptococcus thermophilus Cas9, Staphylococcus aureus Cas9 or Campylobacter jejuni Cas9; (b) a CRISPR-Cas system crRNA comprising a guide sequence capable of hybridizing to a target sequence adjacent to a protospacer adjacent motif (PAM) in a nucleus of a eukaryotic cell and directing the CRISPR-Cas complex to sequence-specifically bind to the target sequence and a tracr mate sequence capable of hybridizing to a tracr sequence; and (c) a tracrRNA comprising a tracr sequence, Thereby a modified eukaryotic cell is obtained, wherein the eukaryotic cell is not a human germ cell.

32. An ex vivo or in vitro method for producing a modified eukaryotic cell, comprising introducing into a eukaryotic cell an engineered, non-naturally occurring CRISPR-Cas vector system, the CRISPR-Cas vector system comprising one or more vectors comprising: (a) a polynucleotide encoding a Cas9 protein, wherein the Cas9 protein is Streptococcus pyogenes Cas9, Streptococcus thermophilus Cas9, Staphylococcus aureus Cas9 or Campylobacter jejuni Cas9; (b) a polynucleotide encoding a CRISPR-Cas system chimeric RNA, wherein the chimeric RNA comprises a guide sequence capable of hybridizing to a target sequence adjacent to a protospacer adjacent motif (PAM) in a nucleus of a eukaryotic cell and directing the CRISPR-Cas complex to sequence-specifically bind to the target sequence, a tracr mate sequence capable of hybridizing to a tracr sequence, and a tracr sequence, Thereby a modified eukaryotic cell is obtained, wherein the eukaryotic cell is not a human germ cell.

33. An ex vivo or in vitro method for producing a modified eukaryotic cell, comprising introducing into a eukaryotic cell an engineered, non-naturally occurring CRISPR-Cas vector system, the CRISPR-Cas vector system comprising one or more vectors comprising: (a) a polynucleotide encoding a Cas9 protein, wherein the Cas9 protein is Streptococcus pyogenes Cas9, Streptococcus thermophilus Cas9, Staphylococcus aureus Cas9 or Campylobacter jejuni Cas9; (b) a polynucleotide encoding a CRISPR-Cas system crRNA, wherein the crRNA comprises a guide sequence capable of hybridizing to a target sequence adjacent to a protospacer adjacent motif (PAM) in a eukaryotic cell nucleus and directing the CRISPR-Cas complex to sequence-specifically bind to the target sequence and a tracr mate sequence capable of hybridizing to a tracr sequence; and (c) a polynucleotide encoding a tracrRNA, wherein the tracrRNA comprises a tracr sequence, Thereby a modified eukaryotic cell is obtained, wherein the eukaryotic cell is not a human germ cell.

34. The system of claim 30, 31, 32 or 33, wherein the Cas9 protein is Streptococcus pyogenes Cas9.

35. The system of claim 30, 31, 32 or 33, wherein the Cas9 protein is Streptococcus thermophilus Cas9.

36. The system of claim 30, 31, 32 or 33, wherein the Cas9 protein is Staphylococcus aureus Cas9.

37. The system of claim 30, 31, 32 or 33, wherein the Cas9 protein is Campylobacter jejuni Cas9.

38. The method of claim 30, 31, 32 or 33, wherein the tracr sequence is at least 30 nucleotides in length.

39. The method of claim 30, 31, 32 or 33, wherein the tracr sequence is at least 40 nucleotides in length.

40. The method of claim 30, 31, 32 or 33, wherein the tracr sequence is at least 50 nucleotides in length.

41. The method of claim 30, 31, 32 or 33, wherein the guide sequence is 15-30 nucleotides in length.

42. The method of claim 30, 31, 32 or 33, wherein the Cas9 protein is a nuclease capable of cleaving both DNA strands.

43. The method of claim 30, 31, 32 or 33, wherein at least one catalytic domain of the Cas9 protein is mutated such that the Cas9 protein is a nickase that lacks the ability to cleave one DNA strand.

44. The method of claim 42, wherein the Cas9 protein comprises a mutation corresponding to D10A, H840A, N854A or N863A of Streptococcus pyogenes Cas9.

45. The method of claim 30, 31, 32 or 33, wherein at least two catalytic domains of the Cas9 protein are mutated such that the Cas9 protein lacks DNA cleavage activity.

46. ​​The method of claim 44, wherein the Cas9 protein comprises a mutation corresponding to D10A of Streptococcus pyogenes Cas9 and a mutation corresponding to H840A, N854A or N863A of Streptococcus pyogenes Cas9.

47. The method of claim 30, 31, 32 or 33, wherein the Cas9 protein is linked to at least one nuclear localization signal (NLS).

48. The method of claim 30, 31, 32 or 33, wherein the Cas9 protein is linked to at least two NLSs.

49. The method of claim 30, 31, 32 or 33, wherein the Cas9 protein is linked to at least one N-terminal NLS and at least one C-terminal NLS.

50. The method of claim 30, 31, 32 or 33, wherein the Cas9 protein is linked to at least one heterologous protein domain.

51. The method of claim 50, wherein the heterologous protein domain has one or more of the following activities: methylase activity, demethylase activity, transcriptional activation activity, transcriptional repression activity, transcriptional release factor activity, histone modification activity, RNA cleavage activity, and nucleic acid binding activity.

52. The method of claim 30, 31, 32 or 33, wherein the polynucleotide encoding the Cas9 protein is codon-optimized for expression in mammalian cells or human cells.

53. The method of claim 30 or 31, wherein the system comprises mRNA encoding the Cas9 protein.

54. The method of claim 32 or 33, wherein the one or more vectors are viral vectors, wherein components (a) and (b) are located in the same vector.

55. The method of claim 54, wherein the one or more vectors are adeno-associated virus (AAV) vectors.

56. The method of claim 30, 31, 32 or 33, wherein the eukaryotic cell is a mammalian cell.

57. The method of claim 30, 31, 32 or 33, further comprising producing a genetically modified non-human animal or plant from the modified eukaryotic cell or its progeny.

58. An isolated modified animal cell or its progeny produced by the method according to claim 30, 31, 32 or 33, wherein the modified animal cell or its progeny comprises an insertion, deletion or substitution of one or more nucleotides in a target genomic locus compared to a corresponding wild-type cell.